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ABSTRACT 
As with the discovery of many physiologically-produced bioactive molecules, fatty 
acid-derived resolvins and protectins have become pharmaceutical development 
targets for the treatment of inflammatory diseases.  The increasing development of 
‘white’ biotechnology, which utilises enzymes as biocatalysts, is an attractive 
alternative to traditional organic synthetic methods in the production of such 
compounds.  This thesis presents the investigation of a plant enzyme, soybean 15-
lipoxygenase-1 (15-sLOX-1), as a biocatalyst for the production of resolvin and 
protectin analogs, intermediates and other related compounds from a range of 
biologically important LC-PUFA.  Several experimental factors have been identified 
which may be used to modify enzyme activity and specificity, and subsequently 
influence the product profile.  The range of products from 15-sLOX-1 were fully 
characterised using a range of analytical techniques to elucidate the chemical 
structures.  The products of secondary enzymatic and non-enzymatic pathways were 
also examined which may affect the yield and purity of the target compounds.  Finally, 
a reusable form of 15-sLOX-1 was produced through immobilisation of the enzyme to 
several functionalised methacrylate porous resins, and was subsequently characterised 
in terms of activity, stability and biocatalytic properties 
The resolvin family contains important anti-inflammatory and pro-resolution 
compounds enzymatically derived in vivo from the polyunsaturated omega-3 fatty 
acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).  More recently, 
docosapentaenoic acid (DPA) has emerged as another potentially important precursor 
in the biological production resolvin compounds.  In this work medium engineering 
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has been used to develop a simple method for the controlled synthesis of two 
dihydroxylated diastereomers of DPAn-3 catalysed by soybean 15-lipoxygenase-1 in 
the presence of short chain n-alcohols, including methanol, ethanol and propan-1-ol.  
The complete structures of the two major products, 7S,17S-dihydroxydocosapenta-
8E,10Z,13Z,15E,19Z-enoic acid (7S,17S-diHDPAn-3) and 7R,17S-
dihydroxydocosapenta-8E,10Z,13Z,15E,19Z-enoic acid (7R,17S-diHDPAn-3), have 
been elucidated using spectroscopic analysis.  The alcohol-dependent R-dioxygenase 
activity of soybean 15-lipoxygenase-1 with mono-hydroperoxide intermediate 
substrates has also been demonstrated with other biologically relevant LC-PUFAs, 
including DHA, EPA and ARA.   
15-sLOX-1 is a well-studied dioxygenase enzyme under aerobic conditions.  However 
when oxygen is the limiting substrate the enzyme exhibits atypical hydroperoxidase 
activity, catalysing the formation of carbonyl, epoxy-alcohol and alkyl-branched 
compounds.  In this study DHA was used as a model substrate to study the 
lipohydroperoxidase activity of 15-sLOX-1 with LC-PUFA under anaerobic 
conditions.  A completely hypoxic reaction system was established where the 
dioxygenase activity of 15-sLOX-1 rapidly depletes oxygen and consumes DHA, to 
produce the 17-hydroperoxy-DHA intermediate.  The products are shown to stem from 
the metabolism of 17-hydroperoxy-DHA by monitoring the substrate and product 
profile throughout the reaction.  The products were detected and characterised by RP- 
and NP-HPLC-DAD, HPLC-TOF-MS, GC-MS, NMR spectroscopy and chiral phase-
HPLC.  Major products from DHA were identified as: (4Z,7Z,10Z,13Z,15E-)17-keto-
heptadecapentaenoic acid, two proposed regio-isomers of hydroxy-16,17-epoxy-
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docosapentaenoic acid, and several isomers of a C5H9-DHA branched compound 
containing a conjugated diene moiety.  In addition the radical scavenger 4-hydroxy-
TEMPO was utilised to establish the detected compounds are products of 15-sLOX-1 
catalytic activity, as well as providing further support for the formation of epoxy-allyl 
radicals from the hydroperoxide substrate.   
Soybean 15-lipoxygenase-1 is routinely utilised for the regio- and stereo-specific 
production of hydroperoxides from biologically important LC-PUFAs.  The resulting 
compounds are important pre-cursors and analogs of anti-inflammatory and pro-
resolution lipid mediators.  In this work the enzyme is successfully immobilised to 
various epoxy and (glutaraldehyde-activated) amino functionalised methacrylate 
resins via covalent linkages.  Incubation conditions for immobilisation were optimised, 
including pH, temperature, and incubation time, enabling binding efficiencies of up to 
68% (68 mg protein/g resin) to be achieved.  The resulting coupled enzyme may be 
recycled up to six times with retention of activity.  However compared to soluble 15-
sLOX-1 the activity of the enzyme upon immobilisation was reduced significantly (5 
– 10% retained activity), and activity further decreased during storage.  The kinetic 
parameters of the soluble and immobilised forms were compared, with immobilised 
15-sLOX-1 exhibiting lower catalytic turnover (kcat) and specificity (kcat/km) constants.  
This mode of immobilisation was also found to reduce the thermal stability of the 
enzyme, while the pH optimum and stability remained consistent.  Despite the 
observed reduction in activity and stability, the immobilised form was efficient in 
catalysing the formation of resolvin and protectin analogues from DHA, EPA, ARA, 
DPAn-3 and DPAn-6 substrates.  This study supports the potential utilisation of 
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immobilised 15-sLOX-1 for the production of hydroperoxides and SPM analogues 
from a range of LC-PUFA, while importantly enabling recovery and re-use of the 
valuable biocatalyst. 
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1. GENERAL INTRODUCTION 
Uncontrolled or chronic inflammation is an important underlying factor in many 
conditions that are becoming increasingly prevalent in Western societies, such as 
cardiovascular disease, arthritis, asthma, neurological disorders and diabetes [1]. In 
Australia, the condition of arthritis is projected to increase from 18.5% in 2007 to 
approximately 23.9% (of the projected population) by 2050 [2].  The prevalence of 
diabetes (type 1 and 2) has increased from 1.5% in 1989-1990 to 4.1% in 2007-2008 
[3-4].  Two in five people over the age of 85 report living with stroke, heart or vascular 
disease (2014) [5], while macular degeneration is the leading cause of blindness 
affecting over 12% of Australians over the age of 50 (2010) and is expected to increase 
to ~ 24% by 2030 in the absence of intervention [6].  The socio-economic impacts of 
these diseases at both individual and government levels is significant.  These include 
decreased quality of life, higher unemployment and dependence on healthcare 
services, and a substantial burden on the existing healthcare system and 
pharmaceutical benefits scheme.  As a result, new strategies to combat the underlying 
chronic inflammation and the associated metabolic pathways must be developed. 
1.1 Specialised pro-resolving lipid mediators 
The term ‘lipid mediators’ encompasses a group of bioactive molecules derived from 
omega-6 and omega-3 long chain polyunsaturated fatty acid (LC-PUFA) precursors 
that possess potent anti- or pro-inflammatory properties within biological systems.  
Pro-inflammatory mediators include the well-known prostaglandins and leukotrienes, 
synthesised in the body from cellular arachidonic acid (ARA).  The known anti-
inflammatory and pro-resolution mediators are divided into four families - lipoxins, 
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maresins, resolvins and protectins, with each family consisting of a range of analogues 
varying in structure and stereochemistry [1, 7-9].   
In vivo, specialised pro-resolving mediators (SPMs) are synthesised from dietary 
sources of omega-3 docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and 
omega-6 ARA.  A historical shift in the dietary intake of these important LC-PUFA in 
Western societies, from an approximately equal omega-3:omega-6 ratio to an omega-
3-deficient diet, has been correlated with an increasing trend in the prevalence of 
conditions where chronic inflammation plays a major role in pathogenesis and disease 
progression (reviewed in [10-11]).  Many naturally-occurring resolvins and protectins 
have been identified within the previous ten years, which has contributed to the 
elucidation of important anti-inflammatory and pro-resolution pathways [9, 12].  This 
has prompted further research into the discovery and characterisation of new SPM 
analogues, and their potential application in diseases where local and systemic 
inflammation is a major contributing factor, including cardiovascular disease, arthritis, 
peritonitis, and cancer.  As such, SPMs have become pharmaceutical targets for drug 
development in the treatment of several conditions, with several resolvin and protectin 
analogues currently in clinical trials for the treatment of asthma, dry eye and 
retinopathy [13-15]. 
A current limitation in the development and production of these compounds is the 
requirement to incorporate specific regio- and stereo-chemistry, as the biological 
effects and potency are known to be heavily dependent on the compound structure [14, 
16-19].  As these mediators are transiently expressed with acute effects, and are 
subsequently rapidly metabolised, biologically-produced SPMs are active at pico- to 
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nano-molar concentrations [17-18, 20-21].  Therefore lipid mediator analogues which 
also have high potency at low concentrations are highly desirable.  Current strategies 
for the production of structurally and stereochemically pure resolvins and protectins 
for pharmacological studies require total organic synthesis [22-25].  These protocols 
are typically very low-yielding, complex and lengthy, require functional group 
protection/deprotection, and employ the use of toxic solvents, reagents and catalysts.  
In addition, multiple purification steps are required to eliminate by-products and 
improve the purity of the target compound [22-23, 25].   
1.2 Enzyme biocatalysts: applications and potential 
An alternative to total organic synthesis in the production of resolvin and protectin 
analogs is the use of plant-based oxygenase enzymes which catalyse the selective 
incorporation of molecular oxygen in to LC-PUFA substrates.  The use of purified 
enzymes as biocatalysts for the production of bioactive compounds has been well 
described in the literature and provides many advantages over total organic synthesis 
[26-29].   
Throughout the past two decades a significant increase in the use of biocatalysts, or 
‘white biotechnology’, for the production of commercially valuable products has been 
observed, with applications in a broad range of industry sectors.  For example, the 
synthesis of 6-aminopenicillanic acid using penicillin acylases (pharmaceutical), 
glucose and fructose syrups from starch using amylases and isomerases (food and 
nutrition) and acrylamide from acrylonitrile using microorganisms from the 
Rhodococcus genus (commodity chemicals) [29-33].  These applications use either 
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purified enzymes, in the soluble or immobilised form, or whole cell catalysts which 
are metabolically inactive but retain the desired enzymatic activity. 
The use of biocatalysts is an attractive alternative to traditional chemical synthesis as 
enzymes offer extremely high regiospecificity, stereospecificity and 
enantiospecificity, for both substrates and products.  These selective features 
significantly reduce the generation of undesirable organic by-products, therefore 
increasing purity and relative yield while reducing waste [29].  Production processes 
may be simplified as protection and deprotection steps are not necessary, and enzymes 
are typically active in mild reaction conditions due to their activity being significantly 
restricted by factors such as pH, temperature, pressure and ionic strength. In addition, 
the use of mild reaction conditions limits both substrate and product degradation and 
conversion.  Finally, the replacement of chemical methods with biocatalysts also 
introduces the capability to eliminate toxic and/or harsh solvents, catalysts and 
reagents, especially the use of heavy metals as inorganic catalysts.   
Whilst the high stereospecificity of enzymes makes them useful as biocatalysts for the 
production of isomerically pure compounds, their use limits the range of potential 
compounds that may be chemically synthesised as the desired stereochemistry may not 
be achievable.  A way to overcome this is to modify (or design) the reaction medium 
to manipulate enzyme properties, a process termed medium engineering [26, 34-35].  
The addition of water-miscible co-solvents to enzymatic reactions was originally used 
to increase the solubility of hydrophobic substrates in aqueous media, however, it was 
soon observed that the addition of organic co-solvents could affect the specificity and 
activity of the enzyme [26, 34-38].   This is especially relevant to the production of 
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resolvin and protectin analogs, as the regio- and stereochemistry of the compounds are 
known to significantly affect their biological potency in anti-inflammatory assays [18, 
39-40].   
The application of biocatalysts, and specifically enzymes, to industrial processes is 
currently limited by production and economic factors.  For example, the ability to 
recover and re-use biocatalysts is an important factor, while maintaining high enzyme 
activity and high product recovery.  The use of soluble enzymes is a major limitation 
as they essentially become a single-use biocatalyst, unless an appropriate method of 
recovery can be found.  This may be overcome by immobilising enzymes on solid 
supports, which may then be physically separated from the reaction medium/product.  
In comparison to chemical synthesis methods, the yields from biocatalysis are typically 
lower (in terms of kg of product per kg of catalyst) [29].  This is mainly due to lower 
starting substrate concentrations and also dilution of product in aqueous systems 
resulting in low product recovery [27, 29].  Therefore the overall production yield may 
not be competitive with chemical methods, even though conversion of substrate to 
product is high.  However, the replacement of common aqueous buffer reaction 
systems (where the concentration of substrate/reagent may be limited by solubility) 
with organic solvent media may offer improvements in yield and recovery.    
1.3 Research objectives 
The overall objective of this research is to investigate the application of soybean 15-
lipoxygenase-1 (15-sLOX-1) for the production of a range of SPM analogs.  This 
includes identification of factors which may be used to modify enzyme activity and 
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subsequently influence the product profile, as well as examine secondary pathways 
which may affect the yield and purity of the target compounds. 
The specific objectives of this thesis are therefore: 
1. To investigate the effect of medium engineering on soybean 15-lipoxygenase-
1 catalysis of LC-PUFAs, and perform complete characterisation of novel 
compounds.  
2. To develop methods to experimentally produce, detect, purify, and characterise 
known and novel compounds.  
3. To study the lipohydroperoxidase activity of soybean 15-lipoxygenase-1 with 
LC-PUFA substrate under anaerobic conditions, and perform complete 
chemical characterisation of novel compounds. 
4. To immobilise soybean 15-lipoxygenase-1 on a range functionalised enzyme 
carrier resins, and utilise the immobilised enzyme for production of SPM 
analogs. 
This thesis consists of seven chapters and an appendix.  Chapter II reviews the relevant 
literature surrounding the target compounds, soybean 15-lipoxygenase-1 (15-sLOX-
1) catalysis, substrates, and reaction products.  Chapter III describes the induction of 
atypical R-dioxygenase activity of 15-sLOX-1 through addition of organic co-solvents 
to the reaction medium.  Chapter IV investigates the lesser-known 
lipohydroperoxidase activity of 15-sLOX-1 with LC-PUFAs, providing insight into 
the catalytic mechanism and formation of novel products.  Chapter V describes the 
immobilisation of 15-sLOX-1 on epoxy- and amino functionalised methacrylate 
resins, and evaluates the stability and reusability capabilities in comparison to soluble 
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enzyme. Chapter VI evaluates immobilised 15-sLOX-1 for the biocatalysis of a range 
of LC-PUFAs and partial characterisation of the products.  Chapter VII includes a 
range of additional methods and protocols to enable stereochemical analysis of 
products, which are not included in the main body of the thesis. 
Appendix A presents a broad literature review of lipoxygenase catalysis (from plant, 
mammal, fungal and bacterial sources) in tabular form, including experimental 
parameters and specific reaction products (where reported), to enable the design of 
targeted enzymatic protocols.   
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CHAPTER II 
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2. LITERATURE REVIEW 
Omega-3 and omega-6 polyunsaturated fatty acids have long been recognised for their 
potent health benefits, however their mechanism of action was not well understood 
prior to the discovery of anti-inflammatory and pro-resolution mediators derived from 
long chain polyunsaturated fatty acids (LC-PUFA) [21].  In vivo these highly bioactive 
compounds are produced from the metabolism of endogenous LC-PUFA through 
enzymatic pathways, including lipoxygenase (LOX) and/or cyclooxygenase (COX) 
enzymes.  As such these lipid mediators are potential targets for the treatment of 
inflammatory diseases and offer an alternative to current clinical treatments, based on 
natural physiological and biochemical pathways. 
This review aims to summarise the potential application of plant lipoxygenases, and 
specifically soybean 15-lipoxygenase-1 (15-sLOX-1), for the production of lipid 
mediator analogues, hydroperoxide intermediates and other by-products.  The catalytic 
mechanism of 15-sLOX-1 is thoroughly examined, as well as the effects of 
experimental conditions on 15-sLOX-1 activity and the subsequent range of 
compounds produced from several plant and mammalian derived LC-PUFA.  The 
review will enable the design of targeted enzymatic synthesis protocols for the 
production of a broader range of lipid mediator analogs. 
2.1 Omega-3 and omega-6 fatty acids 
Biologically-occurring omega-3 (n-3/ω-3) and omega-6 (n-6/ω-6) polyunsaturated 
fatty acids are the predominant substrates of numerous LOX isoforms.  In plant oils, 
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the main LC-PUFAs are omega-6 linoleic acid (LA; C18:2n-6*) and omega-3 α-
linolenic acid (ALA; C18:3n-3).  Together LA and ALA constitute up to 95% of 
dietary PUFA intake in Western diets [41].  Other LC-PUFAs present in plant oils 
include γ-linoleic acid (GLA; C18:3n-6) and dihomo-γ-linolenic acid (DGLA; 
C20:3n-6), however dietary intake is low [41].  In mammals, dietary LA and ALA is 
subjected to further desaturation and elongation to produce arachidonic acid 
(ETE/ARA; C20:4n-6), stearidonic acid (C18:4n-3), eicosapentaenoic acid (EPA; 
C20:5n-3) and docosahexaenoic acid (DHA; C22:6n-3) (Fig. 2.1).  The bioconversion 
of LA and ALA to longer chain metabolites varies between species and is significantly 
affected by dietary (saturated, omega-3 and omega-6) fat consumption as a result of 
metabolic regulation [42-47]. Studies of ALA bioconversion show accumulation of 
EPA following supplementation with ALA [43-45], however limited accumulation of 
DPAn-3 and DHA due to the low efficiency of EPA elongation [43, 45].  Omega-3 
and omega-6 fatty acids have important roles in maintaining cell membrane structure 
and fluidity, regulating cell signalling and also cell function [41].  In addition ARA, 
EPA and DHA are precursors to important anti-inflammatory and pro-resolution lipid-
based mediators. 
                                                   
* Fatty acid nomenclature using lipid numbers.  E.g. C18:2n-6 refers to a C18-chain fatty acid with two 
double bonds (C18:2) starting at the omega-6 (n-6) position.   
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Figure 2.1 In vivo biosynthesis of long chain polyunsaturated fatty acids [42, 48]. 
2.2 Specialised Pro-resolving Mediators (SPM) 
There are currently six defined families of biologically-produced inflammatory 
mediators, derived from cellular ARA, EPA and DHA.  Lipid mediators from other 
LC-PUFAs, including docosapentaenoic acid (DPA: C22:5n-3/n-6), have also been 
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identified following treatment of stimulated cells with the respective PUFA.  The six 
families are – prostaglandins (PG), leukotrienes (LT), lipoxins (LX), resolvins (Rv), 
protectins (PD) and maresins (MaR) (Fig. 2.2).  Prostaglandins and leukotrienes are 
well known pro-inflammatory mediators derived from arachidonic acid by 
cyclooxygenase-2 and 5-lipoxygenase (respectively), as well as several hydrolase and 
synthase enzymes [49-53].  Several E-series prostaglandins have also been reported, 
derived from EPA by cyclooxygenase, including prostaglandin E3 (PGE3) which 
exerts chemoprotective and anti-tumorigenic properties [54-55].  Together 
prostaglandins and leukotrienes activate specific G-protein coupled receptors, 
triggering intracellular signalling cascades including cyclic-AMP, inositol 
triphosphate pathways and expression of downstream protein kinases and cytokines 
[1, 56-57].  As a result these inflammatory compounds are responsible for the 
recruitment and infiltration of leukocytes to affected areas, changes in vascular dilation 
and permeability, and the destruction of pathogenic material [51, 53, 58-60].   
The specialised pro-resolving mediator (SPM) compounds (resolvins, protectins and 
maresins) are discussed in further detail below.  
 
Figure 2.2 A schematic overview of lipid mediator classes and their precursors. 
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Resolvins 
Collectively known as the resolvins family, the E-series (from EPA) and D-series 
(from DHA) resolvin analogues are currently considered to be responsible for much 
of the pro-resolving activity in the resolution phase of inflammation [21, 61-68].  
Resolvins are di- or tri-hydroxy derivatives of EPA and DHA, varying in the location 
and chirality of the hydroxy groups, as well as the configuration of the double bonds.  
E-series resolvins are produced by sequential metabolism of EPA by (aspirin)-
acetylated cyclooxygenase-2 and 5-lipoxygenase through a series of hydroperoxy and 
epoxy intermediates, whereas the D-series resolvins are produced by multiple 
lipoxygenase enzymes, including 15-LOX and 5-LOX [1, 12, 69].  
Serhan and colleagues first discovered resolvin E1 (RvE1) (Fig. 2.4), the first member 
of the E-series derived from EPA, in stimulated murine exudates [21].  In this 
publication the authors describe the detection of novel bioactive lipids generated 
through treatment of human epithelial cells with EPA and aspirin.  The characterised 
compounds, including RvE1 and a 15R-lipoxin analogue, were found to reduce human 
polymorphonuclear (PMN) cell migration and infiltration with high potency – 
significant events in the resolution of inflammation [21].  These findings demonstrated 
the ability of oxygenase enzymes (LOX and COX) to accept PUFAs other than 
arachidonic acid and linoleic acid (as previously established), further accelerating 
research into the discovery of bioactive mediator analogues. 
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Figure 2.4 Chemical structures of resolvin E1 (RvE1; 5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-
EPA) and resolvin E2 (RvE2; 5S,18R-dihydroxy-6E,8Z,11Z,14Z,16E -EPA). 
A further protectin-like product has also been identified and characterised, however is 
assigned to the resolvin family due to the compound exhibiting resolving properties 
(as opposed to protecting properties).  Resolvin D5 (RvD5; 4Z,8E,10Z,13Z,15E,19Z-
7S,17S-dihydroxy-DHA) (Fig. 2.5) is a double dioxygenation product isolated in 
human PMN cells when treated with 17S-hydroxy-DHA [70].  Initial studies 
implicated an anti-inflammatory/pro-resolution effect [70], which was later confirmed 
in an Escherichia coli infection model where RvD5 reduced the resolution interval of 
inflammation and stimulated direct phagocytosis of the bacteria [71]. 
 
Figure 2.5 Chemical structure of resolvin D5 (RvD5; 7S,17S-dihydroxy-4Z,8E,10Z,13Z,15E,19Z-
DHA). 
Protectins 
The protectins family are a group of compounds that are all dihydroxy metabolites of 
DHA, varying only in the R/S configuration of the hydroxy groups and/or the 
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stereochemistry of the double bonds (cis/trans).  The family currently consists of only 
two compounds – protectin D1 (PD1; 10R,17S-dihydroxydocosahexa-
4Z,7Z,11E,13E,15Z,19Z-enoic acid) (Fig. 2.3), and aspirin-triggered-PD1 (AT-PD1; 
10R,17R-dihydroxydocosahexa-4Z,7Z,11E,13E,15Z,19Z-enoic acid) [1, 8, 25, 40, 72].  
PD1 is produced through the 15-lipoxygnease pathway in a single cell type (e.g. 
polymorphonuclear leukocytes, lymphocytes, epithelial cells) from DHA through the 
17S-hydroperoxy-DHA and 16,17-epoxy-DHA intermediates [1, 8-9, 18].  Several 
closely related isomers of PD1, in particular protectin DX (4Z,7Z,11E,13Z,15E,19Z-
10S,17S-dihydroxy-DHA) (Fig. 2.3), and Δ15-trans-PD1 (4Z,7Z,11E,13E,15E,19Z-
10R,17S-dihydroxy-DHA), have also been well characterised both chemically and 
biologically, however are not known to be produced in significant quantities in vivo 
[16].  The protective effects of PD1 (called neuroprotection D1 – NPD1, when detected 
in neural tissue) are well described in the literature, implicating a role in 
neurodegenerative disorders [61, 69, 73].  For example in Alzheimer’s disease, where 
the presence of NPD1 and DHA in cytokine-stressed cells correlated with a decrease 
in the secretion of the amyloid-β peptide and its associated neurotoxicity [73-74].  The 
effects of PD1 have also been well documented in other non-neuronal conditions 
including retinal and macular disease, renal disease and ischaemia-reperfusion injuries 
[18-19, 75-77]. 
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Figure 2.3 Chemical structures of (neuro)protectin D1 ((N)PD1; 10R,17S-dihydroxy-
4Z,7Z,11E,13E,15Z,19Z-DHA) and protectin DX (PDX; 10S,17S-dihydroxy-4Z,7Z,11E,13Z,15E,19Z-
DHA). 
Maresins 
Maresins, derived from DHA, form the latest family of lipid-derived mediators to be 
discovered.  Maresin 1 (MaR1) was identified in the inflammatory exudate of a murine 
peritonitis model during the resolution phase.  In this study by Serhan and co-workers 
[78] the known marker of protectin and D-series resolvin biosynthesis – 17S-hydroxy-
DHA, was identified alongside 14S-hydroperoxy-DHA (14S-HPDHA).  14S-HPDHA 
was subsequently confirmed as a biomarker of a separate 12-lipoxygenase pathway in 
macrophages, generating several bioactive compounds though the epoxidation and 
double dioxygenation pathways.  The most biologically potent compound was 
identified as (4Z,8E,10E,12Z,16Z,19Z)-7R,14S-dihydroxy-DHA (Fig. 2.6), termed 
MaR1 due to its activity as a macrophage mediator in resolving inflammation [20, 79-
80].  Several isomers were also identified that demonstrate symmetry with PD1 
biosynthesis including the double dioxygenation products - (4Z,8E,10Z,12E,16Z,19Z)-
7S,14S-dihydroxy-DHA (analogue of PDX) and (5E,7Z,10Z,12E,16Z,19Z)-4S,14S-
dihydroxy-DHA (analogue of RvD5) [79]. 
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Figure 2.6 Chemical structure of maresin R1 (MaR1; 7R,14S-dihydroxy-4Z,8E,10E,12Z,16Z,19Z-
DHA). 
2.3 Pharmaceutical/nutraceutical potential of SPMs 
Resolvins, protectins and other specialised pro-resolving mediators (SPM) derived 
from LC-PUFAs are a new generation of anti-inflammatory drug candidates based on 
naturally occurring compounds.  As opposed to the use of non-steroidal anti-
inflammatory drugs (for example aspirin) which are designed to block both pro- and 
anti-inflammatory enzymatic pathways via inhibition of lipoxygenase and/or 
cyclooxygenase, the design of SPM analogues is to only target and enhance anti-
inflammation and pro-resolution mechanisms.  
Resolvyx Pharmaceuticals have recently developed a synthetic analogue of RvE1, 
marketed as RX-10045 (licensed to Auven Therapeutics), for the treatment of dry eye 
and other retinal conditions [81-83].  This company is also in the process of developing 
naturally-occurring RvE1 and NPD1 analogues for the treatment of other conditions, 
including asthma, cardiovascular disease and macular degeneration.  Berlex 
Biosciences (now part of Bayer Healthcare) have also developed two synthetic lipoxin 
analogues – ZK-142 and ZK-994, which retain the pro-resolution activity of lipoxin 
A4 (LxA4) [84].  However unlike naturally-produced LxA4, which rapidly undergoes 
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metabolic inactivation in vivo, the synthetic analogues have increased metabolic 
stability making them suitable as pharmaceutical compounds [39, 84-86].    
A current limitation for the pharmaceutical development of SPM analogs is the 
requirement to introduce specific regio- and stereo-chemistry of double bonds 
(cis/trans) and hydroxy groups (R/S) to produce stereochemically pure and 
biologically active structures.  This is commonly achieved through organic synthesis 
protocols, which are often lengthy, complex and employ the use of harsh and toxic 
solvents, reagents and catalysts [22-23, 25].  In biological systems peroxidase 
enzymes, including cyclooxygenase (EC 1.14.99.1) and lipoxygenase (EC 1.13.11) 
isoforms, have been established as important biocatalysts of both pro- and anti-
inflammatory mediators. LC-PUFAs containing one or more 1Z,4Z-pentadiene 
structures are suitable substrates for metabolism by lipoxygenase enzymes.  These 
enzymes catalyse the selective insertion of molecular oxygen in a highly stereo- and 
regio-specific manner to generate mono-, di- and tri-hydro(pero)xylated products, 
making the use of lipoxygenases an attractive alternative to organic synthesis methods 
in the synthesis of SPM analogs.   
2.4 Classification of lipoxygenase 
Lipoxygenases (LOX; EC 1.13.11) are a ubiquitous range of monomeric, non-heme 
iron-containing enzymes traditionally known for the regio- and stereo-specific 
oxidation of polyunsaturated fatty acid substrates.  To date a range of lipoxygenase 
isozymes have been identified and isolated routinely from mammalian (5-, 8-, 12-, 15-
LOX) and plant species (9- and 13-LOX), enabling elucidation of important 
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inflammatory pathways in mammals, and development and defence pathways in 
plants.  LOX have also been identified in coral, bacteria and fungus [87-94].  LOX 
isoforms have been identified from several fungi species which contain a manganese 
catalytic centre, however exhibit similar catalytic activity to iron-containing LOX [95-
96].   
Research on the lipoxygenase family of enzymes, including enzyme 
structure/sequence, metabolism pathways and products, has been ongoing since 
detection of a lipid-oxidase enzyme in soybean by Andre and Hue in 1932 [97] and 
the subject still remains of significant interest.  A PubMed search (accessed through 
the National Center for Biotechnology Information) for the general terms 
‘lipoxygenase’ or ‘lipoxidase’ (limited to the title and abstract of the publication) 
currently returns 14,455 items (accessed 18/07/15).  
Lipoxygenases are most well known as a dioxygenase enzyme, catalysing the 
formation of hydroperoxy-fatty acids from a range of omega-3 and omega-6 
polyunsaturated fatty acids containing one or more 1Z,4Z-pentadiene moieties.  
Common substrates for lipoxygenase metabolism include plant PUFAs ‒ linoleic acid, 
alpha-linolenic acid and gamma-linolenic acid, and mammalian PUFAs ‒ arachidonic 
acid, eicosapentaenoic acid and docosahexaenoic acid.  The catalysed hydroperoxide 
products are synthesised with high regio- and stereo-specificity, which is determined 
by the LOX isoform and also the location of the pentadiene moiety on the fatty acid 
substrate.  A summary of products from various lipoxygenase isoforms, including 
plant, animal, fungal and bacterial, is presented in Appendix A. 
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Classification 
The classification and nomenclature of lipoxygenase isoforms is somewhat complex 
with classification continually progressing as new lipoxygenases are discovered, 
sequenced and characterised by enzymatic activity.  Lipoxygenases are typically first 
classified according to the regio-specificity with their most common substrate, i.e. 
linoleic acid for plant LOX, or arachidonic acid for mammalian LOX [91, 98-99].  This 
classification is represented by the prefix (for example, arachidonate 15-LOX, 
linoleate 9-LOX, arachidonate 5-LOX).  As such, arachidonate 15-LOX oxygenates 
arachidonic acid at position C15 to produce 15-hydroperoxy-ETE.  To date two plant 
LOX (linoleate 9- and 13-LOX) and four mammalian LOX (arachidonate 5-, 8-, 12- 
and 15-LOX) are known.  Stereo-specificity, where known, is also often included in 
the prefix (e.g. 15S-LOX).  Mammalian LOX isoforms are often further classified by 
the prototypical cellular localisation, for example platelet-type and leukocyte-type 
12S-LOX [100-101].  In addition, both mammalian and plant LOX may be classified 
according to the sequence homology as well as the absence or presence of an amino-
terminal transit peptide sequence (type 1 or type 2, respectively) [89, 98].   
To further complicate the classification, nomenclature of commonly studied LOX 
isoforms may be misleading.  Notably a major lipoxygenase from soybean (a type 1, 
S- stereo-specific plant LOX) is classified according to its regio-specificity with 
arachidonic acid (a mammalian PUFA), rather than with the native plant substrate, 
linoleic acid.  As a result this plant enzyme has the nomenclature 15-LOX-1, however 
with its native substrate (linoleic acid) it would be classified as a 13-LOX as it 
produces 13-hydroperoxy-LA.  Therefore it is important in both the undertaking of 
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research and the use of LOX for biocatalysis that the enzyme is appropriately classified 
to prevent misleading results. 
2.5 Soybean 15-lipoxygenase: Catalysis, substrates and specificity 
The first isoform of LOX was identified in soybean (Glycine max) in 1932 by Andre 
& Hue [97] and isolated in 1947 [102].  The crystal structure of soybean 15-
lipoxygenase-1 (15-sLOX-1) has been determined by Minor et al. at a resolution of 
2.6 Å [103] and later at 1.4 Å [104] by X-ray crystallography.  The general structure 
of the protein is spatially divided into two domains ‒ a smaller, catalytically inactive 
N-domain (146 residues) consisting mostly of β-strands; and a larger, loosely 
associated C-domain (693 residues) containing the catalytic iron centre.  The iron atom 
is located within a bundle of α-helices and coordinated to residues His499, His504, His690 
and Ile839, and a water or hydroxide ligand [103-104].  
Soybean 15-lipoxygenase (15-sLOX) may be the most comprehensively studied of all 
lipoxygenase enzymes, in terms of elucidation of catalytic mechanisms, amino acid 
sequence and enzyme structure, metabolism, inhibition, substrates and products, as 
well as the intensity of study since it’s discovery in 1932 [97].  Eight isoforms have 
been identified in soybean to date, these include five vegetative LOX [105] and three 
seed LOX.  For the purpose of this review, only the application of soybean seed 
lipoxygenase for the synthesis of hydro(pero)xy fatty acids will be described. 
The soybean seed lipoxygenases, 15-sLOX-1, 15-sLOX-2 and 15-sLOX-3, are 
characterised by pH optima, substrate specificity and product formation (Table 2.1) 
[106-109].  Currently only 15-sLOX-1 is available commercially as a purified enzyme 
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preparation due to the long-term stability of this isoform (Sigma Aldrich Corp., cat # 
L7395; Cayman Chemical Company, cat # 60700).   
Table 2.1 15-sLOX-1 isoforms and classification. 
Isoform pH optimum Product specificity (with LA substrate) Reference 
15-sLOX-1 9.0 
13S-HPODE (~95%) 
9S-HPODE (~5%) 
[108, 110-111] 
15-sLOX-2 ~ 6.0 
13S-HPODE (~80%) 
9S-HPODE (~20%) 
[106, 108, 110, 112] 
15-sLOX-3 ~ 6.5 
9-HPODE* (~60%) 
13-HPODE* (~40%) 
[106, 108] 
* Mixture of R and S enantiomers. 
15-sLOX-1 catalyses the highly regio- and stereo-specific dioxygenation of LC-PUFA 
containing one or more all-cis-1,4-pentadiene moieties to produce mono and di-
hydroperoxylated compounds.  Regio-specific dioxygenations occur with S- 
stereochemistry of the hydroperoxy group  and rearrangement of the double bonds to 
form a cis,trans- conjugated diene, typically in greater than 95% purity (Fig. 2.7) [111, 
113-115].  For example, in the case of linoleic acid the favoured pathway is the 
formation of 9Z,11E-13S-hydroperoxy-linoleic acid (9Z,11E-13S-HPODE), while 
regio- and stereo-isomers constitute very minor products (Fig. 2.7).  In the case of 
PUFA substrates containing three or more methylene-interrupted double bonds (i.e. 
two or more 1Z,4Z-pentadiene units) sequential dioxygenations may occur to provide 
di-hydroperoxylated products.   
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Figure 2.7 Example of 15-sLOX-1 catalysis indicating regio- and stereo-specificity.  R1 – C8H15O2 
(carboxylic acid end); R2 – C5H11 (methyl end). 
In plants, where linoleic acid (LA), alpha-linolenic acid (ALA) and gamma-linolenic 
acid (GLA) are the major PUFAs, the hydroperoxy products and their metabolites are 
involved in plant defence, growth, and germination.  Production of metabolites often 
involves other enzymes in addition to 15-sLOX-1, such as allene oxide synthase 
(AOS) and hydroperoxide lyase (HPL) [116-117].  Examples of metabolites include 
13-keto-octadecadienoic acid (13-keto-ODE), 13-hydroxy-octadecatrienoic acid (13-
HOTrE), and jasmonates, such as jasmonic acid ((1R,2R)-3-oxo-2-[(2Z)-2-penten-1-
yl]cyclopentyl acetic acid) [116, 118].  15-sLOX-1 activity has also been examined 
with a range of non-native (typically mammalian) substrates, including ARA, EPA, 
DHA and DPA.  In these studies the high regio- and stereo-specificity of 15-sLOX-1 
was maintained producing enantio-rich mono- and di-hydro(pero)xy derivatives, 
which are closely related analogs of biologically produced compounds in mammals 
[113, 119-128].   
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Catalytic mechanism 
Two models for LOX catalysis have been proposed which attempt to determine the 
source of the observed regio- and stereo-specificity.  The first describes the formation 
of an organoiron-intermediate as a result of electrophilic addition of Fe(III) to C1 of 
the all-cis-1,4-pentadiene [129].  Selective abstraction of the hydrogen of the bis-
allylic methylene then occurs, followed by reaction of the intermediate with molecular 
oxygen at the Fe(III)-C1 bond generating a proposed (1S,2E,4Z)-1-hydroperoxy-2,4-
pentadiene [130].  Regio- and stereo-specificity in this model is proposed to be 
controlled by the Fe(III)-pentadiene bond, however the presence of the organoiron-
intermediate has not proven experimentally for the reaction between LOX and PUFA 
substrate [130].  In addition, the crystal structure of 15-sLOX-1 provided by Minor et 
al. [104] suggested the formation of such a complex is unlikely due to the restricted 
access to the iron atom imposed by the side chains of the surrounding residue side 
chains.  The second model is based on steric control/hindrance of binding of the 
substrate within the enzyme active site, resulting in proximity of the n-8 methylene 
group to the catalytic iron and the diffusional access of oxygen [131-132].  This model 
involves the formation of carbon-centred free radicals, which have been previously 
identified by spin-trapping reagents in EPR and radical scavenger experiments [133-
135].  The second model is more widely accepted as the mechanism of 15-sLOX-1 
catalysis based on the routine observation of carbon-centred lipid radicals, and is 
therefore described in further detail below.   
Derivation of kinetic constants in several studies have shown the competitive binding 
of both lipid substrate and hydroperoxide product to a single site within the enzyme 
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[127, 136-137].  Therefore an equilibrium exists between the binding of substrate 
(kS/kyS) and product (kP/kyP) (represented in Fig. 2.8) where the association of one 
substrate may affect the association of the other.  
 
Figure 2.8 Proposed kinetic mechanism for soybean 15-lipoxygenase-1 (adapted from [127]).  E(II), 
LOX-Fe2+; E(III), LOX-Fe3+; S, fatty acid substrate; P, hydroperoxide product; O2, molecular oxygen; 
P-O●, hydroperoxide product-alkoxyl radical; S●, fatty acid substrate radical; k*S, LOX-Fe3+-substrate 
equilibrium constant; k*P, LOX-Fe3+-product equilibrium constant; kS, LOX-Fe2+-substrate equilibrium 
constant; kP, LOX-Fe2+-product equilibrium constant; k1, k2, k3, k4, rate constants. 
The aerobic catalytic cycle of 15-sLOX-1 can be divided into five stages – (i) LOX 
activation, (ii) hydrogen abstraction, (iii) radical stabilisation, (iv) oxygen insertion 
and (v) radical reduction (Fig. 2.9) [91, 99, 117, 132].  Stages (ii) and (iv) are 
responsible for the observed stereo- and regio-specificity of the enzyme, whereas 
stages (i) and (v) enable enzyme activation/regeneration.  As the product itself (i.e. 
hydroperoxide) is required to convert inactive Fe3+ to active Fe2+, the catalytic cycle 
is limited by three factors: product concentration, lipid substrate concentration and 
molecular oxygen substrate concentration.  In addition the catalytic mechanism is 
subject to both substrate and product inhibition [122, 138-139]. 
●  ● 
● 
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Figure 2.9 15-sLOX-1 catalytic mechanism (modified from [91]). S, PUFA substrate; P, 
hydroperoxide product; P*, alkoxyl radical species; a, allyl radical; b, resonance-stabilised allyl 
radical; c, hydroperoxy radical. 
i. LOX activation 
The iron state and ligand coordination of active and inactive 15-sLOX-1 have been 
established through analysis of the three dimensional crystal structure, fluorescence 
and UV-visible absorption spectra, electroparamagnetic resonance (EPR) spectra and 
magnetic circular dichroism (MCD) spectra [104, 128, 140-144].  In the inactive form 
of 15-sLOX-1 the iron centre exists in the native Fe2+ form, coordinated to a hydroxyl 
ligand.  The trace presence of hydroperoxide (often present as a trace autoxidation 
product in PUFA preparations) converts native LOX-Fe2+ to active (also termed 
‘yellow’) LOX-Fe3+ through peroxidase-like cleavage of the hydroperoxide group 
[137, 139-140].  This initial, slow conversion of LOX-Fe2+ to LOX-Fe3+, which is 
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dependent on trace hydroperoxide, is responsible for a lag period in dioxygenase 
activity which is often observed in lipoxygenase kinetics.  The lag phase may be 
eliminated by the addition of pre-formed hydroperoxide (at micromolar concentration) 
[137].  Active LOX-Fe3+ subsequently enters the catalytic cycle initiating the observed 
dioxygenase activity of 15-sLOX-1 with LC-PUFA substrates.   
ii. Hydrogen abstraction 
The abstraction of hydrogen from a methylene-interrupted double bond is the first 
occurrence of both regio- and stereo-specificity of the enzyme catalytic cycle.  
Hydrogen abstraction depends on the orientation of the substrate within the active site 
cavity and also the depth of binding.  Soybean 15-LOX has been shown to accept 
PUFA substrate with either the carboxylate group bound within the active site, with 
the methyl terminal associated to the outer surface (inverse orientation), or with the 
methyl terminal bound within the active site (normal orientation) (Fig. 2.10) [145-
151].  In addition the depth of binding of the substrate in the active site results in 
specific alignment of the n-8 methylene group with the catalytic iron [151-152].  This 
control has been found to be determined by specific amino acid residues located within 
the distal substrate binding cavity [153].  In this study the substitution of Met418 in 
human 15-lipoxygenase with a smaller valine residue (as found in 12-LOX) resulted 
in a shift from 15-LOX activity to a combination of 12- and 15-LOX activity, 
indicating a smaller residue allows deeper binding of the substrate [153].  The strict 
stereospecificity of the hydrogen abstraction has also been demonstrated using tritium-
labelled substrates, where the pro-S-hydrogen of 11-3H-labelled linoleic acid is 
selectively abstracted (97 – 99%) [147, 154-155].   
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Figure 2.10 Theoretical model of normal vs. inverse orientation binding of linoleic acid within the 
catalytic site. 
Hydrogen abstraction by LOX-Fe3+ (with a OH- ligand) is proposed to occur with a 
proton-coupled electron transfer [132, 156-158].  In this mechanism the electron is 
translocated to the ferric iron, reducing it to the ferrous state.  Simultaneous transfer 
of the proton to the hydroxide ligand forms a water ligand.   
Pro-S-hydrogen abstraction from a non-oxygenated PUFA substrate by 15-sLOX-1 
occurs preferentially at the n-8 position with all suitable substrates examined to date, 
resulting in the formation of a carbon-centred pentadienyl radical species [99, 130, 
154-155, 159].  In the case of highly unsaturated substrates (where sequential 
dioxygenations are possible), hydrogen abstraction from mono-hydroperoxy 
substrates is less regio-specific as two structural isomers are often produced (while 
retaining strict stereo-specificity), however a regio-preference is still clearly exhibited 
for two methylene sites at n-13 and n-16 [119-122, 124-126, 147, 160-162].    
iii. Radical stabilisation 
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Following hydrogen abstraction the resulting allyl radical is stabilised through 
resonance of the adjacent double bonds of the pentadiene system, forming a more 
stable conjugated diene radical.  Peroxyl radicals may be formed at the bis-allylic 
position or at either end of this pentadienyl radical depending on oxygen 
availability/accessibility (discussed below).  However as peroxyl formation is a 
reversible reaction, molecular oxygen may associate and dissociate from the activated 
substrate in a ‘flip on, flip off’-type mechanism [163].  Non-conjugated peroxyl 
formation at the bis-allylic position is not favoured as shown by a rapid reverse (or 
‘off’) rate and the absence of the bis-allylic hydroperoxide in 15-sLOX-1 products 
[164-165].  The forward (or ‘on’) reaction at either end of the pentadienyl system 
results in a conjugated peroxyl radical which experiences more stability and a 
significantly longer half-life [164-165].  As a result the formation of a conjugated 
hydroperoxide system is the favoured mechanism.  
In addition, steric effects of the enzyme conformation may also play a role in trapping 
a specific conjugated pentadienyl radical [104, 132].  The pentadienyl radical 
theoretically exists in a planar configuration with the radical delocalised over the 
system, as normally represented in mechanistic schemes.  However the presence of 
bulky amino acid residues in the active site may twist the pentadienyl radical out of 
plane, localising the radical and allowing selective oxygen insertion.   
iv. Oxygen insertion 
Oxygen insertion occurs antarafacially to hydrogen abstraction (i.e. to the opposite 
side of the chain to hydrogen abstraction), therefore products of 15-sLOX-1 exhibit 
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high enantio-purity [91, 154-155, 166].  There is no evidence of binding of oxygen to 
a location within the active site. In addition there appears to be no amino acid residues 
in the proximity of the catalytic iron which have potential to bind oxygen [151, 159].  
Therefore it is likely molecular oxygen is present within hydrophobic regions of the 
enzyme and reacts directly with the substrate radical-iron complex.  As discussed 
above, oxygen insertion is possible at three locations of the activated pentadienyl 
system, at either end of the pentadiene (C1 or C5), or at the bis-allylic methylene 
position (C3), however the former is significantly favoured due to increased stability.  
There are several mechanisms proposed to explain the regio-specificity of oxygen 
insertion for 15-sLOX-1 [132, 167]: (1) Oxygen accessibility through tunnels/pockets 
within the enzyme that guide oxygen diffusion to a specific location; (2) steric 
hindrance of the enzyme guiding oxygen access to one end of the pentadienyl radical; 
(3) peroxyl trapping which is dependent on the proximity of a suitable reductant, likely 
an amino acid residue.  However it is important to consider these mechanisms are not 
mutually exclusive, and specificity of oxygen insertion is likely a result of a 
combination of the factors discussed here.  
(1) Oxygen tunnelling  
Analysis of the crystal structure of 15-sLOX-1 by X-ray crystallography proposed 
several channels which may provide access of molecular oxygen to the enzyme-
binding cavity and in proximity to the active site [103-104].  These channels were 
estimated to be constricted and convoluted, likely requiring rearrangement of residues 
to enable access of molecular oxygen.  Likewise fatty acid substrate binding was also 
found to require rearrangement of residues to enable access of the substrate to the 
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active site cavity [104].  Therefore changes to the structural conformation of the 
enzyme structure upon fatty acid binding may also influence the opening of oxygen 
diffusion channels [168].  However to date analysis of the crystal structure of 15-
sLOX-1 with bound fatty acid substrate has not been performed due to the high 
flexibility of LC-PUFA substrates.  Taking into account the confined substrate binding 
cavity, accessibility of molecular oxygen through tunnelling is capable of imposing 
both regio- and stereo-specificity for the resulting hydroperoxide [131-132, 168]. 
(2) Steric control 
Steric control of oxygen insertion by the enzyme structure is a strong candidate for 
determining 15-sLOX-1 specificity.  This model describes the presence of bulky amino 
acid residues close to the binding site of the pentadienyl radical which impose steric 
hindrance, thereby directing oxygen diffusion to a specific location and side of the 
pentadienyl radical [167].   
Amino acid sequencing of numerous LOX (from various species) has identified a 
residue which is highly conserved as Ala in S-LOX and Gly in R-LOX, and is believed 
to be a major determinant of LOX stereospecificity [166].  In this study by Coffa and 
Brash, Ala-Gly and Gly-Ala substitutions of these residues by mutagenesis was found 
to switch both the regio-and stereospecificity of multiple lipoxygenase isozymes.  As 
a result, human 15S-LOX-2 specificity was changed from 15S- in wild-type to 11R- in 
the Ala416Gly mutant (with ARA substrate), and coral 8R-LOX specificity was 
switched from 8R- in wild-type to 12S- in the Gly427Ala mutant [166].  The authors 
propose an interesting mechanism where the presence of a bulkier alanine residue (side 
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chain – CH3) directs oxygen insertion at the distal end of pentadiene (deeper in the 
catalytic pocket) to produce S-chirality products, whereas the presence of glycine (side 
chain – H) enables oxygen insertion at the proximal end of the pentadiene generating 
R-chirality products [147, 166].  
(3) Peroxyl radical trapping 
As peroxyl radicals are subject to the dioxygen ‘flip-on, flip-off’ mechanism, trapping 
of the peroxyl radical by irreversible reduction to the hydroperoxide may invoke regio 
and stereo-specificity [91, 164-165].  This mechanism for specificity is therefore based 
on the presence of an appropriately positioned reductant, rather than the position of 
oxygen insertion [132], however to date there is no experimental evidence for this 
mechanism. 
15-sLOX-1 substrates 
The main prerequisite for high affinity and catalytic turnover is the presence of the all-
cis-1,4-pentadiene at the omega-6 position (i.e. a methylene group at n-8).  This has 
been demonstrated in the study by Hamberg and Samuelsson [154] where only omega-
6 and omega-3 PUFAs were metabolised by 15-sLOX-1, whereas omega-9 and 
omega-8 substrates did not undergo dioxygenation reactions.   
In laboratory experiments, commonly utilised substrates of 15-sLOX are in the form 
of free fatty acids.  As the natural substrate of 15-sLOX-1, linoleic acid is routinely 
used for analysis of reaction kinetics and product specificity [111, 113-115, 134, 138, 
147, 149-150, 154, 169-173].  The use of linoleic acid also provides the simplest 
reaction mechanism as the substrate may only undergo one dioxygenation to produce 
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one major product (9Z,11E-13S-HPODE).  As a result, product analysis of LA 
metabolites is relatively simple compared to products of longer and more highly 
unsaturated substrates.  Several investigators have also examined the metabolism of 
esterified fatty acids, including methyl esters, triacylglycerols and phospholipids [113-
114, 147, 174-175].  A small number of studies have been conducted using ARA, EPA, 
DHA and DPA (n-3 and n-6) which are described in detail below.  
Several other non-biological substrates have been utilised, including a range of long 
chain alkadien(trien)ylphenols (omega-4 and omega-6) with the presence of free 
functional groups on the phenol moiety found to be a prerequisite for activity [176].  
Though the focus of this review is on the use of naturally occurring LC-PUFAs for the 
production of SPM analogs and pre-cursors, the demonstrated high affinity and 
catalytic turnover of these alternative substrates by 15-sLOX-1 suggests they may be 
candidates for the design of metabolically-stable mimetics which are functional group 
protected (similar to existing lipoxin mimetics) [39, 85]. 
Establishing the specificity of sLOX isozymes 
Following the discovery of a ‘lipoxidase’ enzyme (subsequently termed lipoxygenase) 
in crude soybean preparations in 1932 [97], extraction and purification procedures of 
the enzyme were developed to increase activity and yield [102, 177].  Early studies 
addressed the oxidation of both unsaturated fatty acids (linoleic acid and ALA) as well 
as carotene bleaching, enabling measurement of oxidation rates.   
Hamberg and Samuelsson established that sLOX catalyses the specific oxidation of 
substrates containing methylene-interrupted double bonds at the omega-6 position 
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[154].  The hydroperoxides from several LC-PUFAs were structurally characterised 
for the first time in this study using GC-MS following oxidative ozonolysis and 
spectroscopic techniques, determining sLOX specifically catalyses the formation of a 
hydroperoxide at the omega-6 location with a rearrangement of double bonds to form 
the cis,trans conjugated double bond moiety [154].  For example the major product of 
linoleic acid was found to be (9Z,11E)-13-HPODE [154].  Other 15-sLOX substrates 
included α-linolenic acid, γ-linolenic acid, eicosatrienoic acid (C20:3n-6), ARA, EPA, 
ω-6 docosatrienoic acid (C22:3n-6), and ω-9 docosatrienoic acid (C22:3n-9).  These 
studies of sLOX stereospecificity were extended to longer, odd chain length and more 
highly unsaturated substrates, supporting the proposed requirement of the methylene-
interrupted pentadiene at the omega-6 position for lipoxygenase activity [178].   
The stereochemistry of the resulting omega-6 hydroperoxide was later established 
through spectroscopic and/or chromatographic analysis of products [111, 113-115, 
119, 149], as well as investigation into the stereospecificity of hydrogen abstraction 
and subsequent antarafacial oxygen insertion [154-155].  From linoleic acid substrate, 
the major product was found to be predominantly (9Z,11E)-13S-HPODE, with 
(10E,12Z)-9S-HPODE as the minor product [111, 113, 149, 179].  Likewise from 
arachidonic acid substrate the major product is (5Z,8Z,11Z,13E)-15S-HPETE [111, 
119, 179].   
The early studies of soybean LOX assumed the presence of a single lipoxygenase 
isozyme, however the presence of three isozymes in soybean preparations was 
subsequently identified in 1970 [107, 180].  The isozymes, termed sLOX-1, sLOX-2 
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and sLOX-3, were purified and characterised by isoelectric point, pH profile, substrate 
preference and product specificity [107, 180] (Table 2.1).  Briefly, sLOX-1 exhibits 
optimum activity at pH 9 ‒ 9.5 with linoleic acid (free fatty acid) as substrate [108] 
with 13S- specificity.  15-sLOX-2 shows a higher affinity for arachidonic acid than 
linoleic acid and exhibits optimum activity at pH 6‒7 [108].  With linoleic acid as 
substrate the sLOX-2 isozyme produces 13S-HPODE in an approximately 4:1 ratio 
with 9S-HPODE [106].  Significant activity has also been observed at higher pH when 
methyl esterified fatty acids are utilised, however producing 13- and 9-hydroperoxide 
in an approximately 1:1 ratios [110].  Similar to 15-sLOX-2, 15-sLOX-3 also exhibits 
optimum activity at pH 6 – 7 with linoleic acid (free fatty acid) substrate, although 
activity is lower than that observed from sLOX-1 and sLOX-2 due to substrate 
inhibition [108].  The specificity of this isozyme also appears to be lower than 
observed with sLOX-1 and sLOX-2, producing 9-HPODE and 13-HPODE in 
approximately 2:1 ratio with both R- and S- stereoisomers [106].   
The major soybean isozyme, sLOX-1 [108], is likely responsible for the observed 
product formation in early reports of ‘lipoxidase’ activity, based on the pH at which 
assays/reactions were performed (pH ~ 9), and the observed regio-specificity with 
linoleic acid and other LC-PUFAs (where only one regio-isomer was observed at the 
omega-6 position, i.e. analogous to 13-HPODE from linoleic acid). 
2.6 Production of hydro(pero)xylated compounds from LC-PUFA 
The type-1 isozyme of 15-sLOX is the most widely studied due to its stability, ease of 
separation from sLOX-2 and sLOX-3 [108], and commercial availability.  Although 
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the majority of research to date has used linoleic acid as substrate, studies have also 
been performed using substrates which have potential applications in the production 
of SPM analogs.  The metabolism of biologically important LC-PUFA substrates 
(ARA, EPA, DHA and DPA) by 15-sLOX-1 is discussed in detail in this chapter.  In 
addition, the described products are included in Appendix A together with 
experimental parameters and data. 
Arachidonic acid 
Arachidonic acid, containing four methylene-interrupted double bonds, can undergo 
sequential dioxygenation by 15-sLOX-1 to produce mono- and di-hydroxy derivatives 
under aerobic conditions.  The major product of the first dioxygenation, 
(5Z,8Z,11Z,13E)-15S-hydro(pero)xy-ETE (15S-H(P)ETE), is well described in the 
literature with typical yields ranging from 87% to 100% (Fig. 2.11) [111, 114, 119, 
125-126, 147, 154, 169, 179, 181-184].  15S-H(P)ETE is the intermediate species in 
the biological production of lipoxins (LXA4 and LXB4) by 15-LOX in mammals.  In 
addition the 15-hydro(pero)xy functionality is an important feature in the structure of 
prostaglandin compounds, introduced through peroxidation by cyclooxygenase in the 
production of the prostaglandin H2 intermediate. 
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Figure 2.11 Single dioxygenation reaction of ARA by 15-sLOX-1. 
Isomers of (5Z,8Z,11Z,13E)-15S-HETE include the corresponding enantiomer (15R-
HETE) [111, 114, 119], with this compound typically representing approximately 1 - 
3 % of the total amount of hydroperoxides.  Small amounts of 5-HETE, 9-HETE, 11-
HETE and 12-HETE have also been detected in ARA/15-sLOX-1 incubations, 
cumulatively representing less than 1% of total hydroperoxides [111] and presumed to 
be a result of non-enzymatic oxidation.  One study has reported the production of 15R-
HETE using 15-sLOX-1 in an unusually high yield (13%) compared to other studies 
[114].  However, this study utilised a significantly higher concentration of LC-PUFA 
substrate (4.3 mM), highlighting the importance of substrate concentration in 
determining the extent and specificity of 15-sLOX-1 oxidation.   
In cases where arachidonic acid is the limiting substrate (i.e. there is remaining oxygen 
present in the reaction medium), 15S-H(P)ETE may undergo further dioxygenation to 
produce two major di-hydroperoxylated products – (6E,8Z,11Z,13E)-5S,15S-
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diHPETE [119, 126, 181] and (5Z,9E,11Z,13E)-8S,15S-diHPETE (Fig. 2.12) [125-
126, 181, 184].  The production of these compounds has also been demonstrated using 
15S-H(P)ETE as the starting substrate [147, 162].   
 
Figure 2.12 Dioxygenation of 15-hydroperoxy-ETE by 15-sLOX-1 to produce 5S,15S-diHPETE (left) 
and 8S,15S-diHPETE (right). 
As discussed previously, the second hydrogen abstraction catalysed by 15-sLOX-1 is 
generally less regio-specific, occurring in two locations – at the n-14 (C7) and n-11 
(C10) methylene groups (as indicated in Fig. 2.11).  However oxygen insertion 
remains stereo-specific generating S-chirality di-hydroperoxides.  The specificity of 
the hydrogen abstraction does not appear to be dependent on experimental conditions 
as formation of both regio-isomers is observed under conditions of varying pH, 
substrate concentration and reaction temperature [119, 126, 147, 181].  Therefore the 
reduced specificity may be a result of positioning and binding of the substrate in the 
catalytic pocket.  The second dioxygenation of 15S-HPETE has been shown to occur 
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with substrate bound with the carboxylate group buried within the catalytic pocket, 
with the depth of the pocket likely contributing to the regio-specificity [145-147].  
Evaluation of the literature therefore infers three (non-mutually exclusive) scenarios 
which may account for the occurrence of hydrogen abstraction at two locations: (1) 
An increased flexibility of the carboxylate end of the substrate; (2) an increased 
flexibility in the enzyme conformation at the distal end of the pocket upon binding of 
the more polar carboxylate moiety; or (3) a decreased binding strength at both 
locations therefore neither location is favoured.   
More unusual products of 15-sLOX-1 metabolism of ARA are detected in reactions 
where oxygen is the limiting substrate.  In a study of soybean and human platelet LOX 
metabolism of ARA, de Laclos and co-workers [183] reported the production of 15-
oxo-pentadecatetraenoic acid (15-oxo-PTA) and 15-keto-ETE when ARA (15 μM) 
was incubated with 15-sLOX-1 at low oxygen concentrations, demonstrating the 
lipohydroperoxidase activity of the enzyme (refer to page 53 for further discussion of 
lipohydroperoxidase activity).  Under their conditions, 15-oxo-PTA and 15-keto-ETE 
constituted approximately 3% each of the total product from 15-sLOX-1 when the 
oxygen concentration was reduced to approximately 12 – 13 μM (i.e. lower than the 
starting ARA concentration). 
The formation of all-trans-conjugated isomers of 8(R/S),15S-dihydroxy and 
5(R/S),15S-dihydroxy-ETE diastereomers have also been detected in anaerobic 
incubations of 15S-HETE with 15-sLOX-1 [162].  These compounds are proposed to 
be products of lipohydroperoxidase activity which promotes the formation of the 
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14,15-epoxide (14,15-LTA4; eoxin A4) and cyclopropyl epoxide intermediates.  This 
study also reports the formation of an unusual δ-lactone analogue of 5(R/S),15S-
dihydroxy-ETE, through intramolecular reaction of the cyclopropyl epoxide with the 
(weak) nucleophilic carboxylate group [162].  The formation of diastereomers of the 
di-hydroxylated compounds, as well as the incorporation of H218O under anaerobic 
conditions, suggests they are in fact hydrolysis products of the unstable cyclopropyl 
epoxide intermediate species rather than a true enzymatic product [162].   
Other derivatives of arachidonic acid have also been investigated as substrates for 15-
sLOX-1, including 5S, 8R-, 8S-, 9R- and 9S-HETE, where dioxygenation occurs at the 
15-position with S- stereochemistry to produce 5S,15S-, 8R,15S-, 8S,15S-, 9R,15S-, 
and 9S,15S-diHETE, respectively [147, 160, 185].   
Ivanov and co-workers investigated the reaction of 15-sLOX-1 on non-conjugated 
(5Z,8Z,11Z,14Z)-16-HETE substrate, to determine whether the hydroxy group or the 
lack of a bisallylic methylene at C13 was responsible for the lower affinity of 
(5Z,8Z,11Z,13E)-15S-HPETE by 15-sLOX-1 (compared to arachidonic acid) [186].  
In this study they found (5Z,8Z,11Z,14Z)-16-HETE was metabolised to 15,16-diHETE 
(suggesting methyl end-first orientation in the active site), while the methyl ester of 
16-HETE (and it’s 14,15-dehydro analog) was converted to 5,16-diHETE (suggesting 
a carboxylate end-first orientation).  From this study it is apparent the presence of the 
hydroxy group is not as important in controlling the position and kinetics of the second 
dioxygenation, rather it is orientation of the substrate within the active site and 
presence of the C13 methlylene group [186].  
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Eicosapentaenoic acid 
Significantly less research has been performed using EPA as a substrate for 15-sLOX-
1.  A study by Takagi and co-workers described the formation of conjugated diene- 
and triene-containing products from a range of LC-PUFAs.  In addition multiple 
dioxygenations of substrates containing the all-cis n-6,9,12 system (ALA, ARA, EPA 
and DHA) was observed [171].  However as the study was purely spectroscopic no 
further chemical characterisation of the observed products was performed.  Hamberg 
and Samuelsson identified the single dioxygenation product of EPA as 15-hydroxy-
EPA (15-HEPA; detected as the saturated keto ester derivative – methyl 15-keto-
arachidate), however again no further characterisation was performed [154].  In 
addition, due to the high substrate concentration used in this study (~ 3.78 mM), the 
enzyme was likely substrate and/or product inhibited therefore no major di-
hydroxylated compounds were reported.   
Previous research by Dobson et al. provided the first characterisation of the two di-
hydroxylated compounds from EPA using 15-sLOX-1 – (6E,8Z,11Z,13E,17Z)-5,15-
dihydroxy-EPA and (5Z,9E,11Z,13E,17Z)-8,15-dihydroxy-EPA [126].  These 
compounds were identified when the reaction was performed at pH 9 using a high 
enzyme concentration (5.32 μM) to prevent substrate/product inhibition and to 
kinetically favour the second oxygenation reaction.  When the reaction was performed 
at higher pH (up to pH 12) with a lower enzyme concentration (2.13 μM), the second 
dioxygenation was found to be completely inhibited and 15-HEPA was identified as 
the only product [126].  In this study, the compounds were not fully characterised with 
the stereochemistry of the hydroxy groups remaining to be established experimentally.  
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S-stereochemistry of all hydroxy groups was postulated based only on the known 
activity of 15-sLOX-1 as an S-dioxygenase.  
Docosahexaenoic acid 
Similar to 15-sLOX-1 metabolism of EPA, the mono-dioxygenation of DHA was first 
observed by Takagi and co-workers, however the product was not characterised 
chemically [171].  It was also observed in this study that DHA may undergo further 
oxidation to produce conjugated triene product(s).  The major mono-dioxygenation 
product was later identified as 17-hydroxy-DHA (17-HDHA; detected as the saturated, 
keto-ester derivative – methyl 17-keto-docosanate) [154] and the complete structure 
elucidated as (4Z,7Z,10Z,13Z,15E,19Z)-17S-HDHA [17, 70, 120, 122-124, 160, 179, 
187].  Again, high initial substrate concentrations (1.52 mM) appear to inhibit the 
second dioxygenation of DHA, generating 17S-HDHA as the single major product 
[179].  Unlike linoleic acid and arachidonic acid substrates, where isomers of the major 
mono-hydro(pero)xy product have been routinely reported (i.e. 13S-HPODE and 9S-
HPODE), only a single mono-hydro(pero)xy product of DHA (and EPA) has been 
observed from 15-sLOX-1 catalysis.  The increased specificity of 15-sLOX-1 with 
DHA and EPA substrates therefore may be due to the decreased saturation and/or the 
presence of the omega-3 double bond.  Desaturation decreases structural flexibility of 
LC-PUFAs as free rotation through the pi bond is restricted, therefore more rigid 
binding of highly unsaturated substrates may be expected in the active site potentially 
increasing the specificity of oxygen insertion. 
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Soybean 15-LOX-1 catalyses the production of two major di-hydro(pero)xylated 
compounds from the (4Z,7Z,10Z,13Z,15E,19Z)-17S-HDHA intermediate – 
(4Z,8E,10Z,13Z,15E,19Z)-7,17S-diHDHA and (4Z,7Z,11E,13Z,15E,19Z)-10S,17S-
diHDHA [120-124, 126, 160, 187].  As observed with EPA and arachidonic acid 
substrates, the second dioxygenation of DHA is less regio-specific (occurring at n-13 
and n-16 positions), but the S-stereospecificity of 15-sLOX-1 is proposed to be 
maintained in both cases.  The chirality of the C-10 hydroxy group was established as 
S- based on co-elution of the compound with 10S,17S-diHDHA (produced from 15-
sLOX-1 metabolism of both 10S-HDHA and 17S-HDHA substrates) [160].  In 
addition, Chen and co-workers were able to produce (4Z,7Z,11E,13Z,15E,19Z)-
10R,17S-diHDHA from 10R-HDHA substrate [188].  The chirality of the C-7 hydroxy 
group (of 7,17S-diHDHA) has not yet been determined, however has been proposed 
to be 7S- based on the known activity of 15-sLOX-1.   
Butovich [120] established the formation of 10,17S-diHDHA by soybean 15-LOX-1 
occurs via a double dioxygenation mechanism, rather than an epoxidation-
isomerisation mechanism as previously proposed.  In this study 17S-hydroxy-DHA 
was converted to 10,17S-diHDHA by 15-sLOX-1, eliminating the possibility of an 
epoxidation reaction (due to the requirement of a hydroperoxide for this mechanism) 
[120].  In addition the resulting E,Z,E conjugated triene was indicative of a double 
dioxygenation reaction, whereas epoxidation of the hydroperoxide would result in 
E,E,Z geometry (as observed in leukotriene and protectin biosynthesis).  Chen and co-
workers also showed that this compound is a result of double dioxygenation by 
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analysing incorporation of 18O2 at both C10 and C17 positions of DHA by mass 
spectrometry [160].   
It is important to note the differences, both in structure and the mechanism of 
biosynthesis, between (4Z,7Z,11E,13E,15Z,19Z)-10R,17S-diHDHA (NPD1) produced 
in vivo by mammalian 15-LOX from DHA, and (4Z,7Z,11E,13Z,15E,19Z)-10S,17S-
diHDHA (PDX) produced by incubation of DHA with 15-sLOX-1.  Importantly, the 
stereochemistry of the conjugated double bonds and hydroxy groups (as indicated) 
which are introduced either by a combined dioxygenation/epoxidation mechanism (as 
for mammalian 15-LOX) or double dioxygenation mechanism (as for 15-sLOX-1). 
Several publications have incorrectly reported the production and evaluation of NPD1 
from DHA by 15-sLOX-1 (reviewed in [189]), where in fact the synthesised 
compound was actually the PDX analogue. 
Docosapentaenoic acid (n-3 and n-6) 
Both omega-3 and omega-6 forms of DPA are suitable substrates for 15-sLOX-1 
metabolism, generating products analogous to DHA.  The major mono-hydroxy 
compound from DPAn-3 has been identified as (7Z,10Z,13Z,15E,19Z)-17S-HDPAn-3  
and (4Z,7Z,10Z,13Z,15E)-17S-HDPAn-6 from DPAn-6 [124, 126, 187, 190].  Dangi 
et al. were the first group to report the formation of di-hydroxylated compounds from 
DPA (n-3 and n-6), however only (4Z,7Z,11E,13Z,15E)-10,17S-diHDPA from DPAn-
6 was fully characterised for hydroxy group location, double bond geometry and the 
chirality of the C-17 hydroxy group [124].  The remaining compounds were identified 
in this study and subsequent studies by other research groups as 
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(8E,10Z,13Z,15E,19Z)-7,17-diHDPAn-3 [124, 126], 7,17-diHDPAn-6 [124], 10,17-
diHDPAn-3 [124], and (4Z,7Z,11E,13Z,15E)-10,17-diHDPAn-6 [124, 126, 187].  For 
each of these compounds the stereochemistry of the hydroxy groups remains to be 
experimentally demonstrated.  
Other LC-PUFA 
In addition to the metabolism of the LC-PUFA substrates described above, 15-sLOX-
1 has also been utilised for the dioxygenation of a range of atypical substrates.  Studies 
of these substrates have contributed to the elucidation of 15-sLOX-1 metabolic 
pathways as well as the production and characterisation of potentially useful 
compounds.  Atypical substrates and their respective products are summarised in Table 
2.2, and include monounsaturated fatty acids, cis,trans isomers, and phospholipids 
(PL). 
Of interest is the reaction of LC-PUFA (LA and ARA) esterified in the sn-2 position 
of phosphatidylcholine (PC) and phosphatidylethanolamine (PE) (with either palmitic 
acid or stearic acid in the sn-1 position) [147, 174].  The products of these reactions 
were subjected to transesterification to enable characterisation.  The typical 15-sLOX-
1 product of linoleic acid, (9Z,11E)-13S-hydroxy-ODE, was obtained from 1-
palmitoyl-2-linoleoyl-phosphatidylcholine, while (5Z,8Z,11Z,13E)-15S-hydroxy-ETE 
was also obtained from all phospholipid forms of arachidonic acid (PE/PC and 
stearoyl/palmitoyl) [174].  Due to the energy and spatial requirements associated with 
burying a polar phosphate head group within the small, hydrophobic catalytic pocket, 
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carboxylate-first orientation of binding is unlikely to occur.  Therefore the production 
of these compounds is attributed to a methyl-end first orientation. 
Similar studies have been performed with free arachidonic acid and linoleic acid 
incorporated into phosphatidylcholine-deoxycholate mixed (PDM) micelles where 15-
sLOX-1 exhibited ‘5-LOX’ activity [175].  In these experiments the hydrophobic tail 
of fatty acid substrates exhibited high affinity for the hydrophobic region of the 
micelles, resulting in the more polar carboxylic acids being exposed to the reaction 
medium.  Major products were characterised as 9-hydroperoxy-ODE and 5-
hydroperoxy-ETE from linoleic acid and arachidonic acid, respectively [175].  Similar 
reaction rates and catalytic turnover numbers were achieved utilising PDM-fatty acid 
substrates compared to fatty acids prepared in Tween-20 surfactant (23 μM), although 
incorporation of substrates into micelles reduced the optimum pH of the reaction from 
pH 9.0 to 7.4 [175].   
Although 15-sLOX-1 has been thoroughly established to require a 1Z,4Z-pentadiene 
moiety for catalysis, Clapp and co-workers have reported the oxygenation of 
monounsaturated substrates (9Z)-octadecenoic acid (oleic acid; 9Z-ODE) and (12Z)-
octadecenoic acid (12Z-ODE) to α,β-unsaturated ketones [191-192].  The major 
products were found to be (9Z)-11-oxo-octadecenoic acid and (12Z)-11-oxo-
octadecenoic acid from 9Z-ODE and 12Z-ODE, respectively.  Positional specificity of 
the initial hydrogen abstraction is conserved at C-11, indicating placement of the 
substrate within the active site is the same as with linoleic acid.  Preparative 
incubations were also performed under high oxygen pressure, highlighting the 
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usefulness of hyperbaric conditions with poor LOX substrates.  This study provides 
further support for the carbon-centred pentadienyl radical mechanism, rather than an 
organo-iron intermediate mechanism, as both double bonds (9Z and 12Z) appear to 
equally contribute to the C‒H bond-breaking step.  For the organo-iron intermediate 
mechanism the C12-13 bond is essential, therefore one substrate would be oxygenated 
more readily than the other [191].  However in this study both substrates were 
oxygenated at approximately equal rates, indicating both double bonds contribute 
equally to the C‒H abstraction step.   
Another interesting application to atypical substrates is the reaction of cis,trans 
isomers of linoleic acid with 15-sLOX-1 [149].  In this study the authors observed the 
thermodynamically unfavourable rearrangement of double bonds when (9E,12Z)-
linoleic acid was utilised as substrate.  The major product of this reaction was 
(9Z,11E)-13S-hydroperoxy-ODE, rather than the expected 9E,11E- isomer.  The 
authors propose the energy required for this unfavourable isomerisat ion is either 
provided or decreased by the enzyme itself.  In addition the reaction of (9Z,12E)-
linoleic acid produced (9Z,11E)-13R-hydroperoxy-ODE as the major product, 
demonstrating a useful and simple method for the production of the R-enantiomer. 
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2.7 Dependence of regiospecificity and stereospecificity on experimental 
conditions 
The dioxygenase activity of 15-sLOX-1 has significant dependence on the pH of the 
reaction medium, due to both the catalytic range of the enzyme itself (based on amino 
acid interactions and protein folding) as well as the ionic nature of the carboxylic acid 
substrate (i.e. protonated or deprotonated).  In the studies discussed below, changes to 
the pH of the reaction have been shown to affect both the regio-specificity of the 
reaction, as well as the occurrence of sequential dioxygenation reactions.   
Christopher and co-workers found that decreasing the pH of the reaction from pH 9 to 
pH 7 resulted in a 25% reduction in regio-specificity of 15-sLOX-1 with linoleic acid 
substrate (1.8 mM) [110].  Similar results were also obtained by Funk et al. [114, 149] 
and Van Os et al. [115] using 1 mM linoleic acid.  In each of these studies the substrate 
was solubilised in either a Tween-20 surfactant solution (7 × 10-3 % v/v) or ethanol 
(final concentration 5.3 % v/v).  Therefore interactions between the fatty acid substrate 
and surfactant at differing pH values may play a role in affecting the favoured 
orientation of the substrate in the active site.  Orientation in the active site has also 
been found to be dependent on the ionisation state of the carboxylic acid, with lower 
buffer pH resulting in the protonation of the acid to produce a neutral substrate [113].  
The non-ionised form may then be able to enter the hydrophobic active site carboxylic 
acid end first (to generate 9-HPODE from linoleic acid at pH 6) [113, 147].  
With longer chain and more highly unsaturated substrate, which may undergo 
sequential dioxygenation reactions, the pH of the buffer has been found to play a 
significant role in either favouring or inhibiting the dioxygenation of 17S-
hydroperoxy-DHA through protonation or deprotonation of the carboxylic acid moiety 
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[126].  The presence of the ionised carboxylate group at higher pH (~12) is proposed 
to prevent entry of the fatty acid to the enzyme active site in the carboxylic acid first 
orientation, potentially due to the hydrophobic nature of the catalytic pocket and the 
associated energy requirements for entry to occur [113, 119, 147-148, 169, 193].  
Therefore the major product of the reaction with ARA, EPA, DHA and DPA when 
performed at higher pH was the mono-hydro(pero)xy fatty acid (i.e. 
(4Z,7Z,10Z,13Z,15E,19Z)-17S-HDHA from DHA) as the substrate can only enter the 
active site methyl end first.  Conversely, at the pH optimum of the enzyme (pH 9; 
closer to the pKa of the substrate) the second dioxygenation may occur with the 
carboxylic acid end bound within the active site.  Dioxygenation of mono-hydroperoxy 
substrates in this orientation produces the di-hydro(pero)xylated compounds as the 
only products (i.e. 4Z,8E,10Z,13Z,15E,19Z-7,17S-diH(P)DHA and 
4Z,7Z,11E,13Z,15E,19Z-10,17S-H(P)DHA from DHA).   
While the effect of reaction pH can be explained by the ionisation state of the substrate, 
Berry and co-workers [127] have shown oxygen concentration can affect the regio-
specificity of 15-sLOX-1 through the analysis of kinetic parameters.  This study was 
performed using linoleic acid substrate and monitored the proportion of 13-HPODE 
and 9-HPODE synthesised under varying oxygen concentrations.  At low oxygen 
concentrations (< 5 μM), achieved by N2-purging or the addition of sorbitol (2 M), the 
ratio of 13-:9- HPODE was found to reduce from the prototypical 95:5 ratio to 
approximately 55:45.  A similar, albeit less profound effect was observed with higher 
initial oxygen concentrations (~ 225 μM) where the ratio was found to be 89:11 at the 
end of the oxygen consumption phase.  In comparison, under normal oxygen 
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conditions (~ 1.1 mM) the observed ratio of 13:9 is 95:5.  The release of free carbon-
centred radicals from the active site was indicated under conditions of low oxygen 
concentration using EPR spectroscopy, and has also been implicated in other studies 
[133-134, 194-196].  These radicals are then free to react with residual dissolved 
oxygen (from headspace dissolution) in an unspecific manner to generate both regio-
isomers [127].  Although the evidence supports the release of substrate radicals and 
the subsequent non-specific incorporation of oxygen, the stereochemistry of the 
resulting hydroperoxides were not described in this study.  Experimental data on the 
proportion of R and S enantiomers of each hydroperoxide would enable the authors to 
further support the mechanism presented in this study. 
2.8 Anaerobic reaction of 15-sLOX and production of carbonyl compounds 
The formation of conjugated oxo-diene compounds and fatty acid dimers have been 
reported in a small number of publications, when 15-sLOX-1 incubations are 
performed under anaerobic conditions.  The products are proposed to be the result of 
the lesser known hydroperoxidase activity of 15-sLOX-1, according to the 
mechanisms provided by Garssen and De Groot (summarised in Fig. 2.13) [140, 170, 
197]. 
 
Figure 2.13 Postulated lipohydroperoxidase mechanism using linoleic acid substrate. L, lipid 
substrate. 
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The formation of alkoxyl radicals from linoleic acid by soybean lipoxygenase 
(multiple isoforms) has been implicated indirectly in several studies, through 
measurement of hyperfine structures by EPR. Due to the extremely fast fragmentation 
of alkoxyl radicals (>106 s-1) [198-199], direct measurement of alkoxyl radicals by 
EPR is not possible.  However the carbon-centred pentyl and 2-pentenyl radicals (from 
linoleic and linolenic acid, respectively) resulting from β-scission of the alkoxyl 
radical have been detected [198-199], supporting the mechanism of degradation 
proposed by de Groot et al. [140].   
The hydroperoxidase activity of 15-sLOX-1, induced under anaerobic or hypoxic 
conditions, has been thoroughly investigated with linoleic acid as substrate and major 
products are summarised below (Table 2.3).  The formation of the oxygen containing 
products has been shown to proceed through one of two pathways, both stemming 
from the formation of an alkoxyl radical by the proposed cleavage of the 
hydroperoxide (13S-hydroperoxy-LA; produced under aerobic conditions) by the 
ferrous form of 15-sLOX-1 [170, 172, 197].  The first pathway generates a conjugated 
aldehyde product, 13-oxo-tridecadi-(9Z,11E)-enoic acid, through β-scission of the 
alkoxyl radical [197].  This simultaneously generates a hydrocarbon fragment (n-
pentane in the case of LA) which can be collected using cold-trapping techniques and 
analysed by gas chromatography [197, 200].  This pathway appears to be favoured 
under strictly anaerobic conditions [201].  The second pathway involves 
intramolecular rearrangement of the alkoxyl radical to produce a ketone derivative, 
13-oxo-octadecadi-(9Z,11E)-enoic acid (13-oxo-ODE), or a hydroxy-epoxy 
compound through the formation of an epoxy radical species [172, 201-202]. 
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The production of fatty acid dimers from linoleic acid has also been reported under 
anaerobic conditions [170, 197, 201].  Non-oxygenated dimers have been identified 
by GC-MS, establishing major isomers with branch points at C11-C13 and C13-C13, 
and minor isomers with C9-C11 and C9-C13 branch points [170, 201].  The formation 
of carbon-centred linoleic acid radicals is implicated in order to reduce the non-heme 
Fe(III) to Fe(II) (as shown in Fig. 2.13).  In the absence of molecular oxygen, these 
radicals are released from the enzyme and are available for non-specific recombination 
to form dimeric compounds.  Epoxy-containing dimers have also been reported and 
are proposed to be products of recombination of the epoxy radical species (from the 
alkoxyl radical) with carbon-centred linoleic acid radicals [170, 197]. 
Table 2.3 Summary of products derived from 13-HPODE catalysed by 15-sLOX-1 under anaerobic 
conditions. 
Product Comments Reference 
(9Z,11E)-13-oxo-octadecadienoic acid ~ 40% of total oxodiene [197] 
[170, 197, 
201-203] 
(9Z,11E)-13-oxo-tridecadienoic acid ~ 60% of total oxodiene [197] 
[170, 197, 
201-203] 
Two major dimeric fatty acids – linked at 
C11-C13 & C13-C13 
Two minor dimeric fatty acids – 
linked at C11-C9 & C13-C9 
[170, 201] 
Two proposed trans-epoxy dimers Incomplete characterisation data [170] 
Threo-11-hydroxy-trans-12,13-epoxy-9Z-
octadecenoic acid 
 
[172, 201-
202] 
Pentane 
~ 66 nmol pentane produced per 
200 μM LA incubated with 40 nkat 
15-sLOX-1 
[197-198, 
200-201] 
9-keto-11,13-octadecadienoate Produced from ethyl linoleate [204] 
13-keto-9,11-octadecadienoate Produced from ethyl linoleate [204] 
 
The production of trihydroxy-octadecenoic acids, hydroperoxy-dihydroxy-
octadecenoic acids, hydroxy-epoxy-octadecenoic acids, dihydroxy-octadecenoic acids 
and oxo-octadecadienoic acids have also been shown from the incubation of linoleic 
  
 
56 
 
acid hydroperoxide with 15-sLOX-1 in the presence of a non-lipid hydrogen donor 
(guaiacol) [202].  This study established the requirement of the ferrous form of 15-
sLOX-1 for lipohydroperoxidase activity, as the presence of a hydrogen donor (usually 
fatty acid substrate) enables the reduction of the catalytic iron from Fe3+ to Fe2+ 
through hydrogen abstraction.  In addition, this publication by Streckert et al. [202] 
describes a method for the large-scale synthesis of such products, highlighting the 
importance of avoiding enzyme substrate inhibition by adding substrate in portions 
over an extended period of time.  A similar method was also utilised by Garssen et al. 
[172] for the formation of threo-11-hydroxy-trans-12,13-epoxy-9Z-octadecenoic acid 
from 13-HPODE.   
The majority of the research undertaken on this topic has utilised linoleic acid as 
substrate.  To date, one publication has very briefly reported the detection of analogous 
products from ARA and GLA, however characterisation data of the products was not 
provided [197].  Similar products have been observed from the anaerobic metabolism 
of (9Z,11E,15Z)-13-hydroperoxy-octadecatrienoic acid (13-HPOTrE) from ALA 
[205-207].  The major product of this reaction is the β-scission product, 13-oxo-
tridecadienoic acid (26 mol%).  Several isomeric pentenols, pentene dimers and 2E-
hexenal were also detected and characterised [205].  In this study the purification of 
the LOX isozymes from soybean seeds established the observed C5-cleaving activity 
was due to lipoxygenase, rather than an authentic hydroperoxide lyase enzyme as 
previously proposed [205, 207].   
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2.9 Conclusion 
An extensive review of soybean lipoxygenase, and specifically 15-sLOX-1 catalysis, 
has been presented in this chapter.  The production of a large range of products derived 
from LC-PUFA using 15-sLOX-1 is highlighted, demonstrating the potential of this 
enzyme for the formation of hydro(pero)xy-fatty acids and specialised pro-resolving 
mediator analogues.  Investigation of experimental parameters (such as reaction pH, 
LC-PUFA and oxygen concentration) show the ability to modify the catalytic activity 
of 15-sLOX-1 to generate new reaction products, and also to develop methods for the 
large-scale preparation of compounds. 
For a broader review of lipoxygenase catalysis and products, including those from 
plant, animal, fungal and bacterial LOX, the reader is referred to appendix A.  This 
table summarises the production of hydroperoxides from a range of LC-PUFA, 
experimental data for the production of such compounds, characterised products and 
other relevant information. 
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3. SOLVENT-INDUCED 7R-DIOXYGENASE ACTIVITY OF 
SOYBEAN 15-LIPOXYGENASE-1 IN THE FORMATION 
OF OMEGA-3 DPA-DERIVED RESOLVIN ANALOGS 
3.1 Introduction  
Many naturally occurring resolvins and protectins from inflammatory exudates have 
been identified which have contributed to the elucidation of important anti-
inflammatory and pro-resolution pathways [9, 12].  This gain in understanding has also 
directed the novel therapeutic approaches for the treatment of chronic inflammation 
through the production of specialised pro-resolution mediator (SPM) analogs which 
possess similar bioactivity to naturally-produced compounds.  The family of resolvins 
and protectins, terms coined by Serhan and co-workers [17, 70], have become 
pharmaceutical targets for the treatment of several chronic conditions [13-14], 
including lipoxin analogs for the treatment of asthma [15] and resolvin analogs in the 
treatment of dry eye [13].  A current limitation for the pharmaceutical development of 
SPM analogs is the requirement to introduce specific regio- and stereo-chemistry of 
double bonds (cis/trans) and hydroxy groups (R/S) to produce stereochemically pure 
and biologically active structures.  This is commonly achieved through organic 
synthesis protocols, which are often lengthy, complex and employ the use of harsh and 
toxic solvents, reagents and catalysts [22, 23, 25]. 
In biological systems, peroxidase enzymes such as cyclooxygenase (EC 1.14.99.1) and 
lipoxygenase (EC 1.13.11) isoforms have been established as important biocatalysts 
of both pro- and anti-inflammatory mediators including leukotrienes, lipoxins, 
resolvins, protectins, and maresins. LC-PUFAs containing multiple 1Z,4Z-pentadiene 
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structures are suitable substrates for metabolism by lipoxygenase enzymes.  These 
enzymes catalyse the selective insertion of molecular oxygen in a highly stereo- and 
regio-specific manner to generate mono-, di- and tri-hydro(pero)xylated products, 
making the use of enzymes an attractive alternative to organic synthesis methods in 
the synthesis of SPM analogs.  The stereospecificity of soybean 15-lipoxygenase-1 
(15-sLOX-1) has been well established since its initial application to LC-PUFAs in 
1967 [154], with the enzyme known to synthesise S-chirality hydro(pero)xy groups in 
aqueous buffered systems.  This enantiopreference is due to the stereo- and regio-
specific nature of the initial hydrogen abstraction, the substrate position within the 
active site, and the availability and subsequent antarafacial incorporation of oxygen 
[113-114, 119, 147, 151, 154].   
Whilst the high stereospecificity of many enzymes is what makes them useful as 
biocatalysts, it can also limit their applicability as the desired stereochemistry may not 
always be achievable [36].  Therefore methods to improve and/or change the 
stereospecificity of enzymes are of significant interest.  The addition of water-miscible 
co-solvents to enzymatic reactions was originally used to increase the solubility of 
hydrophobic substrates in aqueous reaction media, however, it was soon found that 
these co-solvents could also affect various aspects of the reaction, including 
stereospecificity [35].  The manipulation of enzyme properties through changing the 
nature of the solvent has been termed ‘medium engineering’ [26, 34-35].  There are 
many reports of changing, and even inverting, enzyme enantioselectivity by modifying 
the reaction medium. For example, Kalkote and co-workers studied the 
desymmetrization of meso-cyclopent-2-en-1,4-diacetate to 4-(R)-hydroxycyclopent-2-
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en-1-(S)-acetate, catalysed by a hydrolase enzyme from Trichosporin beigelii, and 
found that the addition of 10% v/v ethanol enhanced the enantioselectivity of the 
enzyme from 29.1% optical purity (88% yield) to 82.6% optical purity (83% yield) 
[208].  In examining the biocatalytic properties of three Bayer-Villiger 
monooxygenase in aqueous-organic media with organic sulphide substrates, de 
Gonzalo et al. [209] found that organic co-solvents generally decreased the enzyme 
activity, but in some cases, significant improvements in enantioselectivity were 
induced by short chain alcohols, and in a small number of cases, methanol was able to 
cause a reversal of enantiopreference.   
The dioxygenation reactions of biologically relevant PUFAs by commercially 
available 15-sLOX-1 are well characterised in the literature, in particular with 
arachidonic acid (ARA; C20:4 n-6), docosahexaenoic acid (DHA; C22:6 n-3) and 
eicosapentaenoic acid (EPA; C20:5 n-3) substrates [113, 119-128].  However, 
considerably less is known concerning other LC-PUFAs which exist in lower 
concentrations in biological systems, yet remain significant as potential substrates for 
15-sLOX-1.  Among these, omega-3 and omega-6 docosapentaenoic acid (DPA; 
C22:5) (Fig. 3.1) are emerging as interesting potential precursors to resolvin and 
protectin analogs [124, 187], due to their structural similarity to DHA and the presence 
of multiple 1Z,4Z-pentadiene moieties for lipoxygenase catalysis.  DPAn-3 is an 
important dietary omega-3 and a major LC-PUFA present in red meat, with 
Australians consuming similar amounts of EPA and DPAn-3 in their diets [210].  Both 
DPAn-3 and DPAn-6 have themselves been found to possess anti-inflammatory 
activity, including inhibition of angiogenesis [211] and reduction of pro-inflammatory 
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cytokines [212].  To date, there have been few studies focusing on the biosynthesis of 
DPAn-3 resolvin analogs from either purified enzymes [124] or isolated 
cell/inflammatory exudates [190]. 
 
Figure 3.1. DPAn-6 (top) and n-3 (bottom) chemical structures. 
Recently, the products from the double dioxygenation of LC-PUFAs, including DPAn-
3 and DPAn-6, using 15-sLOX-1 have been characterised [126].  In the current work 
we further expand on the synthesis of DPAn-3-derived resolvin analogs using 15-
sLOX-1 as a biocatalyst, demonstrating the ability to affect stereochemistry of 
products through relatively subtle changes in environmental conditions, offering an 
attractive alternative to total organic synthesis in the production of SPM analogs.  
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3.2 Materials and Methods 
3.2.1 Materials 
Soybean 15-lipoxygenase-1 (EC 1.13.11.33, P1, 15.3 Munits/ml, 27.73 mg of 
protein/ml, 0.552 Munits/mg of protein) was purchased from Cayman Chemical (Ann 
Arbor, MI).  All fatty acids (DHA, EPA, ARA, DPAn-3, DPAn-6 and DTAn-6) were 
purchased from Nu-Chek Prep (Elysian, MN).  Supelclean LC-18 SPE cartridges (500 
mg, Supelco Analytical) were purchased from Sigma Aldrich (Castle Hill, NSW, 
Australia).  All Agilent instruments were purchased from Agilent Technologies 
(Mulgrave, VIC, Australia). 
3.2.2 Lipoxygenase-catalysed reaction – general protocol 
LC-PUFA substrates were prepared at a final concentration of 0.08 mM in sodium 
tetraborate buffer (50 mM, pH 9.0) containing the desired concentration of n-alcohol.  
The reaction was initiated by the addition of 15-sLOX-1 (15-150 kunits/ml substrate 
solution) and allowed to proceed for 15 min with gentle stirring at room temperature.  
The resulting hydroperoxides were reduced with 200 μl 1 M sodium borohydride and 
stirred for 15 min.  The solution was then acidified with concentrated acetic acid 
(50 μl), added drop-wise with gentle stirring until foaming ceased. 
For small scale reactions (< 50 ml) products were extracted by SPE under reduced 
pressure (C18, 500 mg bed volume, 3-6 ml cartridge volume).  Cartridges were 
conditioned according to manufacturer’s instructions (1 volume of methanol followed 
by 1 volume of deionised water), the samples were loaded and the bed washed with 1 
additional volume of deionised water.  The bed was dried under vacuum and the 
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products eluted with 1 volume of ethanol.  For preparative-scale reactions (> 100 ml) 
products were recovered by solvent extraction.  Briefly, reaction products were 
extracted with 2 consecutive volumes of chloroform, the organic layers recovered and 
combined.  The solvent was dried with anhydrous sodium sulphate and evaporated 
under reduced pressure. 
3.2.3 Reaction Optimisation  
Substrate concentration 
DPAn-3 concentration was analysed over the range of 0.04 – 0.10 mM.  Substrate was 
prepared as a 10 mM stock solution in ethanol.  Final ethanol concentration was 
maintained at 10 % (v/v).  Reactions were performed as above using 75 kunits 
15-sLOX-1/ml substrate solution. 
Ethanol concentration 
Final ethanol concentration was optimised over the range of 0 – 40% (v/v), with 
constant DPAn-3 concentration (0.08 mM) and 15-sLOX-1 (75 kunits/ml). Substrate 
was prepared as a 10 mM solution in ethanol. 
15-sLOX-1 concentration 
15-sLOX-1 concentration was optimised over the range of 15 – 150 kunits/ml substrate 
solution with constant ethanol (10% v/v) and substrate (0.08 mM) concentration.  
Substrate was prepared as a 10 mM solution in ethanol. 
Alcohol chain length 
Short chain n-alcohols – methanol, ethanol, propan-1-ol, butan-1-ol and pentan-1-ol, 
were incubated with DPAn-3 and 15-sLOX-1 under the optimised conditions (10% v/v 
  
 
65 
 
n-alcohol, 0.08 mM DPAn-3, 45 kunits 15-sLOX-1/ml).  Reactions were performed in 
closed containers to minimise evaporation of volatile solvents and mixtures were 
rigorously stirred to limit the formation of biphasic systems in the case of longer chain 
n-alcohols.  Products were recovered using solvent extraction as described instead of 
SPE due to the greater eluting strength of longer chain n-alcohols. 
3.2.4 Analytical methods 
NP-HPLC analysis 
HPLC analysis was performed using an Agilent 1200 Series HPLC system in normal 
phase mode, equipped with a thermostated column compartment, diode array detector 
and automated fraction collector.  Analytical separations were carried out using a 
Supelcosil LC-Diol column (Supelco, 25 cm × 3 mm, 5 μm;  Sigma Aldrich) with an 
isocratic mobile phase of 95% n-heptane/acetic acid/2,2-dimethoxypropane 
(100:0.1:0.1 v/v) and 5% isopropanol.  Extraction solvent was evaporated under a 
stream of N2 and samples were prepared in mobile phase.  Injection volume was 15 μl.  
The flow rate was 0.5 ml/min and the column temperature was 10°C.  Elution of 
products was monitored at 210 nm, 234 nm, 250 nm and 270 nm. 
For semi-preparative separations, products were methylated prior to analysis using 0.5 
ml methanol and 0.5 ml (trimethylsilyl)-diazomethane (2 M in diethyl ether) for 1 h at 
room temperature.  The methylation reagents were then evaporated under nitrogen and 
the products re-dissolved in mobile phase.  Separations were performed using a 
LiChrospher silica column (Merck, 12.5 cm × 4 mm, 5 μm) with an isocratic mobile 
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phase of 98% n-heptane and 2% isopropanol.  The injection volume was 50 μl, flow 
rate was 1 ml/min and the column temperature was 30°C. 
Chiral-phase HPLC analysis 
Chiral phase analysis was performed on an Agilent 1260 Infinity HPLC system 
equipped with a diode array detector.  Products were methylated prior to analysis as 
described above.  Separations were performed on a Chiralpak AD-H column (25 cm × 
0.46 cm, 5 μm; Daicel) with an isocratic mobile phase of n-hexane and ethanol (1-10% 
v/v) at ambient temperature [213].  The flow rate was 1 ml/min and injection volume 
was 20 μl. 
GC-MS analysis 
Products (~ 1 mg) were subjected to full catalytic hydrogenation over Pt(IV)O2 catalyst 
(10 mg) in 2 ml ethanol for 25 min with a constant stream of hydrogen and stirring.  
The solution was filtered (0.45 μm nylon filter) and the solvent evaporated under 
nitrogen.  Products were then trimethylsilylated using BSTFA (200 μl) and pyridine 
(200 μl) at 100°C for 1 h.  GC-MS analysis was performed on an Agilent 6890N gas 
chromatograph with a 5975 mass selective detector (electron impact ionization).  
Separations were performed on a BPX5 column (10 m × 0.1 mm, 0.1 μm film 
thickness, SGE) with helium carrier gas (0.2 ml/min).   The inlet was maintained at 
250°C with a split ratio of 20:1, and injection volume was 1.5 μl.  The oven 
temperature program was as follows: 150°C for 2 min, increased at 8°C/min to 300°C, 
and held at 300°C for 6 min.  The conditions of the mass selective detector were as 
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follows: electron voltage, -70 eV; MS quad, 150°C; MS source, 230°C; solvent delay, 
3.00 min; scan range, 35.0 – 600.0 amu. 
UV-visible spectrophotometry  
Absorption spectra of products were collected in ethanol using a Cary Series 300 UV-
visible spectrophotometer (Agilent Technologies) with a 1.0 mm path length quartz 
cuvette.  Spectra were collected from 200 - 350 nm in double beam mode with a 
bandwidth of 1 nm and a scan rate of 0.5 nm/s.   
NMR spectroscopy 
1D 1H-NMR and 2D 1H, 1H-COSY NMR experiments were performed on an Avance 
500 MHz FT-NMR spectrometer (Bruker).  Purified products were dissolved in 40 μl 
of deuterated methanol and transferred to an internal capillary within a standard bore 
NMR tube.  64 scans were accumulated and all chemical shifts were measured using 
residual CH3OH peaks as reference (3.31 ppm). 
Time-of-flight-MS (electrospray ionisation) 
Injections were performed using an Agilent 1200 series HPLC system, equipped with 
a binary pump and autosampler.  Mass spectra were collected using an Agilent 6210 
MSD time-of flight (TOF) mass spectrometer operating in positive ionization mode 
(ESI).  Analysis conditions were as follows: drying gas, nitrogen (7 L/min, 350°C); 
nebulizer gas, nitrogen (16 psi); capillary voltage, 4.0 kV; vaporizer temperature, 
350°C; and cone voltage, 60 V.  Data analysis was performed using Agilent 
MassHunter Qualitative Analysis software (version B.03.1). 
Attenuated total reflectance-FTIR spectroscopy of DPAn-3 derived products 
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FTIR spectra were collected using an ALPHA-FTIR spectrophotometer equipped with 
a diamond attenuated total reflection (ATR) sampling accessory (Bruker).  The 
operating parameters were as follows: scanning range, 850 – 4000 cm-1; scans, 124.  
Products were dissolved in hexane, applied to the crystal surface and the solvent 
allowed to evaporate.  Data analysis was performed using Opus software. 
Compound Characterisation 
7S,17S-dihydroxydocosa-8E,10Z,13Z,15E,19Z-pentaenoic acid methyl ester (II); UV-
vis (heptane solvent): 224, 243 nm.  FT-IR (hexane solvent): ߥ෤ (cm-1) = 3012, 2956, 
2925, 2855, 1734, 1645, 1460.  1H NMR (500 MHz, CD3OD): δ (ppm) 6.55 (m, 2H, 
C9,15), 6.00 (t, 1H, C10/C14, J = 10.9 Hz), 5.99 (t, 1H, C10/C14, J = 10.9 Hz) 5.68 (dd, 
1H, C8/C16, J = 15.1 Hz), 5.66 (dd, 1H, C8/C16, J = 15.2 Hz),  5.49-5.44 (m, 1H, C20), 
5.39-5.35 (m, 3H, C11,13,19), 4.12 (dt, 1H, C7/C17, J7,8/16,17  = 6.8 Hz), 4.09 (dt, 1H, 
C7/C17, J7,8/16,17 = 6.6 Hz), 3.09 (t, 2H, C12, J = 7.5 Hz), 2.34-2.30 (m, 4H, C2,18), 2.09-
2.04 (m, 2H, C21), 1.61 (quin, 2H, C3, J = 7.3 Hz), 1.53-1.49 (m, 2H, C6), 1.34-1.33 
(m, 4H, C4,5), 0.95 (t, 3H, C22, J21,22 = 7.6 Hz).  ESI-TOF m/z: [M+Na]+ Calcd for 
C22H34O4Na 385.23493; Found 385.22452.  EI-MS (fully hydrogenated, trimethylsilyl 
derivative): m/z 573 [M − CH3]+, 517 [M − C5H11]+, 402 [M − C9H19O2Si]+, 289 [M − 
C18H39OSi]+, 173 [M − C22H47O3Si2]+. 
7R,17S-dihydroxydocosa-8E,10Z,13Z,15E,19Z-pentaenoic acid methyl ester (III); 
UV-vis (heptane solvent): 244, 227 nm.  FT-IR (hexane solvent): ߥ෤ = 3012, 2956, 
2924, 2854, 1742, 1641, 1461 cm-1.  1H NMR (500 MHz, CD3OD): δ (ppm) 6.58 (dd, 
1H, C9, J8,9 = 14.9 Hz), 6.56 (dd, 1H, C15, J15,16 = 14.3 Hz), 6.02 (t, 1H, C10, J = 10.9 
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Hz), 5.99 (t, 1H, C14, J = 10.8 Hz), 5.68 (dd, 1H, C16, J = 15.4 Hz), 5.62 (dd, 1H, C8, 
J = 15.3 Hz), 5.49-5.33 (m, 4H, C11,13,19,20), 4.31 (dt, 1H, C7, J7,8 = 7.3 Hz, broad), 4.14 
(dt, 1H, C17, J16,17 = 6.4 Hz, broad), 3.10 (t, 2H, C12,  J = 7.5 Hz), 2.34-2.29 (m, 4H, 
C2,18), 2.08-2.03 (m, 2H, C21), 1.61 (quin, 2H, C3, J = 7.2 Hz), 1.49-1.44 (m, 2H, C6), 
1.39-1.36 (m, 4H, C4,5), 0.96 (t, 3H, C22, J21,22 = 7.5 Hz).  ESI-TOF m/z: [M+Na]+ 
Calcd for C22H34O4Na 385.23493; Found 385.23326.  EI-MS (fully hydrogenated, 
trimethylsilyl derivative): m/z 573 [M − CH3]+, 517 [M − C5H11]+, 402 [M − 
C9H19O2Si]+, 289 [M – C18H39OSi]+, 173 [M − C22H47O3Si2]+. 
Circular dichroism spectroscopy of 15-sLOX-1 and prediction of secondary structure 
The far-UV circular dichrosim spectra of 15-sLOX-1 (0.2 mg/ml) was collected in 
10 mM potassium phosphate buffer (pH 8.0) with increasing ethanol concentration (0 
– 100% v/v).  Samples were prepared and analysed in triplicate.  Samples were 
incubated for 12 h at 4°C to ensure complete folding of the protein.  A control sample 
was also prepared by denaturing the protein with concentrated acetic acid.  
Measurements were performed using a Jasco J-815 CD spectrophotometer (ATA 
Scientific, NSW, Australia) and a 1.0 mm pathlength quartz CD cell at ambient 
temperature.  The operating parameters were as follows: analysis range, 190 – 240 nm; 
data interval, 1 nm; bandwidth, 0.5 nm; scan rate, 100 nm/min; accumulations, 5; N2 
flow rate, 5 L/min.  Accumulated data was processed using a 5-point smoothing model 
using the Jasco in-built software (v2.08.04).  Secondary structure predictions (α-helix 
and β-sheet content) were performed using the K2D3 web server (accessed via 
k2d3.ogic.ca//index.html), using a reference database of 16,050 theoretical CD spectra 
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of proteins with known structure and a k-nearest neighbors (k-NN)-like algorithm 
[214].   
Enzyme kinetic parameters 
DPAn-3 and DTAn-6 substrates (10-300 μM) were prepared in oxygenated borate 
buffer (75 mM, pH 9.0) in a 10 mm path length quartz cuvette, and reactions initiated 
with the addition of 20 kunits 15-sLOX-1 prepared in buffer (400 kunits/mL or 
8.68 μM).  Final enzyme concentration was 0.046 μM, equivalent to a concentration 
of enzyme active sites of 0.046 μM (one active site per protein).  Reactions were 
performed at room temperature.  Product formation was monitored at 237 nm for 
conjugated dienes (εM = 23,000 M-1 × cm-1) [120], and data was collected at 0.1 s 
intervals for 0.5 min using a Cary Series 300 UV-visible spectrophotometer (Agilent 
Technologies).  Measurements were performed in triplicate, and the data analysed 
using the Michaelis-Menten kinetic model (GraphPad Prism v6.0d, La Jolla, CA). 
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3.3 Results and Discussion 
3.3.1 Soybean 15-lipoxygenase catalysed reaction of DPAn-3 
Under optimised conditions the reaction of 15-sLOX-1 with PUFA substrate 
containing four or more methylene-interrupted double bonds typically yields two 
dihydro(pero)xy products, both containing a hydro(pero)xy group at the n-6 position, 
and a second hydro(pero)xy group at either n-13 or n-16 positions in approximately 
equal quantities.  This has been routinely observed with ARA, DHA and more recently 
EPA [113, 119-127].  When DPAn-3 and DPAn-6, which vary from DHA only in the 
absence of a single double bond at either the methyl end (n-6) or carboxylic acid end 
(n-3), are utilised as substrate only one major product is detected when analysed by 
both HPLC (Fig. 3.2) and GC-MS.   
  
Figure 3.2. NP-HPLC of 15-sLOX-1 reaction products from DPAn-6 (top traces): 1 - 7S,17S-
diHDPAn-6, 2 - 10S,17S-diHDPAn-6; and DPAn-3 (bottom traces): 3 - 7S,17S-diHDPAn-3, 4 - 
10S,17S-diHDPAn-3.  Dashed line – absorbance at 234 nm; solid line – absorbance at 270 nm.
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This is despite the availability of both n-11 and n-14 locations for hydrogen abstraction 
to generate the two respective n-13-O(O)H and n-16-O(O)H isomers [126] (Fig. 3.3).  
As a result, the major product from DPAn-6 is 10S,17S-dihydro(pero)xy-DPAn-6 
(10S,17S-diH(P)DPAn-6; 78%), while from DPAn-3 the major product is 7S,17S-
dihydro(pero)xy-DPAn-3 (7S,17S-diH(P)DPAn-3; 95%) [126]. 
In investigating this unusual feature of DPA catalysis, a further aspect of the reaction 
has been observed which may be utilised in the synthesis of biologically active resolvin 
analogs.  The addition of low concentrations of short chain n-alcohols, such as 
methanol, ethanol and propan-1-ol, to the reaction medium results in altered 
stereochemistry of products from DPAn-3.  This effect can be influenced by both 
alcohol and 15-sLOX-1 concentration, to generate dihydro(pero)xy compounds with 
R-chirality at carbon 7, rather than the well-known S-stereochemistry usually catalysed 
by 15-sLOX-1. 
3.3.2 Optimisation of reaction conditions to favour 7R-dioxygenase activity 
Reactions were first optimised for final ethanol concentration in the reaction medium 
(0 - 40% v/v) with constant 15-sLOX-1 and DPAn-3 concentration (75 kunits/ml and 
0.08 mM, respectively).  At low ethanol concentration (< 5% v/v), the reaction 
proceeded as normal with complete conversion of DPAn-3 to previously described 
7S,17S-diH(P)DPAn-3 (compound II) through the 17S-diH(P)DPAn-3 (compound I) 
intermediate [124, 126].  As the ethanol concentration was increased, a second 
dihydro(pero)xy compound (III) was observed which elutes approximately 10 min 
later in NP-HPLC (Fig. 3.4A).  Compound III had a characteristic UV-vis absorbance 
spectrum (λmax = 244 nm, suppressed maxima at 227 nm), however exhibited a 
reversed maximum compared to compound II (λmax = 224 nm, suppressed maxima at 
  
 
74 
 
244 nm) (Fig. 3.4B).  Both absorbance spectra are consistent with the presence of two 
interacting conjugated dienes.   
 
Figure 3.4. A: NP-HPLC chromatogram of DPAn-3 dioxygenation products catalysed by 
75 kunits/ml 15-sLOX-1 in the absence (solid line) or presence (dashed line) of 10% (v/v) ethanol (pH 
9.0).  B: UV spectra of analytes measured in ethanol.  
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Under these conditions, the optimum concentration of ethanol for the production of 
III was 10% (v/v) with compound III representing 69.7% of total 
dihydro(pero)xylated products.  At higher ethanol concentrations the formation of all 
products decreased, and the reaction was completely inhibited at 40% (v/v) ethanol 
(Fig. 3.5A). 
 
Figure 3.5. (A) Effect of ethanol concentration on formation of compounds I, II and III using 
75 kunits/ml 15-sLOX-1. (B) Effect of 15-sLOX-1 concentration on formation of I, II and III at 10% 
(v/v) ethanol.  Measured by peak area ratio (from HPLC-DAD). 
The concentration of 15-sLOX-1 was also optimised over the range 15 – 150 kunits/ml 
in the presence of 10% (v/v) ethanol, to maximise production of compound III (Fig. 
3.5B).  Formation of III reached a maximum at 45 kunits/ml 15-sLOX-1, accounting 
for 77.1% of the total dihydro(pero)xy products.  Re-optimisation of ethanol 
concentration at this enzyme concentration enabled an increase in the production of 
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compound III, reaching a maximum purity of 95% at 15% (v/v) ethanol, with complete 
consumption of DPAn-3 substrate. 
3.3.3 Product characterisation 
Methyl esters of compounds II and III were purified by semi-prep NP-HPLC and 
characterised by electron-impact GC-MS (as fully hydrogenated and trimethylsilyl 
ester derivatives), TOF-MS (electrospray ionisation source), NMR, FTIR and UV-
visible spectroscopy.  Analysis of derivatised products by GC-MS confirmed the 
structure of both compounds II and III as 7,17-diHDPAn-3 (refer to Materials and 
Methods for characterisation data).  Briefly, ions with m/z of 289 and 402 were 
detected which are indicative of a hydroxy group at C7, as well as ions with m/z of 
173 and 518 characteristic of a hydroxy group at C17. No other structural isomers were 
detected, indicating dioxygenation occurred at the same positions in both products.  
Purified compounds II and III were analysed by NMR spectroscopy and protons 
assigned based on chemical shift (1H-NMR) and correlation experiments (2D 1H,1H-
COSY) to elucidate the complete structures (Fig. 3.6; Table 3.1).  In support of GC-
MS data, correlation spectroscopy confirmed the presence of hydroxy groups at 
positions C7 and C17 in both compounds.  In the 1H-NMR spectrum (Fig. 3.6) a 
significant downfield shift of ~ 0.2 ppm in the resonance of the C7 proton (4.3 ppm) 
of III, in comparison to II (4.1 ppm), was attributed to a change in chirality at this 
location.  This feature was also accompanied by a slight upfield shift of the adjacent 
C8 proton at 5.6 ppm of III only.  Meanwhile the chemical shift of the C17 proton (4.1 
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ppm) was unchanged from that observed in II, indicating the well-known S-chirality 
of lipoxygenase-derived products was conserved at this location in both compounds. 
 
Figure 3.6. 1H-NMR spectra of II (top trace) and III (bottom trace), measured at 500 MHz.  
Integration values are indicated below each trace. 
The conjugated double bond geometry of compound III was confirmed as E,Z,Z,E, 
consistent with compound II, based on correlation of chemical shifts and calculation 
of J-coupling constants (Table 3.1) [124, 197]. Importantly, correlation was not 
observed between H7 and H17 with protons at ~ 6.0 ppm, a chemical shift 
characteristic of cis protons.  Instead strong correlation was observed with trans 
protons at 5.6 – 5.7 ppm, identified as C8 and C16.  Coupling constants of J8,9 and 
J15,16 were calculated as 14.9 Hz and 14.3 Hz respectively, again characteristic of trans 
protons, while J10,11 and J13,14 were calculated as 10.9 Hz and 10.8 Hz, consistent with 
cis protons.  Additionally, there was no evidence of an E,E conjugated diene at 
approximately 6.2 ppm [120].    
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Table 3.1. 1H-NMR data for compounds II and III. 
 II (7S,17S) III (7R,17S) 
Carbon 1H (ppm) Multiplicity, J-value 
(Hz), integration 
1H (ppm) Multiplicity, J-value 
(Hz), integration 
Methyl 3.64 - - - 3.64 - - - 
1 - - - - - - - - 
2 2.30-2.34 m - 2H 2.29-2.34 m - 2H 
3 1.61 quin 7.3 2H 1.61 quin 7.2 2H 
4 1.33-1.34 m - 2H 1.36-1.39 m - 2H 
5 1.33-1.34 m - 2H 1.36-1.39 m - 2H 
6 1.49-1.53 m - 2H 1.44-1.49 m - 2H 
7 4.09/4.12 dt 6.6/6.8 1H 4.31 dt 7.3 1H 
8 5.66/5.68 dd 15.1 1H 5.62 dd 15.3 1H 
9 6.55 m - 1H 6.58 dd 14.9 1H 
10 5.99/6.00 t 10.9 1H 6.02 t 10.9 1H 
11 5.35-5.39 m - 1H 5.33-5.49 m - 1H 
12 3.09 t 7.5 2H 3.10 t 7.5 2H 
13 5.35-5.39 m - 1H 5.33-5.49 m - 1H 
14 5.99/6.00 t 10.9 1H 5.99 t 10.8 1H 
15 6.55 m - 1H 6.56 dd 14.3 1H 
16 5.66/5.68 dd 15.1 1H 5.68 dd 15.4 1H 
17 4.09/4.12 dt 6.6/6.8 1H 4.14 dt 6.4 1H 
18 2.30-2.34 m - 2H 2.29-2.34 m - 2H 
19 5.35-5.39 m - 1H 5.33-5.49 m - 1H 
20 5.44-5.49 m - 1H 5.33-5.49 m - 1H 
21 2.04-2.09 m - 2H 2.03-2.08 m - 2H 
22 0.95 t 7.6 3H 0.96 t 7.5 3H 
 
Coupling constants of C9 and C15 were not able to be calculated due to the multiplicity 
and overlapping of signals.  Finally, J-coupling constants of J16,17 were found to be 
between 6.4 Hz and 6.6 Hz for both compounds, whereas J7,8 was found to be 7.3 Hz 
for III and 6.8 Hz for II.  This variance in coupling constants between opposite chiral 
centres may provide an effective method for identifying changes in chirality, along 
with changes in chemical shift as discussed.  
Compounds II and III were detected as their Na-adducts [M+Na]+ by TOF-MS, with 
observed ions consistent with the formula C22H34O4Na - Calcd m/z 385.23493; found 
m/z (II) 385.22452 and (III) 385.23326.  In addition FTIR spectra of both compounds 
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were indistinguishable with peaks at 3012 cm-1 (C-H cis stretch), 2956 cm-1 (CH3 
stretch), 2924 - 2925 cm-1 (CH2 asymmetrical stretch), 2854 - 2855 cm-1 (CH2 
symmetrical stretch), 1734 - 1742 cm-1 (carbonyl), 1641 - 1645 cm-1 (alkene) and 1460 
- 1461 cm-1 (CH bend) (Fig. 3.7). 
 
Figure 3.7. (Attenuated total reflectance)-FTIR spectra of compounds II (top trace) and III (bottom 
trace). 
Chiral phase chromatography of the 17-HDPAn-3 intermediate (I) produced in both 
100% aqueous and 10% (v/v) ethanolic conditions indicated that the compound was 
stereochemically pure (> 98%, Fig. 3.8). However, as there are currently no synthetic 
standards of DPAn-3 products commercially available for comparison, assignment of 
S-stereochemistry at C17 is based on previous literature showing that 15-sLOX-1 is a 
catalyst for S-configuration hydro(pero)xy groups [113, 119, 147, 151].  Therefore 
compound II has been tentatively identified as 7S,17S-dihydroxydocosapenta-
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8E,10Z,13Z,15E,19Z-enoic acid.  In the presence of n-alcohols the first dioxygenation 
proceeds as normal to produce 17S-hydroperoxydocosapentanenoic acid, however 
further dioxygenation occurs in the R-configuration producing 7R,17S-
dihydroxydocosapenta-8E,10Z,13Z,15E,19Z-enoic acid (III) as the major product. 
 
Figure 3.8. Chiral phase-HPLC chromatogram of (I) 17-HDPAn-3 (as methyl ester derivative).  
Analysis conditions: mobile phase – n-hexane/ethanol (99/1 v/v); flow rate – 1.0 ml/min. 
3.3.4 Effect of n-alcohol chain length 
The effect of n-alcohol chain length has been investigated in a small number of papers 
[215-218], where inhibition of the enzyme with increasing chain length (n = 1 – 10) 
has been observed.  This reversible inhibition has been attributed to the binding of 
unsaturated straight chain n-alcohols to a hydrophobic site within the active site, 
competitively displacing the PUFA substrate from the catalytic iron centre.   
  
 
81 
 
Mitsuda and co-workers have proposed the bound alcohols occupy a hydrophobic 
region within the active site of soybean lipoxygenase, likely blocking access of the 
1,4-pentadiene system of the substrate to the catalytic site [217].  Analysis of line-
broadening of n-alcohol proton resonances in 1H-NMR spectra also indicate that there 
is an interaction between the iron centre of the LOX enzyme and the alcohol [215].  
The line broadening is a result of proton relaxation enhancement, inferring there is a 
magnetic interaction between the catalytic iron and protons of the n-alcohol.  In this 
study by Slappendel et al. [215], the proton resonances and linewidths of the terminal 
methyl group and protons bound to C1 were examined to calculate the distance 
between the respective protons and the iron atom, with the C1 proton calculated to be 
closer to the iron than the methyl protons (distance ~ 6 Å). 
Based on our observations of the effect of low concentrations of ethanol on 15-sLOX-
1 catalytic activity and the reported inhibitory activity of longer chain n-alcohols, we 
tested the effect of a series of straight-chain saturated n-alcohols (chain length = 1 – 
5) on the 15-sLOX-1 catalysed reaction of DPAn-3 (Table 3.2).  The inhibitory effect 
of longer chain n-alcohols (butan-1-ol and pentan-1-ol) was observed, with a 
significant reduction in both di- and mono-hydroxy products and a substantial amount 
of DPAn-3 substrate remaining.  However it is unclear whether this is a result of direct 
binding of the alcohol to the active site as hypothesised, or due to the limited solubility 
of these longer chain alcohols in aqueous buffer.  Even with vigorous stirring the 
formation of a biphasic environment was observed, in which the PUFA substrate may 
be extracted into the organic phase and therefore is less accessible to the enzyme.  In 
contrast, for the reaction in the presence of shorter chain n-alcohols there was an 
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increase in the production of compound III with increasing chain length, with propan-
1-ol exerting the greatest effect (Table 3.2). 
Table 3.2. Effect of n-alcohol chain length on 15-sLOX-1 activity with DPAn-3 substrate (10% v/v n-
alcohol) (n.d.: not detected). 
n-Alcohol % of Total peak area 
DPAn-3 a (I) 17S- b (II) 7S,17S- b (III) 7R,17S- b 
Methanol n.d. 0.1 47.3 52.6 
Ethanol n.d. 5.8 21.6 72.6 
Propan-1-ol n.d. 5.2 6.5 88.3 
Butan-1-ol 75.1 24.9 n.d. n.d. 
Pentan-1-ol 55.1 44.9 n.d. n.d. 
a Absorbance measured at 210 nm. 
b Absorbance measured at 234 nm. 
 
This may indicate that the binding of the n-alcohol to the active site as previously 
demonstrated not only restricts access of the 1Z,4Z-pentadiene of the PUFA-
hydroperoxide substrate to the catalytic centre for hydrogen abstraction, but under 
appropriate concentrations may also alter the position of substrate within the active 
site cavity enabling access of molecular oxygen to both sides of the pentadienyl 
radical. 
3.3.5 Application of optimised conditions to other LC-PUFA substrates 
The optimised conditions for the production of III 7R,17S-diHDPAn-3 were applied 
to the metabolism of docosatetraenoic acid (DTAn-6; C22:4n-6), a LC-PUFA 
substrate analogous to DPAn-3 in the five carbon alkyl region (C2-C6), which is likely 
to experience the same flexibility when it is bound within the active site during the 
second dioxygenation (Fig. 3.9).   
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Figure 3.9. DPAn-3 and DTAn-6 structure. 
Under standard conditions (0% v/v ethanol and 150 kunits/ml 15-sLOX-1) the major 
product generated from DTAn-6 is 7,17-didihydroxydocosatetraenoic acid n-6 (7,17-
diHDTAn-6).  This assignment was confirmed through analysis by NP-HPLC (Fig. 
3.10A) and GC-MS (Fig. 3.11).  This product exhibits a UV-vis spectrum indicative 
of two associated conjugated dienes (Fig. 3.10B), and is proposed to possess the S,S-
stereochemistry consistent with previously characterised products of 15-sLOX-1 
metabolism [126].   
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Figure 3.10. A: NP-HPLC of dioxygenation products from DTAn-6 substrate catalysed by 15-sLOX-
1 (150 kunits/ml) under standard aqueous conditions.  Dashed line – absorbance at 234 nm; solid line 
– absorbance at 270 nm.  B: UV-visible absorbance spectra (from DAD) of 7S,17S-diHDTAn-6 (solid 
trace) and 10S,17S-diHDTAn-6 (dashed trace).  UV-visible data is normalised. 
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Figure 3.11. (A) GC-MS total ion chromatogram (baseline corrected) of DTAn-6 dioxygenation 
products catalysed by 15-sLOX-1 (150 kunits/ml) under standard aqueous conditions (as fully 
hydrogenated and trimethylsilylated derivatives).  Peaks: a – 7-hydroxy-DTAn-6, b – 17-hydroxy-
DTAn-6 and c – 7,17-dihydroxy-DTAn-6. * Denotes unidentified compound.  (B) Mass spectrum of 
major product c – 7,17-dihydroxy-DTAn-6 (as fully hydrogenated and trimethylsilylated derivative, 
shown inset). 
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However, when the optimised conditions for production of 7R,17S-dihydroxy-DTAn-
6 were applied, the second dioxygenation was significantly inhibited, with only a small 
amount of conversion of 17S-dihydroperoxy-DTAn-6 to dihydroxylated products 
(results not shown).  This reaction was therefore re-optimised for DTAn-6 as shown 
in Fig. 3.12 (14% v/v ethanol and 135 kunits/ml 15-sLOX-1) to achieve 7R,17S-
diHDTAn-6 in 82% purity (Fig. 3.13).  The product structure was again confirmed by 
GC-MS following derivatisation to fully hydrogenated and trimethylsily l esters, and 
established as 7,17-dihydroxy-DTAn-6.   
 
Figure 3.12 A: Effect of ethanol concentration on the formation of 7R,17S-diHDTAn-3 using 
75 kunits/ml 15-sLOX-1. B: Effect of 15-sLOX-1 concentration on the formation of 7R,17S-
diHDTAn-3 at 10% (v/v) ethanol.  Measured by peak area ratio (from HPLC-DAD). 
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Figure 3.13 A: NP-HPLC of dioxygenation products from DTAn-6 substrate catalysed by 15-sLOX-1 
(135 kunits/ml) in the presence of 14% (v/v) ethanol.  Solid line – absorbance at 234 nm; dashed line 
– absorbance at 270 nm. B: UV-visible absorbance spectra of 7S,17S-diHDTAn-6 (dashed line) and 
7R,17S-diHDTAn-6 (solid line). 
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Analysis of enzyme kinetic parameters indicated 15-sLOX-1 has a greater affinity for 
DPAn-3 substrate than DTAn-6, as demonstrated by a higher maximum velocity 
(Vmax), lower kM and higher catalytic turnover constant (Kcat/kM) (Table 3.3).  This 
difference in affinity accounts for the requirement of a higher concentration of enzyme 
to induce 7R-dioxygenase activity with DTAn-6 substrate.  Kinetic parameters were 
calculated according to the following equations: 
V0 = ܸ݉ܽݔ
[S]
ܭܯ + [ܵ]
 
ܭ௖௔௧ = ௠ܸ௔௫E୘
 
Table 3.3.  Kinetic parameters of DPAn-3 and DTAn-6 substrates with 15-sLOX-1.  Measurements 
were performed in triplicate and data fitted to a Michaelis-Menten kinetic model using GraphPad 
Prism 6.0d software. 
 
Parameter DPAn-3 DTAn-6 
Vmax (μM/min) 628.6 ± 39.4 492.1 ± 37.9 
KM (μM) 24.2 ± 5.7 50.1 ± 11.4 
Vmax /KM (min-1) 26.0 9.8 
Kcat (s-1) 8.2 × 105 6.4 × 105  
Kcat/Km (M-1 s-1) 3.2 × 1010 1.3 × 1010 
R2 0.87 0.85 
Where,  
V0  =  Initial velocity  
Vmax  =  Maximum velocity  
[S]  =  Substrate concentration  
KM  =  Substrate concentration at which half maximal velocity is achieved  
Kcat  =  Catalytic turnover  
ET  =  Concentration of enzyme active sites 
 
Both optimised methods were also applied to other biologically significant LC-PUFAs 
– DHA, EPA, ARA and DPAn-6, with some success in the production of R,S-
dihydroxylated products.  However, the total conversion rate remained lower than 
previously observed for DPAn-3 and DTAn-6 substrates.  Major products of these LC-
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PUFAs have been tentatively assigned based on retention time, UV-visible absorbance 
spectra, and GC-MS analysis (following derivatisation) and are summarised in Table 
3.4.  Of interest is the production of diastereomers containing a conjugated triene, 
especially as 10R,17S-dihydroxydocosahexa-4Z,7Z,11E,13Z,15E,19Z-enoic acid is a 
closely related isomer of (neuro)-protectin D1 (NPD1; 10R,17S-
dihydroxydocosahexa-4Z,7Z,11E,13E,15Z,19Z-enoic acid), varying only in the double 
bond geometry at C13 and C15. 
Table 3.4.  Major products from LC-PUFA substrates under optimised conditions for 7R,17S-
diHDTAn-6 by 15-sLOX-1 (14% v/v ethanol, 135 kunits/ml 15-sLOX-1, 0.08 mM substrate). 
Substrate Conjugated diene 
products a 
S,S-:R,S- 
ratio 
Conjugated triene 
products b 
S,S-:R,S- 
ratio ARA 5,15-diHETE 1 : 1.49 8,15-diHETE 1 : 0.15 
EPA 5,15-diHEPA 1 : 0.40 8,15-diHEPA 1 : 0.00 
DPAn-6 7,17-diHDPAn-6 1 : 1.30 10,17-diHDPAn-6 1 : 0.22 
DHA 7,17-diHDHA 1 : 0.88 10,17-diHDHA 1 : 0.11 
a Absorbance measured at 234 nm. 
b Absorbance measured at 270 nm. 
 
Under certain conditions, lipoxygenase catalysed reactions are known to produce other 
non-specific non-enzymatic isomers through free radical initiated chain reactions [188, 
216].  The free radicals are produced enzymatically when a deprotonated substrate 
radical is released from the enzyme prior to oxygen insertion.  These radicals can react 
with oxygen in a non-specific manner forming a range of positional, stereo and 
geometrical isomers.  Typically oxygen will be incorporated at both the [-2] and [+2] 
position from the original carbon-centred radical, with all possible stereo- and 
geometrical (cis,trans and trans,trans-) isomers formed in approximately equal 
quantities [188, 216].  This mix of isomers is not observed here (but may account for 
some very minor products) suggesting the products listed are enzymatically formed. 
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3.3.6 Analysis of enzyme structure by circular dichrosim spectroscopy 
Circular dichroism (CD) spectroscopy is a useful technique for analysing the 
secondary and tertiary structure of peptides and proteins in solution.  The 
conformational motifs of proteins which determine enzyme activity, including α -
helices and β-sheets, exhibit far UV spectra arising from the electronic transitions 
between ground and excited states of molecular orbitals of the amide bonds [219-220].  
The protein secondary structure therefore imposes positional and energy constraints 
on these transitions generating characteristic spectra. Briefly, the n→π* transition of 
α-helices generates negative ellipticity around 222 nm, while the π→π* transition 
produces positive ellipticity around 190 nm and negative ellipticity around 208 nm 
[219, 221-222].  Whereas β-sheets exhibit negative ellipticity at 215 nm due to the 
n→π* transition, and positive ellipticity around 198 nm due to the π→π* transition 
[219, 221-222].  In addition, the chromophores of aromatic amino acids (including 
tyrosine, tryptophan and phenylalanine) in different chemical and spatial environments 
give information regarding the tertiary structure of the protein in the near UV region 
(260 – 320 nm), and also may be indicative of changes in the folding of the protein 
[221]. 
Given the observed effects of n-alcohol on the catalytic activity of 15-sLOX-1, it 
remained to be established if binding of ethanol was inducing a conformational change 
in the structure of the enzyme. The enzyme (0.2 mg/ml) was incubated in 0 – 100 % 
(v/v) ethanol in 10 mM potassium phosphate buffer (pH 8.0) for 12 h at 4°C to ensure 
complete folding of the protein.  The structure of the enzyme was then analysed by CD 
spectroscopy in the far-UV region (190 – 240 nm) at room temperature (Fig. 3.14).  
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Figure 3.14 Baseline corrected far-UV CD spectra of 15-sLOX-1 (0.2 mg/ml) in increasing 
concentrations of ethanol in 10 mM potassium phosphate buffer at pH 8.0.  Samples were incubated 
for 12 hr at 4°C to ensure proper folding. 
Raw data was converted to mean residue ellipticity (MR[θ]) using the formulas shown 
below [222].  α-Helix and β-sheet content was then predicted using the K2D3 web 
server, employing a k-nearest neighbour (k-NN)-like algorithm [214].  Spectra were 
compared against a library of 16,050 reference peptide chains with known structure 
and theoretical CD spectra.  The maximum total error values for all predictions were 
less than 0.45 (Table 3.5). 
MRW = MWܰ − 1 
ܯܴ[θ] = CD × MRW݈ × C  
Where, 
MRW  = mean residue weight (g/mol) 
MW  = molecular weight of the protein (g/mol) 
N  = number of amino acid residues 
CD  = circular dichroism (mdeg) 
l  = cell pathlength (mm) 
C  = protein concentration (mg/ml) 
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Table 3.5.  Predicted secondary structure content of 15-sLOX-1 in increasing ethanol concentrations.   
Predictions were estimated using K2D3 algorithm web server against a reference library of 16,050 
known peptide CD spectra. 
Ethanol (% v/v) Predicted α-helix (%) * Predicted β-sheet (%) * Observed spectrum 
0 14.69 21.30 α-helical 
5 15.52 21.40 α-helical 
10 13.21 21.67 α-helical 
15 15.49 21.45 α-helical 
20 23.59 20.38 α-helical 
40 19.11 22.01 α-helical / β-sheet 
60 13.02 23.41 β-sheet 
80 5.42 23.37 Unfolded 
100 5.21 23.05 Unfolded 
* Maximum total error < 0.45. 
Minor et al. determined the crystal structure of 15-sLOX-1 at a resolution of 1.4 Å by 
X-ray crystallography [104], adding  to the 2.6 Å resolution structure reported by 
Boyington et al. [103].  The general structure of the protein is spatially divided into 
two domains - a smaller, catalytically inactive N-domain (146 residues) consisting of 
a β-sandwich formed by two four-stranded anti-parallel sheets; and a larger, loosely-
associated C-domain (693 residues) consisting of 20 α-helices containing the catalytic 
iron-binding site, as well as two antiparallel β-sheets close to the surface of the enzyme 
(separate from the active site) (Fig. 3.15).  The N-domain of the enzyme is presumed 
to be catalytically redundant, demonstrated in studies where limited proteolysis of the 
β-sheet-rich N-domain at residue 274, resulted in a 60 kDa α-helix-rich fragment 
(spanning the C-domain) which remained catalytically active [223-224].  The C-
domain is known to contain the catalytic iron which is coordinated to three histidine 
ligands of the helices (His499, His504 and His690), the terminal residue (Ile839) and a 
water molecule [104].  In addition the paper by Sudharshan and Appu Rau (1997) 
investigated the far-UV CD spectra of the cleaved C- and N-domain fragments, 
highlighting the characteristic spectra of α-helices and β-sheets respectively [223].   
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Figure 3.15 Schematic diagram of the 3D structure of 15-sLOX-1, highlighting N-domain (I) and C-
domain (II) [225]. 
Analysis of the CD spectra (Fig. 3.13) shows a shift from α-helix structure to β-sheet 
structure in ethanol concentration above 20% (v/v), indicated by a decrease in negative 
ellipticity at 208 nm, and an increase in positive ellipticity at 198 nm.  At 80% and 
100% (v/v) ethanol the CD spectra resemble that of an unfolded protein.  Acid-
denatured (unfolded) protein does not exhibit any ellipticity.  Prediction of α-helix and 
β-sheet content of 15-sLOX-1 show a decrease in α-helix content at higher alcohol 
concentrations (> 20% v/v), indicating a denaturing effect on the enzyme (Table 3.5).  
The unfolding of the catalytically-active C-domain secondary structure is also in 
agreement with the observed catalytic inhibition of the enzyme, where product 
formation was inhibited at ethanol concentrations greater than 20% (v/v).  In contrast, 
no significant effect of ethanol on secondary structure is observed at low 
concentrations (0 – 20% v/v), where the binding of alcohol generates a significant 
catalytic effect.    
These predicted values for secondary structure content are lower than published values 
of native soybean lipoxygenase-1 (Table 3.6) [223, 226], however this may be due to 
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the recent development in instrument capability and performance.  Importantly, 
analysis of proteins at lower wavelengths (190 nm cf. 205 nm) is now possible where 
significant π→π* transitions can now be observed.  In addition, significantly larger 
reference protein chain libraries are now available (16,050 chains compared to 5), 
dramatically improving the accuracy and reliability of predictions.   
Table 3.6.  Comparison of secondary structure predictions for native 15-sLOX-1. 
Study 
α-helix 
(%) 
β-sheet 
(%) 
Wavelength 
range (nm) 
Analysis 
package / 
method 
Reference 
library 
(# proteins) 
Current study (2015) 14.69 21.30 190 – 240 K2D3 16,050 
Sudharshan & Appu Rao 
(1997) [223] 
28 22 200 - 250 CDPROT 10 
Spaapen & co-workers 
(1979) [226] 
34.1 26.9 205 - 245 
Chen et al. 
[227] 
5 
3.3.7 Further discussion 
In the current study the synthesis of resolvin analogs from DPAn-3 and DPAn-6 has 
been demonstrated, however in an altered ratio and significantly higher yield than 
previously described using 15-sLOX-1 [124].  Dangi et al. reported the production of 
two dihydroxylated products, 7,17S-diHDPA and 10,17S-diHDPA, formed through 
the 17S-hydroperoxy intermediate from both n-3 and n-6 starting materials using 15-
sLOX, with low rates of conversion from mono-hydro(pero)xy to dihydro(pero)xy 
products (2 – 4%) [124]. However, in the current study 7S,17S-diHDPAn-3 has 
consistently been observed as the single major product from DPAn-3, with 10S,17S-
diHDPAn-3 representing only ~ 5% of the total products, despite the site required for 
formation of this compound appearing to be readily available for hydrogen abstraction.   
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In the present research the metabolism of DPAn-3 by 15-sLOX-1 has been further 
optimised to enable the formation of two diastereomers of 7,17S-diHDPAn-3 in high 
purity and high yield. The major product, tentatively named RvD5DPAn-3 based on the 
structural similarity to RvD5 from DHA (7S,17S-dihydroxydocosahexa-
4Z,8E,10Z,13Z,15E,19Z-enoic acid) [190], is a double dioxygenation product of 
soybean 15-LOX-1.  The formation of RvD5DPAn-3 has been confirmed in zymosan-
activated isolated human neutrophils after treatment with DPAn-3, with hydroxy 
stereochemistry assumed to be S,S- following previously characterised pathways of 
resolvin biosynthesis [190].   In this work, the synthesis of two RvD5DPAn-3 
diastereomers using 15-sLOX-1 has been demonstrated and reaction conditions 
optimised for the formation of each isomer.  The products have been fully 
characterised to establish double bond and hydroxy group stereochemistry using NMR 
spectroscopy, GC-MS and HPLC analysis.  The synthesis of the corresponding 
diastereomeric pairs from other LC-PUFAs, including EPA, DHA, ARA and DTAn-3, 
has also been demonstrated.  As the potency and bioactivity of SPMs are known to be 
significantly dependent on stereochemical features as a result of selective receptor 
affinities [16, 18, 39-40, 228], the ability to introduce subtle stereospecific features 
into products via enzyme-catalysed methods offers a major advantage over synthetic 
methods in generating bioactive compounds with high chiral purity. 
The effect of n-alcohols on lipoxygenase has been briefly explored previously, in terms 
of inhibition of LOX activity, indicating the C1-C12 n-alcohols competitively inhibit 
metabolism of linoleic acid through binding of the alkyl chain of the alcohol to a 
hydrophobic region close to the catalytic centre of the active site [215, 217-218].  It 
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has also been proposed that this binding restricts access of the pentadiene system of 
the substrate to the catalytic centre, thus preventing hydrogen abstraction [215, 217].  
Previous investigations of enhanced enantioselectivity through medium engineering 
have also suggested one mechanism of action could be through solvent molecules 
binding within the active site, and affecting the association or transformation of one 
enantiomer more than the other [26].  Consistent with previous results, the increasing 
inhibitory effect of alcohols has been observed as a function of alcohol chain length.  
However, it has also been observed that the presence of shorter chain n-alcohols 
(methanol, ethanol and 1-propanol) exerts an effect on the stereospecificity on the 
LOX enzyme at low concentrations. This may indicate that the binding of the alcohol 
to the active site as previously demonstrated, not only restricts access of the substrate 
to the catalytic centre, but under appropriate conditions may alter the position of the 
substrate, enabling access of molecular oxygen to both sides of the pentadienyl radical. 
15-sLOX-1 is well known to catalyse stereospecific S-chirality dioxygenations of LC-
PUFAs containing one or more 1Z,4Z-pentadiene moieties, and to date there have been 
no reports of hydroperoxides with R-stereochemistry from wild-type soybean 15-
lipoxygenase-1.  The structure of 15-sLOX-1 in the active ferrous (II) form has been 
characterised by X-ray crystallography to a resolution of 1.4 Å, identifying the likely 
substrate-binding cavity [104].  Due to the structural flexibility of PUFAs, modelling 
of actual substrate binding within the active site has been subject to speculation based 
on observed product formation and mutagenesis studies [104, 151].  The general 
consensus of binding is with the substrate arranged in a bent conformation extending 
between two subcavities intersected by a constricted region proximal to the catalytic 
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iron, as well as the presence of oxygen pockets or channel close to the subcavities 
[104, 131, 168].  The regiospecificity of the reaction is believed to be greatly controlled 
by how deep the substrate can penetrate the distal subcavity (effectively displacing the 
reacting pentadiene and the proximity of the methylene group for hydrogen 
abstraction), and also the orientation of the substrate within the active site (methyl 
versus carboxylic acid end first) [152-153].  The stereospecificity of the lipoxygenase 
reaction is somewhat more complex and is likely affected by several factors including, 
but not limited to [132, 229-230]:   
i. the selective channelling of oxygen through the protein to a specific region in 
the active site; 
ii. steric shielding of the radical substrate by the enzyme structure to guide oxygen 
accessibility to certain reactive locations of the pentadienyl radical; and 
iii. the localisation or delocalisation of the pentadienyl radical which can favour 
selective reaction.  
This has been demonstrated by the presence or absence of bulky amino acid residues 
within the active site which appear to guide oxygen access to regions of the pentadienyl 
radical [166].  When the presence of short chain n-alcohols and an increased flexibility 
of the substrate are also considered, it is possible that the positioning of the substrate 
restricts antarafacial access of oxygen as a result of alcohol binding and rotation of the 
alkyl region of the substrate.  As a result, oxygen insertion may be favoured on the 
same side as hydrogen abstraction to produce R-chirality products.  
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3.4 Conclusion 
The lipoxygenase family of enzymes have been established as valuable and versatile 
biocatalysts in the production of hydroxy fatty acids from a range of LC-PUFA 
substrates, with demonstrated regio- and stereo-specificity.  In this research the 
versatility of commercially available 15-sLOX-1 has been demonstrated through 
subtle changes in experimental conditions, enabling production of diastereomeric 
compounds analogous to biologically produced resolvin and protectin species.  The 
major compounds from DPAn-3 substrate, (8E,10Z,13Z,15E,19Z)-7R,17S-diHDPA 
and (8E,10Z,13Z,15E,19Z)-7S,17S-diHDPA, have also been characterised to elucidate 
their complete chemical structures.  This stereo-selective feature makes the use of 15-
sLOX-1 an attractive and efficient option in the production of SPM analogs, providing 
a simpler method of producing chirally pure products than current synthetic strategies.  
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4. INVESTIGATING THE ANAEROBIC 
LIPOHYDROPEROXIDASE ACTIVITY OF SOYBEAN 15-
LIPOXYGENASE-1 ON LC-PUFA 
4.1 Introduction  
In addition to the well-known activity under aerobic conditions to produce mono-, di- 
and tri-hydroxy fatty acid derivatives [119][120-122, 124-126], lipoxygenase-1 from 
soybean (15-sLOX-1) has also been shown to possess lipohydroperoxidase activity 
under conditions where oxygen is the limiting substrate, for example during anaerobic 
conditions in the presence of high fatty acid substrate concentrations [136, 170, 197, 
203, 205, 231]. 
Understanding of the lipohydroperoxidase mechanism has important implications for 
the use of LOX in the synthesis of bioactive compounds (for example, resolvins and 
protectins) as enhanced peroxidase activity can significantly reduce the yield of 
desired products.  LOX peroxidase activity may also be an indicator of anaerobiosis in 
biological systems, leading to the formation of toxic aldehydes, ketones and 
hydrocarbon species which contribute to cellular oxidative stress [231-232].  An 
increase in lipid peroxidation (and subsequent radical formation) under hypoxic 
conditions is known to result in the activation of inflammatory pathways and 
production of pro-inflammatory cytokines responsible for cell injury and dysfunction, 
further propagating oxidative stress [232].  Conversely, an oxodiene derivative of 
arachidonic acid – 15-oxo-ETE produced by cyclooxygenase-2 and 15-LOX-mediated 
oxidation [233-235], has been shown to inhibit cell proliferation of endothelial cells 
[236] and in breast cancer cells [237] suggesting a potential anti-angiogenic capacity. 
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Garssen and co-workers have characterised the major products of linoleic acid under 
anaerobic incubation with 15-sLOX-1, including 13-oxodienoic acids (ketone and 
aldehyde) and linoleic acid dimers [170, 197], contributing to the postulated 
mechanism for the LOX peroxidase reaction (Scheme 4.1).  This commonly accepted 
mechanism first proposed by de Groot et al. describes the sLOX-catalysed formation 
of an alkoxyl fatty acid radical from the hydroperoxide substrate [140].  This radical 
is then subject to rearrangement and fragmentation to form the commonly observed 
oxodienes and epoxy-containing compounds from linoleic acid [172, 201-203]. 
Additionally, the formation of carbon-centred linoleic acid radicals is implicated in 
order to reduce the non-heme Fe(III) to Fe(II) for further hydroperoxide-cleaving 
activity.  In the absence of molecular oxygen, these fatty acid radicals are released 
from the enzyme and are available for recombination with unreacted fatty acid 
substrate or oxygen-containing radicals forming dimeric compounds [170, 197]. 
 
Scheme 4.1 Postulated 15-sLOX lipohydroperoxidase mechanism using linoleic acid substrate (LH) 
[136, 140]. 
Investigation of the anaerobic reaction of 15-sLOX-1 with substrates other than 
linoleic acid has been very limited [183, 197], likely due to restricted range of regio- 
and stereo-isomers linoleic acid provides, and the subsequent ease of separation and 
characterisation.  One study has utilised arachidonic acid, α-linolenic acid and γ-
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linolenic acid as substrates, briefly noting the similarity of products to those 
synthesised from linoleic acid, although detailed results were not provided [197].  As 
15-sLOX-1 is now commonly used in the production of hydro(pero)xy fatty acids and 
has demonstrated high affinity for longer and more highly unsaturated fatty acids as 
substrate [124, 126, 169, 171], the range of products from substrates such as DHA, 
EPA and DPA are of interest, and may have biological significance. 
In this work a lipoxygenase/PUFA system has been established where oxygen is 
rapidly consumed, generating and maintaining the hypoxic conditions required for 
lipohydroperoxidase activity.  Initial oxygen concentrations are kept low, while excess 
unreacted PUFA substrate provides a hydrogen source to regenerate LOX-Fe(II).  The 
products were evaluated using a range of analytical techniques, and for the first time 
the products from 15-sLOX-1 catalysed metabolism of biologically relevant PUFAs, 
including DHA and EPA, in the absence of oxygen are described. In addition a free 
radical scavenger – 4-hydroxy-TEMPO, was employed to investigate the origins of the 
observed compounds. 
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4.2 Materials and Methods 
4.2.1 Materials 
Soybean 15-lipoxygenase-1 (EC 1.13.11.33, P1, 15.2 mg/ml, 9.42 Munits/ml) and 2-
methoxy-phenol (guaiacol) were purchased from Sapphire Bioscience (Waterloo, 
NSW, Australia).  All fatty acids (Nu-Chek Prep) were purchased from Adelab 
Scientific (Thebarton, SA, Australia).  Sodium tetraborate decahydrate, sodium 
borohydride, 2,2-dimethoxypropane (98%, Fluka), platinum(IV) oxide, 4-hydroxy-
2,2,6,6-tetramethylpiperidin-1-oxyl (4-hydroxy-TEMPO), N,O-
bis(trimethylsilyl)trifluroacetamide (BSTFA, with 1% trimethylchlorosilane), 
trifluoroacetic acid (TFA), pinacyanol chloride and pyridine were all from Sigma-
Aldrich (Castle Hill, NSW, Australia).  Acetic acid was from BDH Lab Supplies (UK).  
Ethanol, methanol, isopropanol, acetonitrile (HPLC grade, Scharlau) and n-heptane 
(HPLC grade, Honeywell Burdick & Jackson) were purchased from ChemSupply 
(Gillman, SA, Australia).  Deuterated solvents were from Cambridge Isotope 
Laboratories, Inc. (Andover, MA).  Bond-Elut-C18 solid phase extraction cartridges 
(3 ml, 0.5 g) were purchased from Agilent Technologies (Mulgrave, VIC, Australia). 
4.2.2 Determination of critical micelle concentration 
The critical micelle concentration (CMC) of DHA was determined by measuring the 
spectral change of pinacyanol chloride dye [238-239].   DHA solutions of varying 
concentration (in the range of 0.01 mM to 0.60 mM) were prepared in 50 mM sodium 
tetraborate at pH 9.0 and 11.0, and equilibrated at 22°C (ambient temperature).  To 
each solution a methanolic solution of pinacyanol chloride (0.35 mM) was added to 
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achieve final concentration of 5 μM and the absorbance measured at 610 nm.  
Absorption measurements were performed in 1 cm path length quartz cuvettes using a 
Cary Series 300 UV-visible spectrophotometer (Agilent Technologies, Mulgrave, 
Australia).  Measurements were performed in triplicate. 
4.2.3 General reaction protocol 
Anaerobic LOX reactions were performed under reduced oxygen concentrations 
achieved by purging the reaction medium with N2 for 10 minutes. Fatty acid substrates 
(0.1 M in ethanol) were diluted with sodium tetraborate buffer (25 mM, pH 10) to 
achieve a final concentration of 0.50 mM.  Reactions were initiated by addition of 150 
kunits/ml 15-sLOX-1 with stirring, and the vessel sealed immediately.  After 15 
minutes, the solution was acidified with concentrated acetic acid and allowed to stir 
for a further 15 minutes.  Products were extracted using solid phase extraction.  C18 
cartridges were conditioned with methanol and water, the sample loaded and washed 
with a further volume of water, and eluted with 1 volume of ethanol.  The solvent was 
evaporated under a stream of nitrogen and the samples prepared for HPLC analysis.  
Dissolved oxygen consumption was measured using a polarographic O2 electrode 
(Qubit Systems Inc., John Morris) with a two-point calibration and reactions 
performed as described above. 
4.2.4 Analytical methods 
NP-HPLC-DAD  
Analyses were carried out using an Agilent 1200 series HPLC system, equipped with 
a quaternary pump, solvent degasser, autosampler, thermostatted column compartment 
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and diode array detector (Agilent Technologies Australia, Mulgrave, VIC).  Semi-
preparative separations were performed using a semi-prep-Diol column (25 cm × 10 
mm, 5 μm, YMC Japan) equipped with a pre-column filter, using an isocratic mobile 
phase of 95% solvent A (n-heptane with 0.1% (v/v) 2,2-dimethoxypropane and 0.1% 
(v/v) acetic acid) and 5% solvent B (isopropanol) at 2.2 ml/min.  The column 
compartment was maintained at 10°C.  Samples were prepared in mobile phase and 
injection volume was 50 μl. 
RP-HPLC-DAD 
Analyses were carried out using an Agilent 1260 Infinity HPLC system, equipped with 
a quaternary pump, solvent degasser, autosampler, thermostatted column compartment 
and diode array detector.   
Analytical separations were performed using a Kinetex C18 column (15 cm × 4.6 mm, 
5 μm, Phenomenex) with a gradient mobile phase of solvent A (milliQ water with 
0.1% acetic acid) and B (acetonitrile): 40% B to 90% B over 30 min, held at 90% B 
for 20 min and a post-run (40% B) time of 10 min.  Analyses were performed at 
ambient temperature.  The flow rate was 0.5 ml/min, samples were prepared in 
acetonitrile and an injection volume of 15 μl used.   
Chiral analysis was performed using a Lux Amylose-2 chiral column (15 cm × 4.6 mm, 
5 μm, Phenomenex) fitted with a guard cartridge, and solvents A: milliQ water with 
0.1% (v/v) trifluoroacetic acid, and B: acetonitrile.  An isocratic mobile phase of 50 - 
80% B was used at a flow rate of 1 ml/min.  Mobile phase was adjusted to optimise 
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separation capacity.  Analyses were performed at ambient temperature.  Samples were 
prepared in acetonitrile and an injection volume of 15 μl used. 
HPLC-TOF-MS 
Separations were performed as described above for RP-HPLC (Kinetex C18 column) 
using an Agilent 1200 series HPLC equipped with a binary pump, autosampler and a 
time-of-flight mass spectrometer (TOF-MS) operating in positive ion mode.  TOF-MS 
conditions were as follows: drying gas, nitrogen (5 l/min, 350°C); nebuliser gas, 
nitrogen (16 psi); capillary voltage, 4.0 kV; vaporiser temperature, 350°C; and cone 
voltage, 60 V.  Data analysis was performed using Agilent MassHunter Qualitative 
Analysis software (version B.03.1). 
GC-MS 
Samples were prepared for analysis as described previously [126].  Briefly, products 
were fully hydrogenated over PtO2 in ethanol under a stream of hydrogen for 25 min 
with stirring.  The solution was filtered (0.45 μm nylon filter) and the solvent 
evaporated under N2. Products were then trimethylsilylated using BSTFA and pyridine 
at 100°C for 1 h.  Analyses were performed using an Agilent 6890N gas 
chromatograph with a 5975 mass selective detector (EI), equipped with a BPX5 
column (30 m × 0.25 mm, 0.25 μm film thickness, SGE) with helium carrier gas 
(1.2 ml/min). The inlet was maintained at 250°C with a split ratio of 20:1, and an 
injection volume of 1 μl used. The elution temperature program was as follows: 150°C 
for 2 min, increased at 5°C/min to 300°C, and held at 300°C for 13 min.  The 
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conditions of the MSD were as follows: electron voltage, −70 eV; MS quad, 150°C; 
MS source, 230°C; solvent delay, 3 min; scan range, 35.0 – 600.0 amu. 
NMR spectroscopy 
All 1D and 2D NMR experiments were performed using a Bruker Avance 500 MHz 
FT-NMR spectrometer.  HPLC-purified products were dissolved in ~40 μl deuterated 
methanol and transferred to an internal capillary within a standard bore NMR tube.  
All chemical shifts were measured using residual CH3OH peaks as reference. 
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4.3 Results and Discussion 
4.3.1 Monitoring the metabolism of DHA by 15-sLOX-1 under anaerobic conditions 
At high lipid substrate and low dissolved O2 concentrations the anaerobic formation 
of products from DHA by 15-sLOX-1 is observed.  Reactions were performed at 
0.50 mM DHA concentration in N2-purged borate buffer (25 mM) and products 
analysed by RP-HPLC. Under these conditions the reaction medium becomes 
completely anaerobic within 0.6 min due to dioxygenase activity, and DHA substrate 
is rapidly and completely consumed.   
When the reaction products were analysed using RP-HPLC there was an absence of 
compounds routinely observed under aerobic incubation of DHA with 15-sLOX-1 
[120, 122, 126], including di-hydroperoxy-DHA compounds which possess 
characteristic UV-visible spectra (usually eluting between 14.7 - 15.7 min).  Instead, 
several compounds, denoted as Ia/b, IIa/b and IIIa-c in Fig. 4.1, were observed using 
diode array detection.  RP-HPLC analyses were also repeated using TOF-MS detection 
to obtain the molecular weight of each compound.  Evaluation of chromatographic 
data, UV-visible absorption and TOF-MS data enabled preliminary identification of 
these compounds as isomers of 17-oxo-heptadecadienoic acid (Ia/b), hydroxy-epoxy-
docosapentaenoic acid (IIa/b) and C5H9-DHA (IIIa-c) (Table 4.1).   
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Figure 4.1 RP-HPLC-DAD chromatogram (baseline corrected) of DHA products catalysed by 15-
sLOX-1 under anaerobic conditions.  Reaction conditions: 0.50 mM DHA, 150 kunits/ml 15-sLOX-1, 
N2-purged Na-tetraborate buffer, 30 min reaction time.  
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In order to monitor the formation of the products formed under anaerobic conditions 
the reaction was performed on a larger scale (100 ml total volume) and aliquots taken 
at the indicated time points.  The aliquots were reduced with NaBH4 (1 M) to rapidly 
inhibit the enzyme activity, as such products were detected as their reduced 
derivatives.  As shown in Fig. 4.2, the initiation of hydroperoxidase activity is 
observed only at the onset of hypoxia, and continues under completely anaerobic 
conditions.  With the initial rapid consumption of DHA (< 6 sec) there was a 
concurrent production of 17-hydroperoxy-DHA (detected as 17-hydroxy-DHA), as 
well as several minor products which stem from the anaerobic metabolism of the 17-
hydroperoxy intermediate (detected as their reduced derivatives labelled as Ib 
(reduced) and IIIa-c (reduced) in Fig. 4.2).  Within 5 min there was a significant 
conversion of hydroperoxide to these anaerobic products. 
In experiments using N2-purged sodium tetraborate buffer the dissolved oxygen 
concentration was reduced to approximately 0.15 mM (5 - 6 mg/l).  As shown in Fig. 
4.2A, the addition of 15-sLOX-1 (150 kunits/ml) to the substrate solution resulted in 
rapid and absolute consumption of any remaining dissolved oxygen.  Taking into 
account oxygen consumption by the reaction and also the dissolution rate from the 
headspace (which is limited during the purging process, so is assumed to be 
negligible), the apparent oxygen consumption was calculated to be 5.3 mg/l, equalling 
0.5 μmol.  As the dioxygenation of PUFAs by 15-sLOX-1 occurs in a 1:1 ratio, the 
amount of DHA consumed and subsequently converted to 17-hydroperoxy-DHA is 
also 0.5 μmol, or 33% of the total amount of DHA available for the reaction.  
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Therefore, contrary to what is shown in Fig. 4.2, theoretically there should be a 
significant amount of unreacted DHA remaining in the solution.   
 
Figure 4.2 A: Measurement of oxygen concentration upon addition of 0.45 kunits 15-sLOX-1 to 3 ml 
0.5 mM DHA prepared in N2-purged Na-tetraborate buffer (pH 10) at 22°C.  B: Time course 
experiments monitoring the formation of major products only, after reduction with NaBH4 (1 M).  
Major anaerobic products labelled Ib and IIIa-c.  Reactions conditions as described in Materials and 
Methods. 
Currently the absence of residual DHA in the reaction mixture cannot be accounted 
for.  A possible explanation is the aggregation of DHA molecules to form micelles at 
concentrations above the critical micelle concentration (CMC), and subsequent 
adsorption of micelles to the glass walls of the reaction vessel.  The CMC of DHA was 
determined experimentally at pH 9.0 by measuring the increase in absorbance of 
  
 
113 
 
pinacyanol chloride dye at 610 nm [238-239].  The CMC was found to occur between 
0.08 – 0.10 mM (Fig. 4.3), significantly lower than the concentration used in this study 
(0.50 mM).  In addition the critical vesicle concentration of DHA (in 0.1 M sodium 
phosphate, pH 8.8) has also been estimated to occur at a similar concentration (0.06 ‒ 
0.09 mM) by Namani and co-workers [238], therefore it is possible the residual DHA 
is associated in vesicles at higher pH. 
 
Figure 4.3 Determination of the critical micelle concentration of DHA using pinacyanol chloride dye 
(5 μM) at 610 nm.  Measurements were performed in 50 mM sodium tetraborate at pH 9.0 and 
repeated in triplicate.  Error bars indicate one standard deviation. 
4.3.2 Effect of incubation conditions  
The following parameters were investigated to optimise the formation of the anaerobic 
products, and importantly for the production of compound IIIa-c for purification and 
characterisation purposes (Table 4.2). All reactions were performed as described in 
Materials and Methods – General reaction protocol. Briefly, DHA substrate was 
prepared as a 0.1 M solution in ethanol and diluted to the desired concentration in 
buffer, the reactions were performed in sodium tetraborate pH-controlled buffer, with 
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the addition of 150 kunits/ml 15-sLOX-1 initiating the reaction. Reaction vessels 
remained sealed prior to and following the addition of reagents to limit oxygen 
diffusion.  Products were reduced with NaBH4 (1 M) and the solution acidified with 
concentrated acetic acid to inhibit enzyme activity and to prevent spontaneous 
degradation of products. Products were extracted by solid phase extraction and stored 
in ethanol at - 20°C, prior to analysis by NP-HPLC.   
Table 4.2.  Parameters investigated for optimisation of lipohydroperoxidase activity of 15-sLOX-1 
with DHA substrate. 
Parameter Range Standard Optimised 
Substrate concentration (mM) 0.10 – 0.90 0.50 0.50 
Buffer pH 7.0 – 13.0 9.0 10.0 
Buffer concentration (mM) 25 - 100 50 25 
Temperature (°C) 2 - 40 24 24 
Dissolved oxygen concentration (%) * <5, 50, 100 50 50 
Reaction time (min) 0 - 45 15 30 
* Calculated as the percentage of maximum dissolved oxygen saturation at 24°C and 1024 hPa.   
Substrate concentration 
Substrate concentration was analysed to optimise the conversion of intermediate 17-
HPDHA to major products Ib and IIIa-c (Fig. 4.4).  Although total product recovery 
was greatest at ≥ 0.75 mM DHA, the solubility of the substrate in an aqueous buffer 
is restricted at these high concentrations and required vigorous stirring which 
complicated the extraction protocol, especially for larger scale synthesis.  Therefore a 
substrate concentration of 0.50 mM was selected as the optimal substrate 
concentration.  
Buffer pH and concentration 
The pH of the reaction buffer is known to affect production formation from 15-sLOX-
1 catalysis due to protonation or deprotonation of the carboxylic acid of the substrate 
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[113, 119, 125-126, 169].  The enzyme has been shown to be active between pH 7 and 
pH 13 for dioxygenase activity [126].  However, hydroperoxidase activity was 
observed between pH 8 and pH 12, with an optimum selected at pH 10 (Fig. 4.5).  In 
addition, lower buffer concentration (25 mM) was found to favour the formation of 
product IIIa-c (Fig. 4.6). 
 
Figure 4.4 Effect of substrate concentration on the formation of major products Ib and IIIc. 
 
Figure 4.5 Effect of buffer pH on the formation of major products I and III. 
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Figure 4.6 Effect of buffer concentration on the formation of major products I and III. 
Temperature 
Lipoxygenase-catalysed reactions are typically performed at lower temperatures (on 
ice) to avoid non-enzymatic oxidation and isomerisation [120].  In this work an 
increased formation of product Ib and IIIa-c was observed at higher temperatures as 
shown in Fig. 4.7, therefore an ambient reaction temperature (22 ‒ 24°C) was 
selected.   
Oxygen concentration 
The dissolved oxygen concentration of the buffer was adjusted to < 5% (< 0.475 mg/l) 
and ~ 50% (~ 4.75 mg/l) through purging with N2 at 24°C.  The oxygen concentration 
of air-saturated buffer (corresponding to 100% oxygen) was 9.5 mg/l.  Dissolved 
oxygen concentration was monitored during N2 purging using an InLab 605 dissolved 
O2 polarographic sensor equipped with a SevenGo 6 portable meter (Mettler Toledo).  
The reaction vessel was sealed immediately at the required concentration.  As shown 
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in Fig. 4.8 there is no clear dependence of product formation on buffer oxygen 
concentration.   
 
Figure 4.7 Effect of temperature on the formation of major products I and III. 
 
Figure 4.8 Effect of buffer oxygen concentration on the formation of major products I and III.  
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4.3.3 Characterisation of anaerobic reaction products  
Reactions were scaled up for preparative production and isolation of major products.  
Compounds Ib and IIIa-c were purified using semi-preparative NP-HPLC and 
evaluated using a range of spectroscopic and chromatographic techniques to elucidate 
structural and stereochemical features.  
17-oxo-heptadecapentaenoic acid  
Two isomers of 17-oxo-heptadecapentaeoic acid (Ia & Ib) were detected with 
absorption at approximately 280 nm (Table 4.1), consistent with a conjugated dienoic-
aldehyde.  These products are analogous to 13-oxo-tridecadienoic acid produced from 
the anaerobic catalysis of linoleic acid, resulting from β-scission of the alkoxyl radical 
intermediate [197].   
Given the low retention of these isomers when analysed by RP-HPLC they could not 
be resolved under the tested conditions, therefore they were further analysed by NP-
HPLC.  Baseline resolution of the two isomers was achieved, enabling measurement 
of absorbance spectra and isomeric distribution.  The major isomer Ib is proposed to 
retain the conjugated double bond geometry (13Z,15E‒) of the hydroperoxide 
intermediate synthesised by 15-sLOX-1 under aerobic conditions [126] (i.e. prior to 
complete oxygen depletion), exhibiting a λmax at 272 nm. Product Ia (λmax at 269 nm) 
represented 3.5% of the isomeric distribution and may be a result of the isomerisation 
of Ib to the thermodynamically favoured 13E,15E‒ isomer [173, 194, 197].  This 
hypsochromic shift in absorbance from 272 nm to 269 nm is consistent with 
conversion of Z,E isomers to E,E isomers in conjugated dienes [231, 240-241].  
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Reduction of the reaction products with NaBH4 (1 M) caused a shift to longer retention 
times in NP-HPLC, as well as a change in absorbance from 269/272 nm to 232/235 
nm, consistent with the reduction of a conjugated aldehyde to a conjugated alcohol 
(Fig. 4.9).  
  
Figure 4.9 UV-visible spectra of peak Ib before (solid trace) and after reduction (dashed trace) with 
NaBH4 (1M) (normalised data). 
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Table 4.3. NMR data for product Ib – 17-oxo-heptadecapenta-4Z,7Z,10Z,13Z,15E-enoic acid. 
 1H-NMR 13C-NMR  
Carbon ppm Multiplicity, J-value (Hz), 
integration 
ppm 
2 2.30–2.40 m   23.99/35.18 
3 2.30–2.40 m   23.99/35.18 
4 5.37–5.51 m   127.20–130.76 
5 5.37–5.51 m   127.20–130.76 
6 2.87/2.93 t J = 6.0/7.5 2H 26.53/26.58 
7 5.37–5.51 m   127.20–130.76 
8 5.37–5.51 m   127.20–130.76 
9 2.87/2.93 t J = 6.0/7.5 2H 26.53/26.58 
10 5.37–5.51 m   127.20–130.76 
11 5.37–5.51 m   127.20–130.76 
12 3.20 t  J12,13 = 7.5 2H 27.63 
13 6.02 dt J13,14 = 11.0 1H 128.7 
14 6.34 dd J13,14 = 11.1 1H 127.97 
15 7.73 dd J15,16 = 15.1 1H 148.88 
16 6.16 dd J15,16 = 15.1 1H 133.18 
17 9.59 d  J16,17 = 7.9 1H 196.34 
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Peak Ib was isolated by semi-preparative NP-HPLC and analysed by 1H-NMR, 13C-
NMR, 1H,1H-COSY and 1H,13C-HSQC experiments to elucidate the complete 
structure (Table 4.3).  Importantly, the C17-aldehyde was clearly observed with a 
proton resonance at 9.59 ppm, and a carbon peak at 196.34 ppm, as well an absence of 
the terminal methyl group at ~0.95 ppm.  Due to the aromatic-like nature of the 
conjugated oxo-diene, the C15 proton experienced a downfield shift to the aromatic 
region at 7.73 ppm.  Calculation of J-coupling constants also confirmed the double 
bond geometry of the diene as 13Z,15E.  
For the production of the C17 aldehyde from 17-hydroperoxy-DHA, an alkoxyl radical 
intermediate is implicated in order to catalyse β-scission of the terminal fragment [172, 
201, 203, 242].  The formation of alkoxyl radicals from linoleic acid by soybean 
lipoxygenase (multiple isoforms) has been implicated in several studies through the 
analysis of products and indirectly through measurement of hyperfine structures by 
EPR [198-199, 243-244].  However due to the extremely fast fragmentation of alkoxyl 
radicals through β-scission to form oxo-fatty acids and hydrocarbon radicals in 
aqueous solutions (>106 s-1) [198-199], direct measurement of alkoxyl radicals by EPR 
has not yet been possible.  
The postulated mechanism for the formation of the conjugated aldehyde is presented 
in Scheme 4.2, where β-scission of the 17-alkoxyl radical results in the cleavage of the 
terminal C5H9 group.   This results in the formation of the conjugated oxo functional 
group and the reactive pentyl radical. 
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Epoxy-alcohol isomers 
Products IIa and IIb are proposed to be hydroxy-epoxy isomers (Fig. 4.1; peak IIa ‒ 17.18 
min and IIb ‒ 18.23 min), resulting from the formation of alkoxyl radicals and subsequent 
cyclization to the adjacent double bond to form an epoxide compound with a carbon-
centred allyl-radical [172, 201-203].  In the absence of a reactive radical scavenger, 
recombination of the epoxide-intermediate radical with the OH-radical coordinated to 
LOX-Fe(III) in the absence of dissolved oxygen generates an epoxy-alcohol.  This 
mechanism is supported by experiments performed with 18O2-labelled 13-
hydroperoxyoctadecadienoic acid (13-HPODE) by Garssen et al. [172] showing that both 
oxygen atoms in the epoxy-alcohols formed from sLOX arise from the initial 18O2-
hydroperoxide.  This mechanism has also been observed in the analogous hematin-
catalysed formation of epoxy-alcohols from 13-HPODE where the hydroperoxide oxygen 
is conserved in the final product [244-245].  Additionally, the presence of DMPO-adducts 
of hydroxyl, allylic epoxy, peroxyl and acyl radicals have been confirmed from anaerobic 
incubation of linoleic acid with 15-sLOX-1 in the presence of DMPO by EPR 
spectroscopy [195].   
The elimination of the double bond is demonstrated by the absence of conjugation in the 
absorbance spectrum (λmax < 200 nm), as well as a m/z ratio consistent with the formula 
C22H32O4 detected as a sodium adduct by TOF-MS (Table 4.1; peaks IIa & IIb).  Whilst 
this formula is also consistent with the dihydroxy products commonly produced from 
aerobic reactions [120-121, 126, 160], in this case, the reaction products were not reduced 
after the reaction (so would remain hydroperoxides), lacked conjugation and 
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demonstrated increased HPLC retention times, all indicative of the formation of hydroxy-
epoxy isomers.   
A possible pathway for radical formation and rearrangement has been proposed by 
Dikalov and Mason [246].  This scheme describes the rearrangement of the allyl radical 
to either the C9- or C11- position of the 12,13-epoxy-species of linoleic acid, thus 
generating two regio-isomers (Scheme 4.3).  Therefore the identified products are 
proposed to be 13- and 15-hydroxy-16,17-epoxy-docosapentaenoic acid regio-isomers.  
The proposed mechanism for the production of these compounds is presented in Scheme 
4.3.  Due to the low yield of these compounds further characterisation by NMR 
spectroscopy to elucidate the complete structures was not carried out. 
C5H9-DHA branched isomers 
Finally, eluting later than DHA starting material by RP-HPLC (indicating the compounds 
are likely larger in structure and/or more non-polar than DHA) is a group of peaks at 40.6 
– 41.7 min, all with a λmax between 240 ‒ 244 nm indicating they contain a conjugated 
diene (Fig. 4.1; peaks IIIa ‒ c).  Reduction of these compounds with NaBH4 (1 M) had no 
effect on either their retention times or their absorbance spectra.  
The compounds were isolated and subjected to GC-MS following full catalytic 
hydrogenation and trimethylsilylation.  Six peaks were identified (again with a later 
elution time than DHA), all generating a similar mass spectrum, shown inset (Fig. 4.10).  
Analysis of fragmentation patterns indicated that the compounds were isomers of a C5H9-
branched DHA compound.  The following fragments were observed: 73 [TMS]+, 117 
[COOTMS]+, 411 [M - C5H9]+, 467 [M - CH3]+, and 482 [M]+.  
  
 
12
5 
  
 
Sc
he
m
e 
4.
3 
Fo
rm
at
io
n 
of
 e
po
xy
-a
lc
oh
ol
 re
gi
o-
is
om
er
s (
IIa
 &
 II
b)
 fr
om
 1
7S
-h
yd
ro
pe
ro
xy
-D
H
A
, t
hr
ou
gh
 th
e 
17
-a
lk
ox
yl
- a
nd
 1
6,
17
-e
po
xy
-a
lly
l-r
ad
ic
al
 in
te
rm
ed
ia
te
s. 
(R
1 =
 
C
11
H
15
O
2; 
R
2 =
 C
4H
8)
. 
  
 
126 
 
As fragmentation preferentially occurs at branching locations to generate the largest, 
most stable fragments, a loss of C5H9 is observed from all isomers regardless of the 
location of the branch point, therefore analysis of mass spectra cannot be used to 
identify structural isomers.  Additionally, analysis by HPLC-TOF-MS showed the set 
of compounds all had a molecular weight consistent with a C5H9-branched DHA 
structure (Table 4.1).   
 
Figure 4.10 GC-MS total ion chromatogram of peaks IIIa ‒ c (as full hydrogenated, trimethylsilyl 
ester derivatives).  Inset: Mass spectrum of first eluting peak (at 28.4 min). 
The set of isomers (IIIa ‒ c) was analysed by NMR spectroscopy after purification by 
semi-preparative NP-HPLC.  Due to the presence of co-eluting isomers (as 
demonstrated by GC-MS and HPLC-TOF-MS) complex splitting of signals was 
observed in the 1H-NMR spectrum, and calculation of J-coupling constants was not 
possible.  The proposed structure is supported by key features including peaks at 5.9 
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ppm (1H) and 6.3 ppm (1H) corresponding to a conjugated diene, as well as a complex 
methyl signal at 0.95 ppm which integrates to approximately 6H, consistent with the 
presence of two terminal methyl groups per molecule.  In the 13C-NMR spectrum, a 
range of isomers was also observed with multiple signals with varying integration, 
however importantly a signal at 44.96 ppm was detected corresponding to the tertiary 
carbon at the branching location (R3CH, where R = alkyl/alkyl carboxylic acid group).  
This signal was also reflected in the 13C-DEPT-135 spectrum as a positive signal, again 
indicating a tertiary carbon.  Finally, there was no evidence of chemical shifts 
representing oxygen-containing functional groups (other than the carboxylic acid), for 
example hydroxyl (1H: 4.2 – 4.5 ppm; 13C: 73.2 ppm), aldehyde (1H: 9.5-9.6 ppm; 13C: 
190 – 210 ppm), or conjugated oxodiene (1H: characterised by a shift of diene signals 
to aromatic region ~ 7.7 ppm; 13C: 190 – 210 ppm).  
The incorporation of a C5H9 fragment is attributed to the β-scission of the alkoxyl 
radical (to produce the aldehyde), generating a C5H9-radical which then recombines 
with conjugated Ly in the absence of molecular oxygen (Scheme 4.4).  The formation 
of a pentene fragment from DHA is analogous to the production of pentane in the 
metabolism of 13-HPODE by 15-sLOX-1 [197, 200-201].   
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Scheme 4.4 Proposed formation of branched C5H9-DHA compounds regio-isomers (IIIa – IIIc). (R1 = 
C11H15O2; R2 = C4H8). 
4.3.4 Analysis of 4-hydroxy-TEMPO radical-scavenging adducts 
To investigate the origin of the observed compounds from DHA, whether they are 
purely enzymatic or a result of enzyme-initiated free radical degradation, the reactions 
were performed in the presence of a stable radical scavenger.  4-Hydroxy-2,2,6,6-
tetramethylpiperidin-1-oxyl (4-hydroxy-TEMPO), a nitroxyl radical capable of 
forming stable adducts with carbon-centred (L●) and oxygen-centred (LO●) lipid 
radicals through radical recombination [247-248], was incubated with DHA under the 
described experimental conditions at a concentration of 1 mM.  The products were 
analysed by RP-HPLC with photodiode array and TOF-MS detection, as described in 
Materials and Methods.  
Under these conditions 4-hydroxy-TEMPO was able to intercept free radicals and 
significantly suppress the formation of products I-III.  A range of 4-hydroxy-TEMPO 
adducts were detected (Fig. 4.11; peaks A ‒ F), including four non-conjugated oxygen-
containing products (peaks A ‒ D) proposed to be (4-hydroxy-TEMPO)-16,17-epoxy-
docosapentaenoic acid adducts (Table 4.4).  As the epoxy-containing compounds are 
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known to stem from the 17-hydroperoxide intermediate the epoxy group is expected 
to be conserved at C16,17, with rearrangement of the radical to the C13 or C15 position 
[133, 246].  Therefore all isomers of each epoxy-alcohol (threo/erythro-epoxide and 
R/S adduct) may be possible (Scheme 4.5A).  This structure is in agreement with the 
TOF-MS data (Table 4.4) and is consistent with the results of Koshiishi et al. [173] 
using 3-carbomoyl-2,2,5,5-tetramethylpyrrolidine-N-oxyl (CmP) as a radical 
scavenger, where four proposed epoxy-CmP-adducts were observed from incubation 
of linoleic acid with sLOX-1 under anaerobic conditions.  
 
Figure 4.11 RP-HPLC-DAD chromatogram (baseline corrected) of DHA products catalysed by 15-
sLOX-1 under anaerobic conditions in the presence of 4-hydroxy-TEMPO.  Reaction conditions: 0.50 
mM DHA, 150 kunits 15-sLOX-1, 1.0 mM 4-hydroxy-TEMPO, N2-purged Na-tetraborate buffer (pH 
10), 30 min reaction time.  
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Two peaks were detected that indicated conjugation (λmax = 238 nm) and these were 
found to be from (4-hydroxy-TEMPO)-DHA adducts (Fig. 4.11; peaks E and F), likely 
to be 13-/17-regioisomers rather than R/S-stereoisomers based on the utilised 
separation mechanism and in agreement with previous observations (Scheme 4.5B) 
[247].  Analysis of peaks E and F by chiral phase-HPLC indicated these adducts are 
stereochemically pure as only one enantiomer was observed in each case.  In addition, 
highly symmetrical peaks were obtained under several chromatographic conditions 
designed to optimise any potential separation of isomers. 
Previous studies have indicated the radical scavenger CmP facilitates the dissociation 
of lipid allyl radicals from the active site by converting them into nitroxyl radical-lipid 
adducts, thus maintaining the stereo-specificity of 15-sLOX-1 in the adducts [133, 194, 
196].  The stereochemistry of the products observed here are also in support of this 
mechanism.  If L● species were released from the enzyme both R and S stereoisomers 
of each regio-isomer would be expected.  Likewise the isomeric distribution of peaks 
A-D indicates the formation of adducts A and B is favoured over C and D.  
Previous observations of reaction rates between linoleate-derived radicals (L●), O2 
and nitroxyl radicals show the reaction of L● with O2 is faster than with nitroxyl 
radicals [173].  This has also been observed in these experiments where 4-hydroxy-
TEMPO adduct formation is absent under aerobic conditions where lipid substrate is 
completely consumed prior to O2 depletion.  In these experiments the aerobic 
products of DHA catalysed by 15-sLOX-1, 7S,17S-diHDHA and 10S,17S-diHDHA, 
are observed (Fig. 4.12; inset).  In addition, adduct formation is not observed when 
4-hydroxy-TEMPO is incubated with DHA in the absence of 15-sLOX-1.  Therefore 
the anaerobic products described likely arise from LOX-initiated activity (i.e. 
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cleavage of the hydroperoxide), however undergo non-enzymatic degradation (which 
may be inhibited by radical scavenger) to form the detected products. 
 
 
Scheme 4.5 A - Formation of oxygen containing 4-hydroxy-TEMPO adduct regio- and stereo-isomers 
(A – D) through the formation of the alkoxyl radical intermediate.   B – Formation of non-oxygen-
containing 4-hydroxy-TEMPO adduct regio-isomers (E – F) through the formation of fatty acid 
radicals in the absence of oxygen. 
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Figure 4.12 RP-HPLC chromatogram of DHA reaction products catalysed by 15-sLOX-1 under 
aerobic conditions, in the presence of 4-hydroxy-TEMPO (baseline corrected).  Reaction conditions: 
0.10 mM DHA, 150 kunits/ml 15-sLOX-1, air-saturated Na-tetraborate (pH 9.0), 1 mM 4-hydroxy-
TEMPO.  Inset: Expanded region of 10 – 20 min.  * Minor stereo-isomers of major labelled products 
– 7S,17S-diHDHA and 10S,17S-diHDHA. 
4.3.5 Use of 2-methoxyphenol as a co-substrate 
To confirm the requirement of a hydrogen-donating co-substrate for 
lipohydroperoxidase activity of 15-sLOX-1, anaerobic incubations were carried out in 
the presence of the non-lipid hydrogen donor, 2-methoxyphenol (guaiacol).  The use 
of 2-methoxyphenol has been developed as a colorimetric assay for peroxidase activity 
through the detection of the coloured oxidation product, 3,3′-dimethoxy-4,4′-
biphenoquinone [249].   
The 13-hydroperoxide of linoleic acid (13-HPODE) was prepared as described 
previously [126] and the purity confirmed by NP-HPLC.  A small amount of 9-
HPODE was also produced, however importantly no linoleic acid substrate remained.  
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The prepared 9-/13-HPODE was incubated with 15-sLOX-1 in the absence or presence 
of 2-methoxyphenol (20 mM) under the optimised anaerobic conditions, and the 
extracted products analysed by RP-HPLC as described in Materials and Methods.  As 
shown in Fig. 4.13A, when 13-HPODE with 15-sLOX-1 is incubated in the absence 
of a hydrogen donor or other co-substrate, there is no conversion of 13-HPODE to the 
anaerobic products.  However in the incubation of 13-HPODE with 15-sLOX-1 and 2-
methoxyphenol, a compound known to readily donate hydrogen to reduce Fe3+ to Fe2+ 
[202], 13-HPODE is completely consumed (Fig. 4.13B) and converted to anaerobic 
products 13-oxo-tridecadienoic acid and 13-oxo-octadecadienoic acid.  
4.3.6 Lipohydroperoxidase activity with other LC-PUFAs 
The anaerobic metabolism of 13-HPODE in the presence of linoleic acid by 15-sLOX-
1 has been thoroughly investigated, however little is known about the metabolised 
products of other biologically relevant LC-PUFAs.  Arachidonic acid (ARA/ETE; 
C20:4n-6), eicosapentaenoic acid (EPA; C20:5n-3), and more recently 
docosapentaenoic acids (DPA; C22:5n-3 and n-6) are known to be converted by 
mammalian LOXs to important bioactive lipid mediators including leukotrienes and 
resolvins under aerobic conditions [1, 190].  The conditions for anaerobic metabolism 
were applied to this range of substrates and the products analysed by RP-HPLC with 
diode array and TOF-MS detection (Table 4.5).  
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Figure 4.13 RP-HPLC chromatogram of 13-HPODE incubated with 15-sLOX-1 (A) in the absence of 
a hydrogen donor, and (B) in the presence of 2-methoxyphenol.  Absorbance measured at 234 nm. * 
Denotes products; a Denotes trace 13-HPODE. 
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Table 4.5.   A summary of the products identified from the anaerobic metabolism of LC-PUFAs by 
15-sLOX-1 under the described experimental conditions. 
(*) Major products. 
(-) No products detected. 
 
A clear difference between metabolism of omega-3 and omega-6 substrates was 
observed in the product profiles, with only omega-3 substrates (EPA and DPAn-3) 
converted to the C5H9-branched compounds observed in DHA metabolism.  In 
contrast, omega-6 substrates generated major products analogous to linoleic acid 
metabolism, including 15-oxo-ETE and 15-oxo-pentadecatrienoic acid from 
arachidonic acid from ARA, and 17-oxo-DPAn-6 and 17-oxo-heptadecapentaenoic 
acid from DPAn-6.  Ketones were only produced in small quantities from omega-3 
substrates.  Dimers of linoleic acid have been detected and characterised under 
anaerobic conditions previously [170], however under our conditions dimeric 
compounds were only observed from EPA and DPAn-3 substrates as very minor 
products.  Conjugated diene-containing dimers (λmax 235 nm) eluted approximately 
Substrate 
Product 
LA (C18:2n-6) ARA (C20:4n-6) DPA (C22:5n-6) 
Aldehyde 13-oxo-tridecadienoic 
acid * 
15-oxo-pentadecatrienoic 
acid * 
17-oxo-
heptadecapentaenoic acid * 
Ketone 13-oxo-ODE * 15-oxo-ETE * 17-oxo-DPA * 
Epoxy-alcohol - hydroxy-epoxy-ETrE * hydroxy-epoxy-DTA * 
Branched - - - 
Hydroxyl hydroxy-ODE hydroxy-ETE hydroxy-DPA 
Dimer - - - 
Substrate 
Product 
EPA (C20:5n-3) DPA (C22:5n-3) DHA (C22:6n-3) 
Aldehyde 15-oxo-
pentadecatetraenoic acid 
* 
17-oxo-
heptadecatetraenoic acid 
* 
17-oxo-
heptadecapentaenoic acid * 
Ketone 15-oxo-EPA 17-oxo-DPA 17-oxo-DHA 
Epoxy-alcohol hydroxy-epoxy-ETA hydroxy-epoxy-DTA * hydroxy-epoxy-DPA * 
Branched C5H9-EPA * C5H9-DPA * C5H9-DHA * 
Hydroxyl - hydroxy-DPA - 
Dimer EPA dimer DPA dimer - 
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7 min after the C5H9-branched compounds in RP-HPLC, and TOF-MS data was 
consistent with structures of C40H58O4 and C44H66O4 for EPA and DPAn-3 dimers, 
respectively. 
Of note is the production of 15-oxo-ETE from ARA, which has been shown to be a 
bioactive metabolite of 15S-HETE oxidation by 15-hydroxy-prostaglandin 
dehydrogenase in mouse macrophage cells [236], as well as an arachidonic acid 
metabolite of COX-2 in rat intestinal epithelial cells [233] and 15-LOX-mediated 
oxidation in human mast cells [234].  As 15-oxo-ETE has been shown to inhibit cell 
proliferation in certain cell types [236-237], implicating potential as an anti-angiogenic 
compound,  the production of this compound and analogues from other LC-PUFA by 
15-sLOX-1 may be useful in future studies. 
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4.4 Conclusion 
Lipohydroperoxidase activity of 15-sLOX-1 is initiated when oxygen is completely 
depleted in the reaction medium and there is a significant excess of LC-PUFA 
substrate remaining in order to reduce LOX-Fe(III) to LOX-Fe(II).  Several major 
products have been detected and characterised from biologically relevant DHA, EPA, 
DPA and arachidonic acid substrates, including oxodienes (ketones and aldehydes), 
epoxy-alcohols and novel C5H9-substrate branched compounds.  Studies using the 
radical scavenger 4-hydroxy-TEMPO show these products are a result of 15-sLOX-1 
hydroperoxidase activity, catalysing the formation of unstable alkoxyl radical species 
which are then susceptible to radical recombination, rearrangement and/or 
degradation.  
The formation of these compounds has implications for the use of 15-sLOX-1 for the 
production of mono-, di- and tri-hydro(pero)xy fatty acids, as lipohydroperoxidase 
activity significantly reduces the yield of the desired products.  Hydro(pero)xy fatty 
acids produced by 15-sLOX-1 are also routinely used as reagents and test compounds 
without purification, therefore contamination may be likely, which has previously not 
been considered, especially for in vivo/vitro studies.  Finally, detection of these 
compounds in biological samples may serve as an indicator of oxidative stress, 
hypoxia and inflammation.  
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5. COVALENT IMMOBILISATION OF SOYBEAN 15-
LIPOXYGENASE-1 ON VARIOUS FUNCTIONALISED 
METHACRYLATE POROUS RESINS TO ENABLE 
MULTIPLE REUSE OF THE ENZYME 
5.1 Introduction  
An important limiting factor in the use of enzymes as biocatalysts for chemical 
synthesis is the inability to recover active enzyme after the catalytic process, 
effectively making soluble (or free) enzyme an uneconomical and single use 
biocatalyst.  Advances in techniques to immobilise enzymes on solid 
supports/matrices, such as silica-gel matrices and functionalised polymer beads, has 
driven the use of biocatalysts in industrial biotechnology applications [250-251].  
Immobilisation facilitates enzyme recovery and reuse with minimal effect on activity, 
as well as restricting carrythrough of protein material to subsequent processes [252].  
Immobilisation has also been shown to improve the activity and stability, and lengthen 
the half-life of enzymes, even under conditions outside the normal optimal range of 
the soluble enzyme (e.g. extreme pH and elevated temperature) [253-254]. 
Techniques for immobilisation include entrapment, solid support and carrier-free self-
immobilisation.  Entrapment involves entrapping or encapsulating enzyme units 
within a polymer matrix, commonly silica sol-gel formed by hydrolytic 
polymerisation.  Properties of the matrices (e.g. porosity, particle size, composition, 
surface functionalities) may be modified by adjusting polymerisation conditions, 
however entrapment techniques typically achieve low enzyme loading and have mass-
transfer limits due to separation of the enzyme from the reaction medium [250]. 
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Carrier-free, or self-immobilisation, is achieved through the use of bi-functional cross-
linkers, such as glutaraldehyde or dextran-aldehyde, to bind crystallised enzyme units 
together in the absence of a solid support [250, 253].  Although the limited control of 
particle size, increased structural rigidity and protein leaching into the reaction 
medium impose constraints on the activity and use of carrier-free self-immobilised 
enzymes, the technique produces stable particles with highly concentrated enzyme 
activity at low production costs [253]. 
Binding of enzymes to solid supports or carriers by adsorption, ionic or covalent 
bonding is a common method of immobilisation.  Both ionic and adsorption modes of 
binding produce structurally rigid particles which are stable in organic media, however 
the weaker mode of binding (H-bonding and  van der Waals forces) often results in 
leaching of protein into the reaction medium [255].   Covalent bonding utilises solid 
supports functionalised with reactive epoxy, thiol or amino groups.  In this mode of 
binding, the amino groups of surface residues of the enzyme are exploited to provide 
a covalent bond to the functionalised resin [250].  Alkyl spacers may also be 
introduced during the functionalization process, or by activation with glutaraldehyde, 
allowing more flexible linkages between the enzyme and the support.  The strong 
covalent bonds limit leaching of the protein from the resin, however enzyme loading 
is typically lower than ionic and adsorption binding and enzymes may be sterica lly 
constrained due to short, inflexible linkages, resulting in decreased catalytic activity 
[254].  
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For covalent immobilisation of enzyme on a support the pore diameter of the resin is 
an important factor in selecting a carrier, therefore the dimensions of the protein to be 
immobilised must be taken into consideration.  Pore diameters smaller or close to the 
dimensions of the enzyme may result in binding of the enzyme to the exterior surface 
of the resin, resulting in low protein loading.  However, larger pore diameters reduce 
reactive surface area for binding.  In addition, surface-bound enzyme is not protected 
from shear, inhibiting/inactivating detergents, solvents and air/gas bubbles which 
increase mass-transfer limitations [256-257].  
The immobilisation of soybean 15-lipoxygenase-1 has been performed previously for 
the production of hydroperoxides from linoleic acid [258-266] and oxidation of 
xenobiotics [267-269], demonstrating both dioxygenase and hydroperoxidase 
activities of 15-sLOX-1 remain intact upon immobilisation.  15-sLOX-1 has been 
commonly immobilised by entrapment on activated polymer sol-gel [258-259, 264-
265, 270-276], adsorption on ion exchange resins [37, 259] and modified silica [266, 
277], covalent bonding on oxirane (epoxy) resins (Table 5.1) [268-269, 276, 278-279], 
and also using other non-conventional supports (including glass wool, porous glass 
beads and magnesium silicate) [259, 262-263, 267, 276, 280], with immobilisation 
yields ranging from 10 ‒ 66% across all immobilisation techniques and enzyme 
carriers.  Immobilisation efficiency and residual specific activity were found to be 
significantly affected by changes in ionic strength, pH and temperature of the 
immobilisation buffer [258, 270, 276, 281].  As expected, the thermal and pH stability 
of the enzyme was increased upon immobilisation in some studies, with optimal 
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activity increased to 35 - 50°C (compared to 30°C for free enzyme), and the functional 
pH range extended to more acidic reaction mediums [258, 270, 276-277].   
 
The activity of immobilised 15-sLOX-1 is typically characterised with linoleic acid as 
substrate for the formation of total linoleic acid hydroperoxide (HPODE).  Several 
studies have undertaken characterisation of the products of immobilised 15-sLOX-1 
with linoleic acid and arachidonic acid substrates, noting the regiospecificity of the 
enzyme is maintained in the product profile (major products - 13-HPODE and 15-
HPETE, respectively) [258, 264-266, 278].  The aim of this chapter is to optimise the 
incubation conditions for the covalent immobilisation of 15-sLOX-1 on a range of 
commercially available functionalised methacrylate resins, and evaluate the stability 
and reusability of the preparations.  The most suitable candidates will then be selected 
(according to specific activity, stability and reusability) for further examination of 
dioxygenase activity with a range of LC-PUFAs for the production of SPM analogs in 
Chapter VI.
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5.2 Materials and Methods 
5.2.1 Materials 
Soybean 15-lipoxygenase 1 (EC 1.13.11.33, P1, 15.2 mg/ml, 9.52 Munits/ml) was 
purchased from Sapphire Bioscience (Waterloo, NSW, Australia).  Docosahexaenoic 
acid and linoleic acid (Nu-Chek Prep) were purchased from Adelab Scientific 
(Thebarton, SA, Australia).  All enzyme carrier methacrylate resins (epoxy, C2-amino 
and C6-amino; 600 ‒ 1200 Å and 1200 ‒ 1800 Å) were purchased from Purolite Pty 
Ltd (Baulkham Hills, NSW, Australia).  Sodium tetraborate decahydrate, potassium 
phosphate monobasic, potassium phosphate dibasic, sodium chloride, bovine serum 
albumin and glutaraldehyde were purchased from Sigma-Aldrich (Castle Hill, NSW, 
Australia).  Bio-Rad protein assay dye reagent (Bradford reagent) was purchased from 
Bio-Rad Laboratories (Gladesville, NSW, Australia). 
5.2.2 General immobilisation procedures 
Epoxy methacrylate resins 
Resins (0.5 g) were equilibrated in 4 ml 0.1 M potassium phosphate buffer (pH 8.0) 
for 30 min on ice.  Freshly thawed 15-sLOX-1 (5 mg) was diluted in 1 ml 0.1 M 
potassium phosphate buffer (pH 8.0) and added quantitatively to the resin/buffer 
mixture.  The resins were incubated on ice for 24 hours.  After incubation the 
supernatant was recovered and assayed for protein concentration using the Bradford 
method (see below).  Resins were washed with 2 × 5 ml volumes of 50 mM sodium 
tetraborate (pH 9), and a final wash of 5 ml 0.5 M NaCl in 50 mM sodium tetraborate.  
All washes were recovered and assayed for protein concentration by the Bradford 
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method (duplicate).  LOX-immobilised resins were stored at -20°C, and kept on ice 
when in use. 
Amino methacrylate resins 
Resins (0.5 g) were activated with 2% (v/v) glutaraldehyde for 1 hr at room 
temperature with stirring immediately prior to immobilisation reactions.  Resins were 
washed with 5 volumes of 50 mM sodium tetraborate, and equilibrated with 4 ml 0.01 
M potassium phosphate buffer (pH 8.0) for 30 min on ice.  Freshly thawed 15-sLOX-
1 (5 mg) was diluted in 1 ml 0.01 M potassium phosphate buffer (pH 8.0) and added 
quantitatively to the resin/buffer mixture.  The resins were incubated on ice for 24 
hours.  After incubation the supernatant was recovered and assayed for protein 
concentration by the Bradford method (duplicate).  Resins were washed with 2 × 5 ml 
volumes of 50 mM sodium tetraborate (pH 9), and a final wash of 5 ml 0.5 M NaCl in 
50 mM sodium tetraborate.  All washes were recovered and assayed for protein 
concentration by the Bradford method (duplicate).  15-sLOX-1-immobilised resins 
were stored at -20°C, and kept on ice when in use. 
5.2.3 Bradford protein concentration assay 
A series of bovine serum albumin (BSA) standards were prepared (0.00 ‒ 1.00 mg/ml).  
Samples were prepared and diluted as appropriate within the linear range of the assay 
(0.00 ‒ 1.00 mg/ml).  Bio-Rad protein assay dye reagent concentrate was diluted 1 part 
reagent to 4 parts deionised water and filtered under vacuum immediately prior to 
performing the assay.  50 μl of BSA standard or sample was incubated with 2.50 ml 
reagent for 10 min, with measurements taken within 30 min.  The absorbance of the 
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protein solution was measured at 595 nm using a Cary Series 300 UV-visible 
spectrophotometer (Agilent Technologies, Mulgrave, VIC, Australia).  Analyses were 
performed at room temperature in a 10 mm path length quartz cuvette.  Measurements 
were performed in triplicate (standards) or duplicate (samples), and blank absorbance 
values subtracted.   
5.2.4 Dissolved oxygen consumption assay 
The enzyme activity of soluble and immobilised 15-sLOX-1 was measured by the 
initial rate of dissolved oxygen consumption (V0).  Measurement of dissolved O2 
concentration was carried out using a polarographic O2 electrode (Qubit Systems Inc., 
John Morris, Australia) with a two-point calibration. 
Assays were performed in a total volume of 3 ml in 50 mM sodium tetraborate (pH 
9.0) at 25°C, with constant moderate stirring.  Soluble or immobilised 15-sLOX-1 
(0.75 mg) was added to the buffer and allowed to temperature equilibrate (until oxygen 
concentration stabilised).  Linoleic acid substrate was freshly prepared as a 10 mM 
solution in 50 mM sodium tetraborate (containing 10% v/v ethanol; final ethanol 
concentration was 0.1% v/v).  Reactions were initiated with the addition of 30 μl 10 
mM linoleic acid solution (final concentration ‒ 0.1 mM), and allowed to proceed until 
oxygen concentration again stabilised.  Measurements were performed in duplicate.  
LOX activity was calculated as initial velocity (V0) for the consumption of oxygen 
(mg/l/min).  
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5.2.5 Kinetic parameters for soluble (LOXSol) and immobilised LOX (LOXImm)  
Activity assays were performed as described above for dissolved oxygen consumption.  
Linoleic acid substrate was prepared as 1 mM or 10 mM solutions in 50 mM tetraborate 
(10% v/v ethanol), and the activity of soluble and immobilised LOX measured in the 
substrate concentration range 0 – 0.25 mM.  Measurements were performed in 
triplicate and the data analysed using the Michaelis-Menten kinetic model (GraphPad 
Prism, v6.05, La Jolla, CA). 
5.2.6 Thermal stability of soluble LOX and immobilised LOX 
Soluble lipoxygenase (0.75 mg) was incubated at the following temperatures for 0 ‒ 
120 min: 2°C (on ice), 22°C (ambient), 40°C, 60°C and 80°C.  Residual LOX activity 
was measured according to the standard dissolved oxygen assay conditions (0.1 mM 
linoleic acid, 50 mM sodium tetraborate, pH 9.0, 25°C).  Incubations and 
measurements were performed in duplicate. 
For calculation of thermal inactivation values, T50 and Topt, 15-sLOX-1 (soluble and 
immobilised) was incubated for 10 min at 5°C intervals between 25°C and 80°C.  LOX 
activity was measured immediately after incubation according to the standard 
dissolved oxygen assay.  Incubations and measurements were performed in duplicate. 
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5.3 Results and Discussion 
For this study the covalent binding of lipoxygenase to functionalised resin was selected 
as the most appropriate mode of immobilisation.  This type of immobilisation produces 
structurally rigid particles with multipoint attachment of the enzyme, the resins are 
easily recovered by filtration and are mechanically stable, while protein leaching is 
minimised and mass-transfer is not as limited as in other techniques.  Pre-
functionalised enzyme carrier resins were acquired from Purolite Lifetech TM 
(Australia).  Resins were selected based on their binding mode, mechanical stability, 
pH range and pore diameter.  As a result, two epoxy and four amino functionalised 
resins were selected, varying in pore diameter (600 ‒ 1200 Å and 1200 ‒ 1800 Å) and 
alkane spacer length (C2 and C6; in the case of amino resins).  For clarity the selected 
resins will be referred to herein in their abbreviated form, as shown in Table 5.2. 
Table 5.2 Abbreviations of resins used in this study. 
Pore diameter 
Resin 
600 ‒ 1200 Å 1200 ‒ 1800 Å 
Epoxy EM600 EM1200 
C2 amino C2AM600 C2AM1200 
C6 amino C6AM600 C6AM1200 
 
5.3.1 Bradford protein determination assay 
Protein loading was determined by the difference in starting protein concentration and 
of subsequent washes using Bradford method [282].  This method measures the 
increase in absorbance of ‘Coomassie brilliant blue’ stain (G-250) at 595 nm, resulting 
from the interaction between the dye and ionisable groups of the protein.  Bovine 
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serum albumin was used as a standard for protein concentration, producing a standard 
calibration curve over the linear range of 0.10 ‒ 1.00 mg/ml (Fig. 5.1).   
 
Figure 5.1 Standard curve for bovine serum albumin protein standard using the Bradford protein 
determination method.  Linear range: 0.01 ‒ 1.00 mg/ml.  Measurements were performed in triplicate.  
Maximum standard deviation < 0.02. 
5.3.2 Preliminary screening of immobilisation and optimisation 
Preliminary immobilisations were carried out in potassium phosphate buffer (pH 8.0) 
at 2 – 4°C (incubated on ice) for 24 h.  As per the manufacturer’s recommendations, 
immobilisation on epoxy-functionalised methacrylate resins was performed in higher 
ionic strength buffer (0.05; 0.10 M potassium phosphate), whereas for amino-
functionalised resins a lower ionic strength was used (0.005; 10 mM potassium 
phosphate).  Amino-functionalised resins were activated with 2 % (v/v) glutaraldehyde 
prior to immobilisation, and washed five times to eliminate residual glutaraldehyde.  
Initial 15-sLOX-1 concentration was 5 mg protein per 0.5 g of resin for preliminary 
screening. 
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Post-immobilisation – unbound protein determination 
The number of washes required to completely remove non-covalently bound protein 
from the resin was determined to ensure accurate protein loading calculations. The 
supernatant (Fig. 5.2; sample S) was recovered following incubation (1.0 mg/ml 15-
sLOX-1 with 0.5 g of resin), and the resins washed with 3 × 5 ml volumes of rinsing 
buffer – two volumes of low ionic strength buffer (0.025; 50 mM sodium tetraborate; 
W1 & W2), and a final wash with 0.5 M NaCl in 50 mM sodium tetraborate (ionic 
strength 0.275; W3).  All solutions were recovered and assayed for protein 
concentration using the described Bradford method.  At the end of the washing process 
the residual protein was undetectable, as shown in Fig. 5.2.  The same washing process 
was also found to be suitable for all other resins (not shown).    
 
Figure 5.2 Number of washes required to remove unbound soluble 15-sLOX-1 from epoxy 
methacrylate resin (1200 ‒ 1800 Å).  Protein determination by Bradford method (linear range: 0.10 – 
1.00 mg/ml). S, supernatant; W1-3, washes (as described in Materials and Methods). 
Incubation time  
Optimal incubation times were determined by monitoring soluble protein 
concentration of the supernatant.  Aliquots (50 μl) from the bulk immobilisation 
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mixture were taken at the indicated time points and diluted as required (to within the 
linear range of the assay; 0.1 – 1.0 mg/ml). 
 
Figure 5.3. Effect of incubation time on immobilisation of 15-sLOX-1 on EM1200, C2AM1200 and 
C6AM1200 resins.  Incubation conditions: 5 mg soluble 15-sLOX-1; 0.5 g resin; 5 ml 0.01 M 
potassium phosphate, pH 8.0; on ice (2 ‒ 4°C); no stirring.   
As shown in Fig. 5.3, immobilisation on epoxy-functionalised resins (EM1200) 
proceeded rapidly reaching ~ 50% bound protein within 2 h, and maximum binding 
within 12 h.  In contrast, immobilisation on amino-functionalised resins experienced a 
slower degree of binding, however achieved an equivalent (C2AM1200) or higher 
yield (C6AM1200) with incubation times up to 48 h.  These differences in 
immobilisation rates are consistent with the increased reactivity of the epoxide species, 
compared to the carbonyl ligand (achieved by glutaraldehyde activation of the amino-
functionalised resins). 
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5.3.3 Optimisation of incubation conditions 
Epoxy methacrylate (pore diameter: 1200 ‒ 1800 Å) (EM1200) 
Epoxy (or oxirane) functionalised resins allow stable and multipoint covalent 
attachment of enzymes through ring-opening of the epoxy group under alkaline 
conditions, and subsequent nucleophilic attack by the surface residue primary amines 
(Fig. 5.4).  This type of binding has been commonly used for the immobilisation of 
enzymes, and several studies describe the use of lipoxygenase (including soybean and 
potato tuber) immobilised on Eupergit resins (an analogous oxirane support) [268-269, 
273, 276, 278-279].  Binding efficiencies in these studies (where described) vary 
greatly from as low as 13% up to 56%, with varying degrees of residual LOX activity 
and stability (refer to Table 5.1).  This variability demonstrates the importance of 
incubation conditions, such as temperature, coupling buffer ionic strength and pH, and 
incubation time for efficient immobilisation of lipoxygenase. 
 
Figure 5.4. Immobilisation of enzyme on epoxy carrier resin.  
To optimise the binding capability of the epoxy resin several parameters were 
examined.  Based on previous literature, a potassium phosphate coupling buffer of 
higher ionic strength (0.1 M; I = 0.05) was used for all incubations.  Standard 
incubation conditions were as follows: 5 mg protein, 0.5 g resin, 5 ml coupling buffer, 
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incubations performed on ice for 12 h without stirring.  For optimisation experiments 
the following parameters were examined – coupling buffer pH (range 6.0 ‒ 10.0), 
incubation temperature (on ice, ambient temperature or 35°C), and agitation (no 
stirring, mechanical stirring or rotation).  The total recovered LOX (TRL) activity of 
the immobilised 15-sLOX-1 was also determined (using a dissolved oxygen 
consumption assay).  TRL activity was calculated as the percentage of soluble LOX 
activity remaining when incubated under the same conditions, therefore takes into 
account the removal of unbound enzyme as well as the reduction in activity. 
According to the manufacturer’s specifications, the pH limits of the epoxy resin to 
maintain operational stability is between pH 5 – 9.  As shown in Figure 5.5A, the 
binding efficiency of 15-sLOX-1 to EM1200 was greatest at pH 9.0.  Similar loading 
was achieved up to pH 10.0 with no observable physical degradation of the resin.  
Alkaline conditions favour ring-opening of the epoxy group, therefore the resin is 
susceptible to non-specific reaction with strong nucleophiles, including amino 
hydroxyl groups and 1°, 2° and 3° amines.  The pKa of the lysine amino side chain of 
the enzyme (the major residue responsible for covalent attachment) is 10.5, therefore 
at alkaline pH the reactivity of the side chain is increased and may readily undergo 
reaction with the (ring-opened) epoxy resin [254].  As the TRL activity was greatest 
at pH 8.0, with a minimal decrease in enzyme loading, pH 8.0 was selected as optimal 
for this type of immobilisation. 
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Figure 5.5 Effect of incubation conditions (A: buffer pH; B: temperature; C: stirring type) on 
immobilisation of 15-sLOX-1 on EM1200.  Standard incubation conditions: 5 mg soluble 15-sLOX-1; 
0.5 g EM1200 resin; 5 ml 0.1 M potassium phosphate, pH 8.0, 12 h incubation; on ice (2 ‒ 4°C); no 
stirring.   
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An increased loading was achieved on increasing the incubation temperature from 4°C 
to 35°C (54% to 76% efficiency) (Fig. 5.5B).  This is likely due to increased energy 
resulting in a greater number of collisions between the resin and enzyme units.  
However increased incubation temperature significantly reduced the activity of the 
enzyme, therefore performing incubations on ice was considered to be most 
appropriate method to maintain optimal catalytic activity.   
Agitation of the incubation mixture by rotational stirring was also found to improve 
loading as well as maintain enzyme activity (Fig. 5.5C).  According to manufacturer’s 
specification, the functionalised resins for covalent attachment are mechanically stable 
using magnetic stirring (for up to three hours in water at room temperature, RPM not 
specified) [283].  In these experiments the use of magnetic stirring (mechanical) 
enabled adequate loading, however under visual inspection of the recovered resin, 
particulates were observed as a result of bead breakage. In addition the activity of the 
enzyme was found to decrease significantly (compared to no stirring and rotational 
stirring). 
Amino methacrylate carrier resins 
Covalent attachment using amino-functionalised resins requires pre-activation to 
provide carbonyl species for reaction with amino moieties of the enzyme (Fig. 5.6). 
Glutaraldehyde, a bi-functional cross-linker, is commonly used as an activator of solid 
supports for enzyme immobilisation [284-286].  The method for glutaraldehyde 
activation is simple and efficient, resulting in the formation of di-imino functionality 
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upon reaction with the NH2 surface residues of enzymes.  This type of covalent binding 
allows multipoint attachment to produce stable immobilised enzyme.   
To date, the immobilisation of 15-sLOX-1 has not been performed using 
glutaraldehyde-activated amino methacrylate resins.  Several studies have utilised 
glutaraldehyde-activated silica [266] and polyacrylamide sol-gels [258, 270], again 
with varying residual activity (~1% to 50% of free LOX activity) and binding 
efficiencies of approximately 50%.  In this study, two amino-based resins are 
investigated with different alkane spacer chains between the methacrylate resin and 
the terminal amino group.  Previous data shows that if the support is rigid and the 
spacer arms are short all enzyme units should maintain their relative positions and 
structure [256].  The length of the spacer chain therefore may have effects on the 
rigidity and flexibility of the enzyme, potentially resulting in constriction of the 
enzyme conformation and the degree of attachment [284].  This in turn may have 
implications for the TRL activity of the immobilised enzyme.   
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Figure 5.6. Pre-activation of amino-functionalised carrier resins (where n = C2 and C6) with 
glutaraldehyde, and covalent immobilisation of enzyme. 
Previous studies of immobilisation of several enzymes (including glutaryl-7-ACA-
acylase and D-amino acid oxidase) on glutaraldehyde-activated supports indicated the 
mechanism of binding was significantly affected by the ionic strength of the coupling 
buffer [284].  In this study by Betancor and co-workers [284], it was found that by 
using buffers of low ionic strength the immobilisation proceeded first by adsorption of 
the enzyme on to the support via ion exchange interactions, followed by rapid covalent 
attachment.  Whereas in higher ionic strength coupling buffers a slower rate of 
immobilisation was observed through direct covalent attachment.  These results 
suggested immobilisation conditions could also control the location of binding of the 
enzyme to the support, as low ionic strength buffers would favour binding to 
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negatively charged areas of the protein surface (due to the initial ionic interactions), 
whereas at higher ionic strength binding would be favoured at areas with high amino 
group reactivity.    
For this study the coupling of 15-sLOX-1 on glutaraldehyde-activated amino resins 
was performed in lower ionic strength buffers (I = 0.005; as per the manufacturers 
recommendations) to exploit both ion-exchange and covalent interactions. The effect 
of attachment chain length was also briefly investigated in this study by using two 
amino-functionalised resins with either a C2 or C6 linker (as described in Fig. 5.6).  As 
was done for epoxy resins, several parameters were investigated to optimise the 
immobilisation on amino functionalised resins – coupling buffer pH, incubation 
temperature and stirring.  All resins were activated with 2% (w/v) glutaraldehyde for 
1 hour at room temperature.  Activated resins were washed thoroughly to ensure 
complete removal of residual unreacted glutaraldehyde prior to incubation with 
enzyme.  TRL activity was calculated as the percentage of soluble LOX activity 
remaining when incubated under the same conditions, therefore takes into account the 
removal of unbound enzyme as well as the reduction in catalytic activity.  
C2-amino methacrylate (pore diameter: 1200 ‒ 1800 Å) (C2AM1200) 
As discussed previously performing the immobilisation at higher pH typically favours 
binding due to increased reactivity of amino residues on the protein surface.  However, 
for glutaraldehyde-activated amino carriers immobilisation was favoured at lower pH, 
resulting in a ~ 50% decrease when the pH was increased from 6.0 to 10.0 (Fig. 5.7A).  
This observation is likely due to the instability of glutaraldehyde at alkaline pH [284].  
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As observed for the epoxy-functionalised resins, optimal enzyme activity occurred 
when incubations were performed at pH 8.0.  Likewise, optimal lipoxygenase activity 
was achieved when incubations were performed on ice (~ 4°C) despite increased 
loading at higher temperatures (Fig. 5.7B), and rotational stirring resulted in 95% 
loading efficiency however enzyme activity was slightly reduced (Fig. 5.7C).  
C6-amino methacrylate (pore diameter: 1200 ‒ 1800 Å) (C6AM1200) 
The coupling of 15-sLOX to glutaraldehyde activated C6-amino resins occurred with 
a similar efficiency to the C2-amino resin, and similar enzyme loading values were 
achieved for all variables (Fig. 5.8).  However the TRL activity of the C6-linker 
activated amino resins was found to be lower than that observed for the C2-linker resin 
under all incubation conditions.  The similar enzyme loading values indicate the same 
mode of binding occurred (i.e. the formation of the di-imino functionality), therefore 
the length of the alkyl linker likely plays a key role in maintaining the structure of the 
enzyme.  Two theoretical possibilities exist to account for the reduced activity: (1) The 
increased flexibility instilled by the longer alkyl linker may reduce the stability of the 
enzyme preparation [250]; and (2) the density and spatial distribution of attachments 
may impose structural constraints, steric hindrance, or restrict substrate access [250, 
284], as C6 linkers can be expected to extend further around the enzyme than the C2 
linker.  However, the effect of linker length was not examined further in this study. 
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Figure 5.7. Effect of incubation conditions (A: buffer pH; B: temperature; C: stirring type) on 
immobilisation of 15-sLOX-1 on C2AM1200.  Standard incubation conditions: 5 mg soluble 15-
sLOX-1; 0.5 g C2AM1200 resin; 5 ml 0.01 M potassium phosphate, pH 8.0, 24 h incubation; on ice (2 
‒ 4°C); no stirring. 
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Figure 5.8 Effect of incubation conditions (A: buffer pH; B: temperature; C: stirring type) on 
immobilisation of 15-sLOX-1 on C6AM1200.  Standard incubation conditions: 5 mg soluble 15-
sLOX-1; 0.5 g C6AM1200 resin; 5 ml 0.01 M potassium phosphate, pH 8.0, 24 h incubation; on ice (2 
‒ 4°C); no stirring. 
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5.3.4 Application of optimised conditions to complete resin range 
The combined optimised conditions are summarised in Table 5.3, and were applied to 
the complete range of resins in two pore diameters (600 ‒ 1200 Å: EM600, C2AM600, 
C6AM600; and 1200 ‒ 1800 Å: EM1200, C2AM1200, C6AM1200).  Resins were 
evaluated for enzyme loading and LOX activity.  In addition, the stability of the 
preparations during consecutive freeze-thaw cycles (representative of storage 
conditions) was examined. 
Table 5.3 Summary of optimised conditions for immobilisation of 15-sLOX-1. 
 Epoxy (EM) C2 amino (C2AM) C6 amino (C6AM) 
Incubation buffer 
Potassium phosphate 
0.1 M 
Potassium phosphate 
0.01 M 
Potassium phosphate 
0.01 M 
Ionic strength 0.05 0.005 0.005 
pH 8.0 8.0 8.0 
Temperature 4°C (on ice) 4°C (on ice) 4°C (on ice) 
Agitation Rotation Rotation Rotation 
Incubation time 24 hr 48 hr 48 hr 
 
Under the described optimum incubation conditions similar loading values were 
achieved for both pore diameter ranges of the epoxy functionalised resin with a starting 
enzyme concentration of 10 mg protein/g resin (Fig. 5.9A).  For the amino 
functionalised resins a smaller pore diameter enabled slightly increased binding 
(C2AM600 and C6AM600).   
The catalytic mass of immobilised enzyme has been previously estimated to account 
for only small amounts (typically ~ 10%) of the total immobilised enzyme mass 
(catalytic and non-catalytic) [287].  To optimise the efficiency of these biocatalysts the 
space-time yield must be improved by producing immobilised enzymes with high 
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loading and increased volume activity [287].  Therefore in order to increase the loading 
in this study the enzyme concentration was increased to 100 mg protein/g resin, 
achieving a final enzyme loading range of 59 – 68 mg protein/g resin (Fig. 5.9B) with 
total retained activity of approximately 5 – 10 % of the soluble enzyme form.  
 
Figure 5.9 Immobilisation efficiency A: 10 mg soluble 15-sLOX-1 per 1 g resin under optimised 
conditions.  B: 100 mg soluble 15-sLOX-1 per 1 g resin under optimised conditions.  
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The dioxygenase activity and stability of the range of resin-bound enzyme and soluble 
15-sLOX-1 was analysed using the previously described dissolved oxygen 
consumption assay.  Briefly, soluble and immobilised 15-sLOX-1 were stored at 
−20°C and defrosted at two-day intervals, for five consecutive cycles (all preparations 
were thawed on ice immediately prior to performing the activity assay).  Resin-bound 
enzyme was assayed as single-use preparations (i.e. it was not recovered and reused in 
subsequent assays) to examine the effect of storage, and to eliminate the contribution 
of enzyme inactivation due to catalysis. 
As shown in Fig. 5.10A, the use of resins with a smaller pore diameter (600 – 1200 Å) 
resulted in an increase in 15-sLOX-1 activity for all functionalised resins, despite 
similar protein loading efficiencies of both pore diameter resins.  This effect has been 
observed previously where a smaller pore size (< 1000 Å) has been correlated with 
increased retention of activity (with comparable enzyme loading) [288]. Ideally, 
enzyme units are uniformly distributed over the support surface to generate a 
monolayer of enzyme.  However in the case of larger pore size resins, where surface 
area is reduced, interactions between individual units may occur resulting in the 
formation of multi-layers of enzyme.  In this case enzyme activity may be limited by 
substrate diffusion constraints as well as by blocking the entry of the enzyme active 
site, resulting in similar loading values but an apparent reduction in activity [288].  
LOX activity significantly decreased upon one cycle of storage for most resins, with 
residual activity after five consecutive cycles ranging from 9% (C2AM600) to 24% 
(EM600) of the initial activity.  In contrast soluble 15-sLOX-1 exhibited unexpected 
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stability, experiencing an approximate 23% decrease in activity after five freeze-thaw 
cycles (77% residual activity) (Fig. 5.10B).   
Based on the increased binding efficiency and total recovered LOX activity achieved 
using epoxy and C2-amino functionalised resins, these resins were selected to continue 
stability, kinetic and catalysis studies. 
5.3.5 Estimation of kinetic parameters 
Kinetic parameters were estimated for both forms (soluble and immobilised) of 15-
sLOX-1 using the described dissolved oxygen consumption assay.  Briefly, 0.75 mg 
15-sLOX-1 was added to solutions of linoleic acid over the concentration range 0.01 
‒ 0.60 mM and the initial velocity of the reaction (V0) measured.  Measurements were 
performed in duplicate, and kinetic parameters were calculated using the Michaelis -
Menten kinetic model as previously described (refer to page 88) and are summarised 
in Table 5.4. 
Table 5.4 Estimation of kinetic parameters for LOXSol and LOXImm. Measurements were performed in 
duplicate and the data fitted to a Michaelis-Menten kinetic model. 
Parameter 
 
LOXImm LOXSol 
 EM600 EM1200 C2AM600 C2AM1200 
Vmax (mM/min) 0.076 0.16 0.053 0.053 4.64 
Km (mM) 0.097 0.119 0.184 0.138 0.371 
kcat (s-1) 1.7 × 103 3.6 × 103 1.2 × 103 1.2 × 103 1.05 × 105 
kcat/km (M-1 s-1) 1.8 × 107 3.0 × 107 6.5 × 106 8.6 × 106 2.8 × 108 
R2 0.96 0.89 0.97 0.97 0.98 
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As indicated by the estimation of kinetic parameters, soluble 15-sLOX-1 exhibits 
greater affinity of the enzyme for the substrate as shown by a significantly higher 
catalytic turnover number (kcat), 1.05 × 105 s-1.  This value is orders of magnitude 
greater than those observed for all immobilised forms (1.2 ‒ 3.6 × 103 s-1).   
The specificity constant (kcat/km) is used as a measure of how efficiently the enzyme 
converts substrate to product, therefore is a useful comparison of enzyme efficiency in 
cases where similar turnover numbers are achieved.  The specificity constant takes into 
consideration the affinity of the enzyme (kcat) as well as the substrate concentration 
(km).  Again, soluble 15-sLOX-1 exhibits a greater specificity constant than all the 
immobilised forms (2.8 × 108 M-1 s-1).  However in the case of LOXImm, 15-sLOX-1 
bound to epoxy-functionalised resins exhibited greater catalytic efficiency, 
demonstrated by a kcat/km constant one order of magnitude greater than that observed 
for the amino-functionalised resin.  EM1200 exhibited the highest efficiency, with a 
turnover number of 3.6 × 103 s-1 and specificity constant of 3.0 × 107 M-1 s-1.  The 
differences in these experimental reaction constants are consistent with those observed 
by Kermasha et al. using immobilised/soluble 15-sLOX-1 in aqueous and organic 
solvent systems [37-38].  In these publications, the immobilisation of 15-sLOX-1 on 
ion-exchange supports resulted in a significant decrease in activity and catalytic 
efficiency compared to the soluble form of the enzyme.      
A loss of catalytic activity has been observed previously in the immobilisation of the 
lipoxygenase enzyme on functionalised solid supports [266, 270, 281, 289].  In the 
case of reactive epoxy and carbonyl activated resins, the occurrence of multi-point 
attachment may result in conformational changes, steric hindrance and impose 
diffusional limitations for the substrate [276, 281, 289].  Chikere et al. have also 
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observed the decline in the activity of 15-sLOX-1 within several days of 
immobilisation, which the authors have attributed to the distortion of the iron-
coordinating ligands [276].  Additionally in this study the ionisation state of the 
catalytic iron of the soluble (or free) and immobilised 15-sLOX-1 was analysed by 
EPR spectroscopy.  Coupling of the enzyme to the Eupergit C resin in high ionic 
strength coupling buffer generated EPR signals (g = 4.3) corresponding to an Fe3+ 
(catalytically active form) concentration close to equimolar to the concentration of 
bound enzyme.  In contrast, when coupling was performed in low ionic strength buffer 
the signal corresponding to Fe3+ was significantly depressed and a loss of activity was 
observed [276].  Therefore in the present study further optimisation of the coupling 
buffer ionic strength may allow improvements in the activity yield and/or stability. 
5.3.6 Effect of immobilisation on pH stability 
Previous studies of lipoxygenase have reported an increase in the stability of the 
enzyme upon immobilisation at lower pH for both dioxygenase and 
lipohydroperoxidase activities [268, 276].  In addition there are several reports of 
immobilisation resulting in a shift of the optimum pH to either more basic pH [37], or 
to more acidic pH [276, 278-279, 281] depending on the nature of the support and the 
site/region at which the enzyme is bound to the support.   
In this study the pH profile of soluble and immobilised 15-sLOX-1 was evaluated in 
the range of 6.0 – 12.0 using the assay conditions described previously.  Three buffers 
were used: 50 mM potassium phosphate (pH 6.0 ‒ 8.0), 50 mM sodium tetraborate 
(HCl adjusted; pH 8.5 – 9.0) and 50 mM sodium tetraborate (NaOH adjusted; pH 9.5 
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‒ 12.0).  The pH dependence of 15-sLOX-1 (soluble) showed a symmetrical profile 
(Fig. 5.11A), displaying an optimum at pH 9.0.  As demonstrated previously, a 
decrease in activity of soluble 15-sLOX-1 is observed under more acidic conditions, 
while the enzyme experiences stability up to pH 12 [126].  For all LOXImm preparations 
the symmetrical profile and optimal activity at pH 9.0 remained (Fig. 5.11B & C).  An 
irregular profile was observed for both EM600 and EM1200 resins with secondary 
optima at ~7.0 and 10.5 (Fig.5.11B).  All preparations, except EM600, experienced a 
loss of activity at higher pH compared to that observed with soluble 15-sLOX-1.  As 
basic reaction conditions have been previously shown to control the extent of 
dioxygenation of highly unsaturated substrates [126, 171], a reduction in activity at 
higher pH may have implications for the synthesis of pure mono-hydroperoxides (as 
previously demonstrated at pH 12 [126]).  
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Figure 5.11 Effect of buffer pH on specific activity measured by dissolved oxygen consumption.  A: 
LOXSol; B: LOXImm EM600 & EM1200; C: LOXImm C2AM600 & C2AM1200.  Conditions: 0.1 mM 
linoleic acid, ~ 0.75 mg 15-sLOX-1, 25°C.  Error bars indicate 1σ.  
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5.3.7 Thermal stability of LOXImm and LOXSol 
The thermal stability of soluble 15-sLOX-1 was first evaluated as a function of time.  
In these experiments the enzyme was incubated at a constant temperature (2 ‒ 80°C) 
for a defined period of time (0 – 120 min).  Residual activity was then measured using 
the oxygen consumption assay described.  As shown in Fig. 5.12, soluble 15-sLOX-1 
retained 70% of the initial activity upon incubation for 120 min up to 60°C.  This 
enzyme preparation (acquired from Cayman Chemical as whole cell lysate) 
experienced significantly higher thermal stability than previously reported for the free 
enzyme, where a rapid loss of activity has been observed above 30 ‒ 40°C [258, 270, 
276-278].  Purification procedures are known to result in a loss of activity of enzymes 
due to removal of the protein from the cellular environment, exposure to heavy metals 
and inhibitors, or denaturation of the enzyme due to changes in solution conditions 
[290].  A decrease in total activity units is observed upon purification of 15-sLOX-1 
using ammonium sulphate precipitation and ion exchange chromatography [107, 177, 
180].  Therefore the lack of purification in the preparation of the 15-sLOX-1 used in 
this study may account for the unexpectedly high stability of the enzyme. 
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Figure 5.12 Effect of incubation temperature on initial reaction rate of LOXSol as a function of 
incubation time.  (Data presented as the percentage of initial velocity at 0 min) 
Kinetic stability refers to the length of time a protein remains active when incubated 
under certain conditions [252].  A common measure for assessing kinetic stability is 
the optimum operating temperature (Topt), and the temperature at which the activity of 
the enzyme is reduced 50% following incubation for a defined amount of time (T50).  
The thermal inactivation curves of soluble and immobilised 15-sLOX-1 are presented 
in Figure 5.13.  From these curves the Topt and T50 values were calculated (Table 5.5).   
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Figure 5.13 Effect of incubation temperature on the specific activity of A: LOXSol; B: LOXImm 
EM600 & EM1200; and C: LOXImm C2AM600 & C2AM1200.  Incubation period – 10 min.  
Measurements were performed in duplicate.  Error bars indicate 1σ. 
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Table 5.5 Thermal inactivation values, Topt and T50, of soluble and immobilised LOX. 
Preparation Topt (°C) T50 (°C) 
Soluble 25 67 
EM600 30 48 
EM1200 40 53 
C2AM600 30 53 
C2AM1200 30 49 
 
Fig. 5.13 shows the highest specific activity (Topt) for LOXSol occurred at 25°C, while 
LOXImm exhibited an increase in optimum temperature to 30 – 40°C.  As observed in 
the previous experiment, soluble 15-sLOX-1 exhibited unusually high stability and 
retention of activity at temperatures up to 65°C, with a T50 value of 67°C.  In contrast, 
the T50 value was reduced to approximately 48 ‒ 53°C upon immobilisation. From this 
data there appears to be no thermally protective effect, rather there is a detrimental 
effect, of this type of immobilisation to EM and C2AM resins used in these 
experiments.   
Several studies have detailed the effect of immobilisation of 15-sLOX-1 on thermal 
stability, indicating the type of techniques and support employed plays a role in 
determining the stability of the preparation at high temperatures.  Kermasha et al. [37] 
reported an optimal temperature of 70°C for 15-sLOX-1 immobilised on an ion-
exchange resin (Dowex 50WX4-220) in a ternary micellar system (sodium 
carbonate/iso-octane).  Karadag et al. [270] and Chikere et al. [278] have both reported 
an optimum temperature of 30 ‒ 40°C on activated polyacrylamide gel and Eupergit 
250L, respectively.  While Parra-Diaz reported an optimal temperature of 15°C for 15-
sLOX covalently bound to carbonyl di-imidazole activated support [289].  
Additionally, comparison of the temperature-activity profiles of the LOXImm 
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preparations shows similar inactivation curves, suggesting the reduction in stability 
may be due to the stability and/or degradation of the resins themselves at higher 
temperatures.   
5.3.8 Reusability potential of LOXImm 
To evaluate the reusability potential of the immobilised 15-sLOX-1 preparations, the 
resins were subjected to consecutive dissolved oxygen assay cycles.  Between each 
cycle the resin was thoroughly washed with sodium tetraborate buffer to remove 
hydroperoxide product.  The effect of recycling on the activity of LOXImm is presented 
in Fig. 5.14.  After the first cycle, 15-sLOX-1 immobilised on epoxy-functionalised 
supports retained 37% (EM1200) and 44% (EM600) of the initial activity.  Meanwhile 
enzyme coupled to activated-C2-amino resins retained between 19% (C2AM1200) and 
28% (C2AM600) of the initial activity, however suffered minor losses over subsequent 
cycles.  Following seven consecutive cycles 15-sLOX-1 bound to the C2AM600 resin 
retained ~22% of the initial activity, whereas activity was reduced to ~14% for 
C2AM1200, and ~3% for both EM600 and EM1200. 
To ensure the reduction in activity was not due to protein being leached from the 
support during the assay experiments, the reaction mixtures were assayed for protein 
concentration over three cycles using the method described for loading calculations.  
The maximum protein concentration that could potentially be detected (based on the 
calculated amount of bound protein) was ~ 0.25 mg/ml solution.   
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Figure 5.14 Effect of recycling on the relative enzyme activity of LOXImm A: epoxy-functionalised 
supports; and B: activated amino-functionalised supports. Relative activity was calculated as the 
percentage of residual activity detected from the first assay (cycle 0). 
However protein was undetectable in each of the three samples.  Therefore the 
decrease in activity is likely due to the catalytic inactivation/inhibition of the enzyme, 
rather than loss of the enzyme itself. 
Similar results have been obtained previously by other research groups.  For example, 
Kermasha et al. reported a 10% yield of activity after 4 cycles using 15-sLOX-1 bound 
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to an ion-exchange resin [37], while bound to the Eupergit C resin the enzyme retained 
~30% of the initial activity following 7 cycles of use [276].  Chikere and co-workers 
also described the difficulty in removing the hydrophobic 13-HPODE product 
following each of the incubations, reporting the absorbance at 234 nm of the washing 
solutions did not decrease to zero after several volumes of buffer [276].  Therefore the 
apparent inactivation of the enzyme may be due to insufficient removal of the 
hydroperoxide product, known to cause product inhibition of soluble 15-sLOX-1. 
5.3.9 Analysis of products from linoleic acid catalysed by LOXImm  
To confirm the specificity of 15-sLOX-1 is maintained in the immobilised form, 
reactions using LOXImm were performed as described in previous chapters for the 
production of hydroperoxy compounds from fatty acid acid substrate however with the 
omission of the addition of 1 M NaBH4 (refer to Materials and Methods page 63).  
Briefly, LOXImm (all preparations; ~3 mg equivalent bound 15-sLOX-1) was incubated 
with linoleic acid (0.1 mM) in sodium tetraborate buffer (50 mM; pH 9.0).  
Hydroperoxy reaction products were extracted by solid phase extraction, and analysed 
by normal-phase HPLC and GC-MS using the analysis methods described previously 
(refer to page 65-66). 
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Figure 5.15 NP-HPLC chromatogram of reaction products from the incubation of linoleic acid with 
15-sLOX-1 bound to EM600 enzyme carrier resin.  Solid line – absorbance at 210 nm; dashed line – 
absorbance at 234 nm. Peak a: linoleic acid, peak b: 13S-HPODE, peak c: 9S-HPODE. 
As shown in Fig. 5.15, full conversion of linoleic acid substrate (peak a) to the 
corresponding hydroperoxide is achieved upon incubation with resin-bound 15-sLOX-
1.  The major product (Fig. 5.15; peak b) obtained from the incubation of 15-sLOX-1 
coupled to the EM600 resin was identified as 13-hydroperoxy-ODE (13-HPODE), 
based on co-elution with 13-HPODE produced from soluble 15-sLOX-1 and analysis 
by GC-MS (results not shown).  The corresponding isomer, 9-hydroperoxy-ODE (Fig. 
5.15; peak c), is detected in both experimental and negative control incubations 
(linoleic acid only; peak a) and is due to autoxidation of the substrate preparation.  
Analogous results were also achieved using all other enzyme carriers.  These findings 
demonstrate the regio-specificity of 15-sLOX-1 is fully conserved upon this mode of 
immobilisation.    
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5.4 Conclusion 
In this study soybean 15-lipoxygenase-1 was successfully immobilised on a range of 
functionalised enzyme carrier resins.  The enzyme was coupled to the supports with 
an efficiency of 59 ‒ 68%.  The immobilised form exhibited a significant decrease in 
catalytic activity, with only 5 – 10% retention of the initial (soluble) LOX activity.  
The affinity of the enzyme for linoleic acid substrate was also significantly reduced 
compared to LOXSol, as demonstrated by smaller kinetic constants (kcat and kcat/km).  
Despite the reduction in activity the preparations were able to be recovered and 
recycled several times, with activity remaining for up to six cycles.  Leaching of the 
protein from the support was also shown to be limited as a result of strong, covalent 
linkages.  However the rigidity of these linkages likely restricted the conformation of 
the enzyme, resulting in the reduction in activity.  Further development of the 
immobilisation techniques may facilitate increased enzyme activity and/or loading. 
The aim of enzyme immobilisation, in addition to recovery of the enzyme, is to 
improve the operational stability.  Immobilisation has previously been shown to 
improve thermal stability, pH range and storage stability of a range of enzymes.  
However in this study no protective effect of immobilisation of 15-sLOX-1 was 
observed.  In contrast, coupling to the selected resins reduced the thermal stability of 
15-sLOX-1 (lower T50), a similar pH range was observed, and the storage stability of 
the enzyme was reduced.  The optimum temperature of the enzyme was increased from 
~ 25°C to 30 - 40°C, however soluble 15-sLOX-1 experienced unexpected stability up 
to 50°C with only small reductions in activity.  Despite the reduction in activity and 
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stability, LOXImm was able to catalyse the complete conversion of linoleic acid to 
hydroperoxide product under standard reaction conditions for LOX catalysis.  The 
regio-specificity of the immobilised enzyme was maintained with linoleic acid 
substrate, producing 13-hydroperoxy-ODE as the major product.   
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6. APPLICATION OF IMMOBILISED 15-SLOX-1 FOR THE 
SYNTHESIS OF MONO- AND DI-HYDROXY RESOLVIN 
ANALOGS 
6.1 Introduction  
The immobilisation of enzymes on solid supports has been previously shown to 
increase the operational stability of the enzyme, enabling catalysis to be performed in 
a wider range of pH and/or temperature conditions [253-254, 258, 270, 276-277].  A 
major advantage of immobilisation, in addition to this increased stability and activity, 
is the ability to physically recover and re-use the enzyme for repetitive catalysis (where 
sufficient activity is retained).  As a result, advances in techniques to covalently 
immobilise enzymes on solid supports/matrices has driven the use of enzyme 
biocatalysts in biotechnology applications [250-251]. 
The immobilisation of soybean 15-lipoxygenase-1 (15-sLOX-1) on a number of 
functionalised supports has been reported in the literature, as discussed previously 
(refer to Chapter V).  In these studies, the immobilisation efficiency and residual 
activity has been typically reported using a spectrophotometric assay monitoring the 
formation of hydroperoxides from linoleic acid, for example, using a xylenol orange 
assay or molecular absorption at 234 nm [37, 270, 291].  Fewer studies have analysed 
the regio-chemistry of the hydroperoxide products and most have utilised linoleic acid 
as substrate, generating 13-HPODE as the major product [37, 258, 261, 264, 278-279].  
However, the R/S-stereospecificity of immobilised 15-sLOX-1 in the production of 
13-HPODE, and other substrates, is yet to be experimentally determined.   
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As linoleic acid is a substrate which has a limited range of potential products due to 
the lack of multiple 1,4-pentadiene moieties for catalysis, it is of research interest to 
investigate if the dioxygenase activity and specificity of immobilised 15-sLOX-1 is 
maintained with longer and more highly unsaturated substrates.  Laakso [264] reported 
the absence of the double dioxygenation of ARA by 15-sLOX-1 covalently coupled to 
agarose, with 15-H(P)ETE being detected as the major product by gas 
chromatography.  These observations were also supported by quantitative oxygen 
consumption and conjugated diene formation which corresponded to a single 
dioxygenation reaction, and with no evidence of anaerobically formed carbonyl 
compounds [264].   
Based on the known activity of soluble (free) 15-sLOX-1 for the production of mono- 
and di-hydroxy resolvin analogs which are biologically active [120-122, 124, 126, 160, 
187], including resolvin D5 (RvD5) and protectin DX (PDX), there is potential for the 
economical preparation of these compounds using recyclable immobilised 15-sLOX-
1.  Therefore the aim of this study is to investigate: 
i. If immobilised 15-sLOX-1 is capable of accepting highly unsaturated LC-
PUFA substrates to catalyse the single and double dioxygenation reactions; 
ii. if the regio- and stereo-specificity of 15-sLOX-1 is conserved in the 
immobilised form with the range of substrates; and,  
iii. if the hydroperoxidase activity of the enzyme remains intact for the anaerobic 
metabolism of hydroperoxides.  
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6.2 Materials and Methods 
6.2.1 Materials 
Soybean 15-lipoxygenase-1 (EC 1.13.11.33, P1, 10.0 Munits/ml, 26.09 mg protein/ml, 
0.383 Munits/mg protein), (4Z,7Z,10Z,13Z,15E,19Z)-17R/S-hydroxy-
docosahexaenoic acid and (5Z,8Z,11Z,13E)-15R/S-hydroxy-eicosatetraenioc acid 
(Cayman Chemical, Ann Arbor, MI) were purchased from Sapphire Bioscience 
(Waterloo, NSW, Australia).  All fatty acids (> 99 % purity) (Nu-Chek Prep, Elysian, 
MN) were purchased from Adelab Scientific (Thebarton, SA, Australia).  All Agilent 
instruments and LC-18 SPE cartridges (Bond Elut C18) were purchased from Agilent 
Technologies (Mulgrave, Australia).  Enzyme carrier methacrylate resins (epoxy and 
C2-amino; 600 ‒ 1200 Å and 1200 ‒ 1800 Å) were purchased from Purolite Pty Ltd 
(Baulkham Hills, NSW, Australia).  Sodium tetraborate decahydrate, potassium 
phosphate monobasic, potassium phosphate dibasic, bovine serum albumin and 
glutaraldehyde were purchased from Sigma-Aldrich (Castle Hill, NSW, Australia).  
Bio-Rad protein assay dye reagent (Bradford reagent) was purchased from Bio-Rad 
Laboratories (Gladesville, NSW, Australia). 
6.2.2 Immobilisation of lipoxygenase 
C2-amino methacrylate resins (1 g) were activated with 2% (v/v) glutaraldehyde for 
1 h at room temperature with rotational stirring, immediately prior to immobilisation 
reactions.  Resins were washed with 5 volumes of sodium tetraborate (50 mM) and 
equilibrated with 5 ml 0.01 M potassium phosphate buffer (pH 8.0) for 30 min on ice. 
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Epoxy methacrylate resins (1 g) were equilibrated in 5 ml 0.1 M potassium phosphate 
buffer (pH 8.0) for 30 min on ice.   
Freshly thawed 15-sLOX-1 (80 mg) was diluted in 5 ml potassium phosphate (pH 8.0; 
epoxy – 0.1 M, C2-amino – 0.01 M) and added quantitatively to the resin/buffer 
mixture.  The resins were incubated on ice for 24 h with rotational stirring.  After 
incubation the supernatant was recovered and assayed for protein concentration by the 
Bradford method (in duplicate).  Resins were washed with 2 × volumes of sodium 
tetraborate (50 mM).  All washes were recovered and assayed for protein 
concentration.  LOX-immobilised resins were stored at − 20°C, and kept on ice when 
in use. 
Bradford protein concentration assay 
A series of bovine serum albumin (BSA) standards were prepared (0.00 ‒ 1.00 mg/ml).   
Samples were prepared and diluted as appropriate within the linear range of the assay 
(0.00 ‒ 1.00 mg/ml).  Bio-Rad protein assay dye reagent concentrate was diluted 1 part 
reagent to 4 parts deionised water and filtered under vacuum immediately prior to 
performing the assay.  50 μl of BSA standard or sample was incubated with 2.5 ml 
reagent for 10 min, with measurements taken within 30 min.  The absorbance of the 
protein solution was measured at 595 nm using a Cary Series 300 UV-visible 
spectrophotometer (Agilent Technologies, Mulgrave, VIC, Australia).  Analyses were 
performed at room temperature in a 10 mm path length quartz cuvette.  Measurements 
were performed in triplicate (standards) or duplicate (samples), and blank absorbance 
values subtracted.   
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Dissolved oxygen consumption assay 
The enzyme activity of soluble and immobilised 15-sLOX-1 was measured by the 
initial rate of dissolved oxygen consumption (V0).  Measurement of dissolved O2 
concentration was carried out using a polarographic O2 electrode (Qubit Systems Inc., 
John Morris, Australia) with a two-point calibration. 
Assays were performed in a total volume of 3 ml in 50 mM sodium tetraborate (pH 
9.0) at 25°C, with constant moderate stirring.  Soluble or immobilised 15-sLOX-1 
(0.75 mg) was added to the buffer and allowed to temperature equilibrate (until oxygen 
concentration stabilised).  Linoleic acid substrate was freshly prepared as a 10 mM 
solution in 50 mM sodium tetraborate (containing 10% v/v ethanol).  Reactions were 
initiated with the addition of 30 μl 10 mM linoleic acid solution (final concentration ‒ 
0.1 mM), and allowed to proceed until oxygen concentration again stabilised. 
Measurements were performed in duplicate.  LOX activity was calculated as initial 
velocity (V0) for the consumption of oxygen (mg/l/min).  
6.2.3 LOX catalysed reactions – general protocol 
LOX catalysed reactions were performed as described previously [126].  For all 
reactions fatty acid substrates were prepared as 0.1 M solutions in ethanol and 
incubation buffers were air-saturated prior to performing the reactions.  For single 
dioxygenation reactions, fatty acids were diluted to 0.1 mM in 10 ml sodium 
tetraborate (50 mM) adjusted to pH 12 (10 M NaOH).  Reactions were initiated by the 
addition of resin equivalent to 2 mg immobilised LOX, with stirring at room 
temperature for 45 min.  Resins were recovered and washed with two volumes of 
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50 mM sodium tetraborate to remove adsorbed product/substrate.  Washes were 
combined with the initial substrate/product solution.  Products were reduced with 1 M 
NaBH4 (200 μl), acidified with concentrated acetic acid (50 μl) and extracted using 
C18 SPE cartridges.  Samples were stored in ethanol at –20°C prior to analysis.  For 
double dioxygenation reactions, incubations were performed using 0.1 mM substrate 
in sodium tetraborate (50 mM) at pH 9 using 5 mg of immobilised LOX.  All other 
experimental conditions and procedures remained constant.   
For anaerobic incubations to induce lipohydroperoxidase activity, reactions were 
performed as described in Chapter IV (refer to page 104).  Briefly, fatty acid substrate 
(0.5 mM) was prepared in nitrogen-purged sodium tetraborate (25 mM, pH 10.0) at 
room temperature.  Reactions were initiated with 5 mg of immobilised 15-sLOX-1 and 
the reaction vessels immediately sealed.  Reactions were stopped after 30 min with the 
addition of 1 M NaBH4 (200 μl) and the solution acidified with concentrated acetic 
acid.  Products were extracted as described above, and analysed by NP-HPLC. 
6.2.4 Analytical methods 
NP-HPLC analysis 
HPLC was performed using an Agilent 1200 series HPLC system in normal phase 
mode, equipped with a thermostatted column compartment and diode array detector.  
Analytical separations were carried out using a Supelcosil LC-Diol column (Supelco, 
25 cm × 3 mm, 5 μm; Sigma Aldrich) with an isocratic mobile phase of 95% n-
heptane/acetic acid/2,2-dimethoxypropane (100:0.1:0.1 v/v) and 5% isopropanol.  
Extraction solvent was evaporated under a stream of nitrogen and samples were 
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prepared in mobile phase.  Injection volume was 15 μl.  The flow rate was 0.5 ml/min 
and the column temperature was 10°C.  Elution of the products was monitored at 210 
nm, 234 nm, 250 nm and 270 nm.  
Chiral HPLC analysis 
Analyses were carried out using an Agilent 1260 Infinity HPLC system, equipped with 
a quaternary pump, solvent degasser, autosampler, thermostatted column compartment 
and diode array detector.  Separations were performed using a Lux Amylose-2 chiral 
column (15 cm × 4.6 mm, 5 μm, Phenomenex) fitted with a guard cartridge, and 
solvents A: milliQ water with 0.1% (v/v) trifluoroacetic acid, and B: acetonitrile.  An 
isocratic mobile phase of 70% solvent B was used at a flow rate of 1 ml/min.  Analyses 
were performed at ambient temperature.  Samples were prepared in acetonitrile and an 
injection volume of 15 μl used. 
GC-MS analysis 
Products (~ 1 mg) were subjected to full catalytic hydrogenation over PtO2 catalyst 
(10 mg) in 2 ml ethanol for 25 min with a constant stream of hydrogen and stirring.  
The solution was filtered (0.45 μm nylon filter) and the solvent evaporated under 
nitrogen.  Products were then trimethylsilylated using BSTFA (200 μl) and pyridine 
(200 μl) at 100°C for 1 h.  GC-MS analysis was performed on an Agilent 6890N gas 
chromatograph with a 5975 mass selective detector (electron impact ionization).  
Separations were performed on a BPX5 column (30 m × 0.25 mm, 0.25 μm film 
thickness, SGE) with helium carrier gas (1.2 ml/min).   The inlet was maintained at 
250°C with a split ratio of 20:1, and injection volume was 1.5 μl.  The oven 
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temperature program was as follows: 150°C for 2 min, increased at 5°C/min to 300°C, 
and held at 300°C for 13 min.  The conditions of the mass selective detector were as 
follows: electron voltage, -70 eV; MS quad, 150°C; MS source, 230°C; solvent delay, 
3.00 min; scan range, 35.0 – 600.0 amu.  
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6.3 Results and Discussion 
6.3.1 Immobilisation of soybean 15-lipoxygenase-1 
The immobilisation of 15-sLOX-1 to epoxy- and amino-functionalised resins was 
performed under optimised conditions, as described in Chapter V (page 162).  Enzyme 
was incubated at a concentration of 80 mg per 5 ml potassium phosphate buffer (pH 
8.0), achieving final loading efficiencies between 54 – 63% (Table 6.1).  Both loading 
efficiencies and specific activities are consistent with the results obtained under 
optimised conditions described in Chapter V. 
Table 6.1 Immobilisation of 15-sLOX-1 and evaluation of retained activity. 
LOX form Protein loading (mg/g) Loading efficiency (%) 
Specific activity  
(U/mg protein) a 
EM600 50.6 ± 0.3 63.3 0.701 
EM1200 48.9 ± 0.1 61.1 0.409 
C2AM600 48.2 ± 4.9 60.3 0.042 
C2AM1200 43.1 ± 2.3 53.9 0.058 
Soluble - - 2.752 
a Specific activity is defined as units of activity per mg of protein (U/mg) i.e. μmol of oxygen 
consumed min-1 mg-1 of protein. 
6.3.2 Dioxygenation of LC-PUFA by LOXImm 
Reactions were performed as described in previous work by Dobson and co-workers 
for the controlled formation of mono- and di-hydroxy fatty acids by 15-sLOX-1 [126].  
In that study two experimental methods were developed for the single and double 
dioxygenation reactions of DHA by 15-sLOX-1.  Important parameters were 
determined to be buffer pH, enzyme concentration, and substrate concentration [126].  
These experimental conditions were applied to the metabolism of a range of LC-PUFA 
by immobilised 15-sLOX-1 and compared to the products generated from the soluble 
form.  Due to the similar loading efficiency and specific activity of all resins, only 
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EM600 and C2AM600 resins were investigated with the complete range of substrates 
in this study. 
Single dioxygenation 
Fatty acid substrates (DHA, EPA, ARA, DPAn-3 and DPAn-6) were incubated with 2 
mg (equivalent) of LOXImm (EM600 and C2AM600) or LOXSol in sodium tetraborate 
(pH 12) for 45 min on ice [126].  Longer incubation times were employed due to the 
low specific activity of the coupled enzyme.  Following incubation, the resins were 
washed with additional volumes of buffer to maximise the recovery of the product.  
The reaction products were then analysed by NP-HPLC and the product profile 
(retention time and absorbance spectra) compared to that obtained from the incubation 
of LOXSol (Fig. 6.1).  Additionally, the reproducibility and conversion of substrate to 
product was evaluated. 
15-sLOX-1 immobilised to both EM600 and C2AM600 resins was efficient in 
converting LC-PUFA starting material to mono-hydroxy products, analogous to those 
observed from soluble 15-sLOX-1 [126].  As shown in Fig. 6.1B, the reaction of 
LOXImm (EM600) with DHA produced one single mono-hydroxy product, identified 
as 17-hydroxy-DHA by GC-MS, the same as produced from soluble 15-sLOX-1 (Fig. 
6.1A).  Additionally both compounds exhibited the same UV-visible absorbance 
spectra with λmax at 235 nm.   
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Figure 6.1 Example NP-HPLC chromatogram of A: LOXSol and B: LOXImm (EM600) single 
dioxygenation reaction products from DHA substrate. Signals collected at 210 nm (solid line), 234 nm 
(dashed line) and 270 nm (dotted line). 
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For the reaction of LOXImm with other LC-PUFAs (EPA, ARA, DPAn-3 and DPAn-
6) the major product was found to be consistent with those observed from LOXSol 
(refer to Table 6.2). Several regio-isomers were also detected in some incubations, 
typically accounting for less than 20% of the total mono-hydroxy products.  To identify 
each of the major and minor products, samples were prepared for analysis by GC-MS.  
Extracted reaction products were fully hydrogenated and converted to their 
trimethylsilyl ester/ether derivatives.  The identified products (and their respective 
GC-MS fragments) from LOXImm are summarised in Table 6.2.   
Table 6.2 Summary of single dioxygenation products identified from LOXImm.  Products were 
detected and characterised by NP-HPLC-DAD and GC-MS. 
EM600 Major products GC-MS fragments Minor products GC-MS fragments 
DHA 17-HDHA 73,117,173,429,485 - - 
EPA 15-HEPA 73,117,173,401,457 - - 
ARA 15-HETE 73,117,173,401,457 11-HETE 73,117,229,345,457 
DPAn-3 17-HDPAn-3 73,117,173,429,485 7-HDPAn-3 
13-HDPAn-3 
73,117,289,313,485 
73,117,229,373,485 
DPAn-6 17-HDPAn-6 73,117,173,429,485 7-HDPAn-6 
10-HDPAn-6 
13-HDPAn-6 
73,117,289,313,485 
73,117,271,331,485 
73,117,229,373,485 
     
C2AM600 Major products GC-MS fragments Minor products GC-MS fragments 
DHA 17-HDHA 73,117,173,429,485 - - 
EPA 15-HEPA 73,117,173,401,457 11-HEPA 
12-HEPA 
73,117,229,345,457 
73,117,215,359,457 
ARA 15-HETE 73,117,173,401,457 - - 
DPAn-3 17-HDPAn-3 73,117,173,429,485 7-HDPAn-3 
10-HDPAn-3 
13-HDPAn-3 
73,117,289,313,485 
73,117,271,331,485 
73,117,229,373,485 
DPAn-6 17-HDPAn-6 73,117,173,429,485 4-HDPAn-6 
7-HDPAn-6 
10-HDPAn-6 
13-HDPAn-6 
73,117,173,429,485 
73,117,289,313,485 
73,117,271,331,485 
73,117,229,373,485 
 
The pH of the buffer is known to play a significant role in either favouring or inhibiting 
the second dioxygenation of DHA through protonation or deprotonation of the 
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carboxylic acid moiety.  The presence of the ionised carboxylate group at basic pH is 
postulated to prevent entry of the fatty acid to the enzyme active site with the 
carboxylate end first, potentially due to the hydrophobic nature of the catalytic pocket 
and the associated energy requirements for entry to occur [113, 119, 147-148, 169, 
193].  Therefore the major product of the reaction when performed at higher pH was 
the mono-hydro(pero)xy fatty acid (i.e. (4Z,7Z,10Z,13Z,15E,19Z)-17S-HDHA from 
DHA).  These results demonstrate the regio-specificity of the enzyme is maintained in 
the immobilised form, indicating the orientation of the substrate within the active site 
remains in the normal (methyl end first) orientation [145, 147-149, 151]. 
The effects of immobilisation of 15-sLOX-1 on the enzyme selectivity and specificity 
has not been studied to date.  However, several studies using other enzymes have 
demonstrated the ability to enhance or change selectivity and enantio-specificity 
through immobilisation, including lipases, alkylsulfatases, chloroperoxidases and 
acylases [254, 292-300].  For example, Aoun and Babouléne [292] have shown the 
adsorption of a chloroperoxidase on various types of talc drastically improved the 
regio-selectivity of the enzyme and limited the production of oxidative by-products.  
Palomo and co-workers [293] immobilised lipase from Candida rugosa on several 
supports via covalent, ionic and adsorption interactions, generating a range of 
immobilised lipase with different orientations and microenvironments.  The authors 
showed that the enantioselectivity and specificity of the enzyme was able to be 
modified depending on the type of immobilisation.  As a result, lipase could be 
transformed from an S-selective enzyme with adsorbent binding to R-selective with 
covalent binding [293].  These effects may be attributed to changes in the enzyme 
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microenvironment upon binding to the solid support (e.g. 
hydrophobicity/hydrophilicity, diffusional limitations), changes in the enzyme 
conformation instilled upon binding and the functionality of the binding mechanism 
(e.g. type and length of spacer arms, mode of binding, immobilisation conditions) 
[254, 287-288].   
In the case of 15-sLOX-1 there appears to be a minor effect of immobilisation on regio-
specificity.  Although the regio-chemistry of the major products remain consistent with 
those observed from LOXSol, the detection of regio-isomers from some substrates 
indicate the position of the substrate within the active site may be altered.  This may 
be due to changes in the conformation of the enzyme itself or the microenvironment 
of the resin-enzyme preparation.  These changes may also be consistent with the 
significantly reduced activity and stability of immobilised 15-sLOX-1 as described 
previously (Chapter V). 
Substrate conversion 
Substrate conversion was calculated using the residual unreacted substrate peak area 
in NP-HPLC against a linear calibration curve for DHA.  Complete substrate 
conversion of DHA, EPA and ARA to the respective mono-hydroxy products was 
achieved with 15-sLOX-1 bound to both EM600 and C2AM600 resins.  However for 
both n-3 and n-6 forms of DPA, approximately 16 – 24% of unreacted substrate was 
detected in the incubation mixtures for each resin.  Complete substrate conversion was 
also observed for the incubation of DHA with 15-sLOX-1 coupled to EM1200 and 
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C2AM1200 resins, however these resins were not applied to the full range of substrates 
(i.e. EPA, ARA. DPAn-3 and DPAn-6). 
Reproducibility 
Incubations with DHA substrate and EM600 were performed in triplicate to assess the 
reproducibility of the reactions.  Although the regio-specificity of the enzyme was 
found to be consistent, the conversion of substrate as well as the recovery of product 
was found to vary significantly with RSD values of 41.4% (EM600) and 51.3% 
(C2AM600) for product recovery.  In contrast, the reaction of soluble 15-sLOX-1 was 
found to be very reproducible with a RSD of 6.5% for the single dioxygenation 
reaction of DHA.  Recovery of the product from incubation mixtures using 
immobilised 15-sLOX-1 has been previously reported to be problematic, with multiple 
volumes of washing buffer required [276].  This is likely due to adsorption of the 
hydrophobic product to the polymer resin, and the associated diffusional limitations of 
the product from within pores [276].  Therefore in these experiments the use of organic 
solvent extraction may offer a more efficient method for recovering the hydroperoxide 
product from functionalised methacrylate resins. 
Double dioxygenation  
To catalyse the double dioxygenation of LC-PUFA, it has previously been shown that 
a higher enzyme concentration is required than for the single dioxygenation [126].  The 
soluble enzyme has demonstrated lower affinity for hydro(pero)xy fatty acid 
substrates, as exhibited by a lower turnover rate, lower Vmax and increased kM, therefore 
the second dioxygenation is favoured at higher concentrations of enzyme [119, 186].   
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For the synthesis of di-hydroxylated products, fatty acid substrates (DHA, EPA, ARA, 
DPAn-3 and DPAn-6) were incubated with 5 mg of soluble or immobilised 15-sLOX-
1 (EM600 and C2AM600) in 50 mM sodium tetraborate (pH 9) for 1 hr on ice.  Again, 
longer incubation times were employed due to the lower specific activity of the 
enzyme.  As was done for the single dioxygenation reactions, the resins were washed 
thoroughly and the extracted reaction products analysed by NP-HPLC.   
As shown in Fig. 6.3A, the reaction of soluble 15-sLOX-1 under the conditions 
required for double dioxygenation results in the complete conversion of DHA to two 
di-hydroxylated products, previously characterised as (4Z,7Z,11E,13Z,15E,19Z)-
7,17S-dihydroxy-DHA (7,17-diHDHA) and (4Z,8E,10Z,13Z,15E,19Z)-10,17S-
dihydroxy-DHA (10,17-diHDHA) [120, 122, 126].  The reaction of 15-sLOX-1 bound 
to EM600 resin with DHA substrate was also found to synthesise the same two 
products, however with a lower yield (Fig. 6.3B).  The major product of the LOXImm 
reaction under conditions for double dioxygenation was the mono-hydro(pero)xy 
intermediate, 17-hydroxy-DHA.  A small amount of DHA starting material was also 
detected as indicated.  The di-hydroxy products were further analysed by GC-MS (as 
their saturated, trimethylsilyl ester/ether derivatives) to confirm the locations of the 
hydroxy groups in both regio-isomers (Fig. 6.4).  Briefly, fragments with m/z ratios of 
183, 331 and 359 are indicative of hydroxy groups at C10 and C17, while m/z ratios 
of 173, 289 and 401 are indicative of hydroxy groups at C7 and C17. 
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Figure 6.3 NP-HPLC chromatogram of A: LOXSol and B: LOXImm (EM600) double dioxygenation 
reaction products from DHA substrate.  Signals collected at 210 nm (solid line), 234 nm (dashed line) 
and 270 nm (dotted line).  Inset: UV-visible absorbance spectra of di-hydroxy products (collected 
from online DAD). 
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Figure 6.4 A: GC-MS total ion chromatogram of LOXImm (EM600) reaction products from DHA 
substrate.  Reaction products were derivatised to their saturated, trimethylsilyl ester/ether derivatives 
for analysis; B: Mass spectrum of 10,17-dihydroxy-DHA (at 28.73 min); C: Mass spectrum of 7,17-
dihydroxy-DHA (28.77 min). 
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Table 6.3 summarises the products identified from the range of LC-PUFAs using 15-
sLOX-1 immobilised to EM600 and C2AM600 resins.  For those products not detected 
by GC-MS, tentative identification is based on retention time in NP-HPLC analyses 
and UV-vis absorption spectra.  Reaction products from all substrates were quantified 
using a linear calibration model based on the absorbance of the conjugated diene and 
triene chromophores of (4Z,8E,10Z,13Z,15E,19Z)-7S,17S-diHDHA and 
(4Z,7Z,11E,13Z,15E,19Z)-10S,17S-diHDHA, respectively (Fig. 6.5).   
Table 6.3 Summary of double dioxygenation products identified from LOXImm using NP-HPLC-DAD 
and GC-MS analysis. 
EM600 Products GC-MS fragments UV-vis λmax 
(nm) b 
Conversion (mol 
%) 
DHA 7,17-diHDHA 
10,17-diHDHA 
73,117,173,289,401,517,573 
73,117,173,331,359,517,573 
226 (242) 
270 (260/280) 
12.6 
23.7 
EPA 5,15-diHEPA 
8,15-diHEPA 
73,117,173,261,399,489,545 
73,117,173,303,359,489,545 
224 (242) 
269 (260/280) 
8.9 
4.9 
ARA 5,15-diHETE 
8,15-diHETE 
73,117,173,261,399,489,545 
73,117,173,303,359,489,545 
224 (242) 
269 (260/280) 
8.2 
5.7 
DPAn-3 7,17-diHDPAn-3 73,117,173,289,401,517,573 225 (244) 19.5 
DPAn-6 7,17-diHDPAn-6 
10,17-diHDPAn-6 
a 
73,117,173,331,359,517,573 
224 (242) 
269 (260/280) 
2.3 
6.0 
     
C2AM600 Products GC-MS fragments UV-vis (λmax) 
(nm) b 
Conversion (mol 
%) 
DHA 7,17-diHDHA 
10,17-diHDHA 
73,117,173,289,401,517,573 
73,117,173,331,359,517,573 
226 (242) 
270 (260/280) 
10.3 
16.9 
EPA 5,15-diHEPA 
8,15-diHEPA 
73,117,173,261,399,489,545 
73,117,173,303,359,489,545 
224 (242) 
269 (260/280) 
6.2 
6.2 
ARA 5,15-diHETE 
8,15-diHETE 
73,117,173,261,399,489,545 
73,117,173,303,359,489,545 
224 (242) 
269 (260/280) 
6.2 
9.2 
DPAn-3 7,17-diHDPAn-3 a 225 (244) 3.6 
DPAn-6 10,17-diHDPAn-6 a 269 (260/280) 4.2 
a Products were detected by HPLC-DAD but not observed in GC-MS analysis following 
derivatisation. 
b Brackets indicate secondary absorption maxima. 
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Figure 6.5 NP-HPLC calibration curves for (4Z,7Z,11E,13Z,15E,19Z)-10S,17S-diHDHA (left) and 
(4Z,8E,10Z,13Z,15E,19Z)-7S,17S-diHDHA (right). 
As shown in Table 6.3, 15-sLOX-1 coupled to EM600 and C2AM600 resins 
successfully catalysed the production of di-hydroxylated fatty acids from biologically 
important LC-PUFA. Most notably, immobilised 15-sLOX-1 catalysed the production 
of 7,17-dihydroxy-DHA (resolvin D5) [16] and 10,17-dihydroxy-DHA (protectin DX) 
[160] (Fig. 6.6), as well as analogous compounds from EPA, ARA, DPAn-3 and 
DPAn-6.  These compounds are analogs of biologically produced resolvin compounds, 
and are known to exhibit potent anti-inflammatory and pro-resolution effects in vivo/ 
in vitro [20, 122, 124, 160, 187, 190].   
 
Figure 6.6 Chemical structures of resolvin D5 and protectin DX. 
There was an absence of regio-isomers in both HPLC and GC-MS analyses, indicating 
the well-known specificity is retained for the second dioxygenation.  The lack of di-
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hydroxylated regio-isomers indicate any conformational or environmental changes 
which may have occurred during the immobilisation procedure have no effect on the 
second dioxygenation.  Although the R/S and cis/trans stereochemistry of these 
compounds remains to be experimentally confirmed, these results support the potential 
use of immobilised 15-sLOX-1 for the production of such compounds. 
As discussed previously, 15-sLOX-1 coupled to functionalised resins exhibited lower 
activity and catalysed only partial conversion to the dihydroxylated products 
described.  Based on these findings the amount of LOXImm was increased to 10 mg per 
reaction in order to increase the formation of the desired products.  However no 
significant change was exhibited in the product profile, with 17-HDHA remaining the 
major product of the reaction.  It is not yet clear whether the incomplete conversion of 
17-hydroxy-DHA to the di-hydroxy products is due to the low lipoxygenase activity 
and stability of the enzyme in the immobilised form (as discussed in previous 
chapters), a reduced affinity of the enzyme for hydroperoxide substrate due to changes 
in the structure of the enzyme, or diffusional/access limitations of the substrate itself.  
Laakso [264] reported the absence of the double dioxygenation of arachidonic acid 
using 15-sLOX-1 coupled to an agarose support (in a continuous flow reactor system), 
with 15-hydroxy-ETE observed as the major product.  To date, no other studies have 
utilised longer and highly unsaturated PUFAs for double dioxygenation by 
immobilised 15-sLOX-1. 
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6.3.3 Chiral-HPLC analysis 
Soluble 15-sLOX-1 is a prototypical S-dioxygenase under aqueous (borate buffer, pH 
9) experimental conditions, catalysing the formation of hydro(pero)xy products with 
S-chirality in greater than 95% purity [111, 113-115, 119, 147, 149].  To establish if 
the stereospecificity of 15-sLOX-1 is maintained in the immobilised form, single 
dioxygenation products were subjected to analysis by chiral phase HPLC.   
As shown in Fig. 6.7, LOXImm (EM600) selectively catalysed the formation of S-
chirality mono-hydroxy products from DHA and ARA, producing 17S-HDHA (100%) 
and 15S-HETE (98.1%) respectively.  The same results were obtained from incubation 
of substrates with 15-sLOX-1 coupled to the C2AM600 resin.  Single major peaks 
were also observed in the chiral analysis of 15-HEPA, 17-HDPAn-3 and 17-HDPAn-
6 produced by both LOXImm resins.  However, due to a lack of commercially available 
racemic standards for these compounds absolute assignment was not possible in this 
study.  Based on experimental evidence of 15-sLOX-1 as an S-dioxygenase and the 
detection of single enantiomers, the remaining products are tentatively identified as 
15S-HEPA, 17S-HDPAn-3 and 17S-HDPAn-6. 
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Figure 6.7 Chiral phase HPLC chromatograms of A: 17-hydroxy-DHA – racemic standard (solid 
line), and LOXImm (EM600) product (dashed line); B: 15-hydroxy-ETE – racemic standard (solid 
line), and LOXImm (EM600) product (dashed line).  Signals collected at 234 nm. 
As demonstrated in previous chapters, diastereomers can be chromatographically 
separated using non-chiral phase HPLC columns, for example the separation of 
7R,17S- and 7S,17S-dihydroxy-DPA.  In addition the diastereomers of 7R/S,17S- and 
10R/S,17S-dihydroxy-DHA, (produced from racemic 7R/S- and 10R/S-hydroxy-DHA 
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by 15-sLOX-1) have been separated using the NP-HPLC analytical method described 
in Materials and Methods (results not shown).  In the current study, peaks indicative 
of diastereomers were not observed for any substrate.  Based on the retention times of 
the detected peaks the chirality of the second dioxygenation is also proposed to occur 
with S-chirality as demonstrated previously [160, 187], however this remains to be 
experimentally determined.   
6.3.4 Lipohydroperoxidase activity of LOXImm with DHA substrate 
As discussed in Chapter IV, 15-sLOX-1 exhibits lipohydroperoxidase activity when 
dissolved oxygen concentration is reduced and an excess of unreacted fatty acid 
substrate remains in solution.  Cleavage of the hydroperoxide by the accumulated 
ferrous form of 15-sLOX-1 results in the formation of conjugated oxodienes, epoxy 
alcohols and branched compounds (Fig. 6.8) [136, 140, 170, 197, 203].  
 
Figure 6.8 Postulated 15-sLOX lipohydroperoxidase mechanism using linoleic acid (LH) substrate 
[136, 140]. 
The formation of these compounds has implications for the use of 15-sLOX-1 for the 
production of mono- and di-hydro(pero)xy fatty acids, as lipohydroperoxidase activity 
significantly reduces the yield of the desired products.  Several authors have reported 
the hydroperoxidase activity of immobilised 15-sLOX-1 with xenobiotics, reporting 
the oxidation of chlorpromazine (3-(2-chlorophenothiazin-10-yl)-N.N-dimethyl-
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propan-1-amine; an anti-psychotic medication) and the synthetic insecticide 
aminocarb (4-dimethylamino-3-methylphenyl-N-methylcarbamate) [267-269].  The 
aim of these experiments is therefore to determine if the hydroperoxidase activity of 
the enzyme with LC-PUFAs remains intact when 15-sLOX-1 is immobilised to the 
solid support.   
Reactions were performed under experimental conditions optimised for 
lipohydroperoxidase activity, as described previously (refer to Chapter IV).  Briefly, 
immobilised 15-sLOX-1 was incubated with DHA (0.50 mM) in N2-purged sodium 
tetraborate buffer for 30 min.   Products were reduced with NaBH4 (1 M) to the 
corresponding alcohols, and acidified prior to extraction and analysis by NP-HPLC.   
As shown in Fig. 6.10, immobilisation of 15-sLOX-1 to EM600 resin did not inhibit 
the lipohydroperoxidase activity of the enzyme.  Incubation of DHA with 15-sLOX-1 
bound to EM600 resin under anaerobic conditions resulted in the formation of several 
compounds derived from 17-hydroperoxy-DHA (detected as the reduced alcohol - 17-
hydroxy-DHA in Fig. 6.9), which are attributed to the hydroperoxidase activity of the 
enzyme.   
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Figure 6.9 NP-HPLC chromatogram of LOXImm (EM600; 5 mg) reaction products from DHA 
substrate (0.50 mM) under anaerobic conditions.  Signals collected at 210 nm (solid line) and 234 nm 
(dashed line).  Peak A – C5H9-DHA branched compounds; Peak B – postulated hydroxy-16,17-epoxy-
docosapentaenoic acid; Peak C – (4Z,7Z,10Z,13Z,15E)-17-hydroxy-heptadecapentaenoic acid. 
These compounds, labelled A, B and C in Fig. 6.10, are consistent with the compounds 
observed upon incubation of DHA with soluble 15-sLOX-1 under the same anaerobic 
conditions.  Peak A has been previously shown to consist of a range of C5H9-DHA 
branched isomers, products of pentyl and conjugated-DHA radical recombination.  
Peak B is proposed to be a degradation product of the 17-alkoxy-DHA radical – 13/15-
hydroxy-16,17-epoxy-docosapentaenoic acid, displaying an absence of an optically 
active chromophore (λmax < 210 nm).  However the epoxy-alcohol isomers from DHA 
have not yet been fully chemically characterised.  Finally, peak C has been previously 
identified by mass spectrometry and NMR spectroscopy as (4Z,7Z,10Z,13Z,15E)-17-
hydroxy-heptadecapentaenoic acid, the reduced form of the enzymatically produced 
17-oxo-heptadecapentaenoic acid.  
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6.4 Conclusion 
Soybean 15-LOX-1 covalently coupled to EM600 and C2AM600 resins was found to 
successfully catalyse the dioxygenation of biological LC-PUFAs, including DHA, 
EPA and arachidonic acid, generating a range of mono- and di-hydro(pero)xy fatty 
acids.  The reaction products of LOXImm were partially characterised by NP-HPLC-
DAD, GC-MS and chiral phase HPLC, and compared to those produced from LOXSol.  
In addition to the prototypical S-dioxygenase activity, immobilised 15-sLOX-1 was 
also shown to retain lipohydroperoxidase activity with hydroperoxide substrates.  
15-sLOX-1 bound to both EM600 and C2AM600 resins catalysed complete 
conversion of DHA, EPA and ARA substrates to mono-hydro(pero)xy products, while 
for DPAn-3 and n-6 only partial conversion was achieved (76 – 84 mol%).  Major 
products of the single dioxygenation reaction included resolvin intermediates - 17S-
HDHA, 15S-HETE, and analogous products from EPA, DPAn-3 and DPAn-6.  While 
the regio-specificity of the enzyme was maintained with DHA substrate, catalysing 
specific oxygen insertion at the omega-6 positions, the immobilised enzyme exhibited 
reduced specificity with some substrates compared to the soluble form for the single 
dioxygenation reaction.   
Immobilised 15-sLOX-1 was also found to successfully catalyse the double 
dioxygenation of LC-PUFAs.  Products included resolvin D5 (7S,17S-dHDHA), 
protectin DX (10S,17S-diHDHA), resolvin D5DPAn-3 (7S,17S-diHDPAn-3) and 
analogous products from EPA, ARA and DPAn-6.  Conversion of substrates to 
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dihydroxy products was calculated to range from 7.8 – 35.6 mol%, with DHA 
undergoing the highest rate of conversion to dihydroxy compounds. 
The current development and use of immobilised biocatalysts for the synthesis of 
bioactive compounds highlights the potential of immobilised, recyclable 15-sLOX-1 
for the production of specialised pro-resolving mediator analogs.  This study represents 
the first report of double dioxygenation reactions of 15-sLOX-1 covalently coupled to 
functionalised methacrylate resins, producing a range of resolvin analogs from 
biologically important LC-PUFA.   
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7. STEREOCHEMICAL ANALYSIS OF HYDROXY FATTY 
ACIDS AND SYNTHETIC PROTOCOLS  
7.1 Introduction 
Stereochemical analysis of hydroxy fatty products plays a vital role in the 
characterisation of 15-sLOX-1 activity. The determination of regio- and stereo-
chemical features has enabled reaction pathways to be elucidated, providing insight 
into the mechanism of catalysis.  In addition, complete chemical characterisation of 
products is important for compounds to progress to biological activity evaluation and 
the development as potential pharmaceuticals.   
The application of chiral phase HPLC is a simple method for the detection and 
separation of enantiomers.  The development of carbohydrate-based columns 
derivatised with chiral ligands has enabled greater resolution of underivatised hydroxy 
fatty acids, and many methods have been developed using chiral cellulose and 
amylose-based stationary phases [122, 160, 194, 213, 301-303].  However these 
analyses have also indicated that the more remote the hydroxy group is from the 
carboxylic acid, the more difficult the enantiomers are to separate [304].  For example, 
5R/5S-HETE are better resolved than are 8R/S-HETE [305] and 15R/15S-HETE [306].  
As a result, the separation of enantiomers of very long chain hydroxy-fatty acids (e.g. 
C22, C24) is likely to increase in difficulty, especially where the hydroxy group is 
located close to the terminal methyl group.   
A major limitation of chiral phase HPLC is the requirement of chiral standards to 
elucidate (1) the potential to resolve the enantiomers using the selected column and 
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mobile phase, and (2) the absolute chirality based on co-elution with known standards.  
A limited range of chiral standards of hydroxy fatty acids from ARA, EPA and DHA 
are available commercially, however these standards are expensive to purchase and 
standards are not available for other substrates of interest such as DPAn-3 and n-6.  
Therefore methods to produce standards of target hydroxy fatty acids is of research 
interest. 
An alternative to chromatographic techniques for stereochemical analysis is the 
application of spectroscopic techniques, such as circular dichrosim (CD).  CD 
spectroscopy measures the absorption of left-handed (LH) and right-handed (RH) 
circularly polarised light.  The differential absorption of LH and RH by chiral centres 
results in elliptically polarised light, which generates the CD spectrum [221].  This is 
illustrated in Fig. 7.1, where both S- and R- chiral centres exhibit the same UV-visible 
absorbance, however in terms of ellipticity, S- exhibits a positive spectrum and R- 
generates a negative spectrum.  Likewise an achiral chromophore or racemic mixture 
of the two centres (S/R) does not generate a CD spectrum. 
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Figure 7.1 The relationship between the absorption and CD spectra (represented as ellipticity) of S- 
and R- chiral centres. (Reproduced from [221]).
In the case of hydroxy fatty acids containing a conjugated diene moiety, the hydroxy 
group itself must be optically active to enable analysis by CD.  Schneider and co-
workers [307] have previously reported the conversion of 9S-HODE and 13S-HODE 
to the respective naphthoate esters, through direct esterification and also using a 
Mitsonobu-type reaction to catalyse the inversion of stereochemistry.  The 
introduction of a secondary chromophore to the molecule allows determination of 
absolute chirality through interaction between the two chromophores.  This through 
space coupling, which is twisted depending on the chirality of the group, results in the 
observation of positive and negative Cotton effects in the form of a bisignate CD 
spectrum [307].  Therefore chiral standards are not required for this technique as the 
observed Cotton effects indicate absolute chirality.   
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Due to the inherent limitations of each technique, including the requirement of 
authentic chiral standards (HPLC) and derivatisation of hydroxy fatty acids (CD), a 
combination of CD spectroscopy and chiral phase HPLC should be used to establish 
absolute chirality.  This chapter presents the derivatisation of hydroxy fatty acids to 
enable stereochemical analysis by circular dichroism (CD) spectroscopy and the 
production of R- and S- enantiomers of fatty acids from a chirally pure starting 
material.  The methods described can be applied to any hydroxy fatty for the 
production of the opposing enantiomer, and provides an effective method for the 
production of chiral standards of target compounds.  
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7.2 Materials and Methods: 
7.2.1 Materials 
Soybean 15-lipoxygenase-1 (EC 1.13.11.33, P1, 10.0 Munits/ml, 26.09 mg protein/ml, 
0.383 Munits/mg protein) (Cayman Chemical, Ann Arbor, MI) was purchased from 
Sapphire Bioscience (Waterloo, NSW, Australia).  Arachidonic acid and linoleic acid 
(Nu-Chek Prep, Elysian, MN) were purchased from Adelab Scientific (Thebarton, SA, 
Australia).  Sodium tetraborate decahydrate, silica TLC plates (F254, 1 mm), silica SPE 
cartridges (500 mg bed weight), trimethylsilyl-diazomethane, benzoic acid, 
triphenylphospine, diethyl azodicarboxylate, Dess-Martin periodinane reagent, 
sodium thiosulfate, sodium hydrogen carbonate, cerium(III) chloride heptahydrate, 
sodium borohydride and sodium chloride were all purchased from Sigma-Aldrich 
(Castle Hill, NSW, Australia).  Anhydrous sodium sulfate, methanol and ethyl acetate 
were purchased from Merck Millipore (Bayswater, Victoria, Australia). 
13S-HODE and 15S-HETE were prepared from LA and ARA respectively, using 15-
sLOX-1 according to method of Dobson and co-workers [126].  The compounds were 
methylated using TMS-diazomethane and methanol (1:1) at room temperature for 1 h 
and the solvents evaporated under N2.  Products were extracted by SPE using a silica 
cartridge.  The cartridge bed was conditioned with 1 volume of n-heptane, the sample 
loaded in n-heptane, followed by 1 additional volume of n-heptane.  The products, 
13S-HODE ME and 15S-HETE ME, were eluted with 1 volume of isopropanol and 
evaluated using NP-HPLC. 
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7.2.2 Preparation of 13R-benzoate-ODE ME 
The 13R-benzoate ester derivative of 13S-HODE ME was prepared using a modified 
protocol from Schneider et al. [307]. 13S-HODE ME (0.05 mmol) was evaporated to 
dryness under a stream of N2 and dissolved in dry THF (2.5 ml).  A slight excess of 
benzoic acid (0.06 mmol) and triphenylphosphine (TPP; 0.06 mmol) was added and 
stirred until all reagents dissolved.  To this mixture, 10 μl of diethyl azodicarboxylate 
was added drop wise, the vessel sealed and stirred for 15 min at room temperature.  
The solvent was evaporated under N2 and the residue re-dissolved in dichloromethane.  
Products were isolated using preparative TLC (silica 60 F254, 1 mm).  For removal of 
TPP (as the TPP oxide; Rf 0.14) a solvent system of n-pentane/diethyl ether (2:1) was 
used.  Substrate and product co-eluted under these conditions (Rf 0.86), therefore were 
recovered and re-chromatographed using a solvent system of n-pentane/diethyl ether 
(5:1) to isolate the product (Rf 0.68).  Unreacted 13S-HODE (Rf 0.54) and the product 
were recovered and analysed by NP-HPLC under the conditions described below, 
however an isocratic mobile phase composition of 8% isopropanol and 92% n-
heptane/2,2-dimethoxypropane/acetic acid was used in these analyses.   
7.2.3 Preparation of 13S-benzoate-ODE ME 
The 13S-benzoate ester derivative of 13S-HODE ME was prepared using a modified 
protocol from Schneider et al. [307].  Approximately 20 μg of 13S-HODE ME was 
dissolved in 50 μl of acetonitrile.  To this, ~ 2 μmol of 1,8-diazabicyclo-[5.4.0]undec-
7-ene (DBU), ~ 2 μmol of benzoyl chloride and a few grains of dimethylaminepyridine 
(DMAP) were added.  The mixture was left overnight at room temperature.  The 
solvents were evaporated under N2, the product re-dissolved in 2 ml dichloromethane 
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and washed with two volumes of water.  The solvent was dried with anhydrous sodium 
sulphate, filtered and evaporated under N2.  Samples were prepared in acetonitrile for 
spectroscopic analysis. 
7.2.4 Dess-Martin oxidation protocol 
15S-HETE ME (~ 0.5 mg) was dissolved in 1 ml of dry dichloromethane in a round 
bottom flask and ~ 1 mg Dess-Martin Periodinane (DMP) reagent added.  The solution 
was sealed and mixed for 20 min at room temperature, to form a cloudy solution.  
Completion of the reaction was checked using TLC (silica 60 F254, 1 mm) with a 
solvent system of n-heptane/diethyl ether (60:40).  The product was detected with an 
Rf of 0.42 and complete conversion of starting material (Rf 0.18).  The solvent was 
evaporated under N2 and the product dissolved in ethyl acetate (4 ml).  The reaction 
product was then washed with two volumes sodium thiosulfate (100 g/l) (stirred for 10 
min each), two volumes of sodium hydrogen carbonate (100 g/l), two volumes of water 
and finally dried with anhydrous sodium sulphate. The solvent was filtered and 
evaporated to dryness under N2.  The residue was re-dissolved in 95% n-heptane/2,2-
dimethoxy propane/acetic acid (100:0.1:0.1 v/v/v) and 5% isopropanol for analysis by 
NP-HPLC with diode array detection.  NP-HPLC analysis was performed as described 
below. 
7.2.5 Luche reduction protocol 
15-keto-ETE ME (~ 0.3 mg), synthesised as described above from the oxidation of 
15S-HETE ME using DMP reagent, was dissolved in dry methanol (5 ml) in a round 
bottom flask.  To this, approximately 10 mg of cerium(III) chloride (dried under 
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vacuum) was added and stirred on ice.  Sodium borohydride (~ 10 mg) was added to 
the mixture in portions over 10 min with continuous stirring on ice.  The solution was 
sealed and stirred for 2 h on ice, until the effervescence ceased and the solution became 
cloudy.  The reaction products were diluted with 5 ml deionised water and extracted 
using ethyl acetate (2 × 5 ml volumes).  The organic phase was washed with brine, 
dried with anhydrous sodium sulfate and filtered.  Reaction products were analysed 
first using NP-HPLC to confirm reduction to 15-HETE ME, and chiral phase HPLC 
to confirm the presence of a racemate.   
7.2.6 Analytical methods 
Circular dichroism spectroscopy 
The circular dichroism spectra of the products were collected in acetonitrile 
(absorbance was adjusted to ~ 1 AU).  Parameters for CD analysis were as follows: 
Jasco J-815 CD spectropolarimeter, 1 mm pathlength, range – 300 - 200 nm, data pitch 
– 0.1 nm, band width – 1 nm, scanning rate – 50 nm/min, 3 accumulations. 
NP-HPLC analysis 
NP-HPLC was performed using an Agilent 1200 series HPLC system, equipped with 
a quaternary pump, solvent degasser, autosampler, thermostatted column compartment 
and diode array detector.  Analytical separations were carried out using a Supecosil 
LC-Diol column (25 cm × 3 mm, 5 μm; Supelco) with an isocratic mobile phase of 
composition of 5% isopropanol and 95% n-heptane/2,2-dimethoxypropane/acetic acid 
(100:0.1:0.1 v/v/v), or as otherwise described.  Injection volume was 15 μl, flow rate 
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was 0.5 ml/min and the column temperature was 10°C.  Elution of products was 
monitored at 210 nm, 234 nm, 250 nm and 270 nm. 
Chiral phase HPLC 
Chiral phase RP-HPLC was performed using an Agilent 1260 Infinity HPLC system, 
equipped with a quaternary pump, solvent degasser, autosampler, thermostatted 
column compartment and diode array detector.  Chiral analysis was performed using 
a Lux Amylose-2 chiral column (15 cm × 4.6 mm, 5 μm, Phenomenex) fitted with a 
guard cartridge, and solvents A: milliQ water with 0.1% (v/v) trifluoroacetic acid, and 
B: acetonitrile.  An isocratic mobile phase of 80% B was used at a flow rate of 
1 ml/min.  Analyses were performed at ambient temperature.  Samples were prepared 
in acetonitrile and an injection volume of 30 μl used.  Signals were monitored at 
210 nm, 234 nm, and 270 nm.   
For time-of-flight mass spectrometry (TOF-MS) experiments, separations were 
performed using an Agilent 1200 series HPLC equipped with a binary pump, 
autosampler and a time-of-flight mass spectrometer operating in positive ion mode.  
TOF-MS conditions were as follows: drying gas, nitrogen (5 l/min, 350°C); nebuliser 
gas, nitrogen (16 psi); capillary voltage, 4.0 kV; vaporiser temperature, 350°C; and 
cone voltage, 60 V.  Analyses were performed using the chiral HPLC method 
described above, however with the following adjustments: flow rate, 0.5 ml/min; 
mobile phase composition, 90% B.  Data analysis was performed using Agilent 
MassHunter Qualitative Analysis software (version B.03.1). 
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7.3 Results and Discussion 
7.3.1 Dess-Martin periodinane (DMP) protocol:  Oxidation of the conjugated 
hydroxy moiety to the conjugated ketone 
The Dess-Martin periodinane (DMP) reagent is used for the oxidation of hydroxy 
functional groups to ketones (Scheme 7.1) [124, 308-310].  A slightly modified 
procedure to that described in [310] was used for the production of 15-keto-ETE from 
15S-HETE ME.  The resulting enone can then be utilised for the production of chiral 
standards through reduction of the ketone to the racemic hydroxy fatty acid.   
 
Scheme 7.1. DMP oxidation (modified from [311]). 
The Dess-Martin reagent is a hypervalent iodine compound which employs mild 
reaction conditions to catalyse the selective oxidation of alcohols in high yields and 
purity [311].  In addition the resulting iodo-compound by-product is easily separated 
from the product with a mild basic work-up [311].  Briefly, 15S-HETE ME 
(synthesised using 15-sLOX-1 according to Dobson et al.) and DMP were dissolved 
in dichloromethane for 20 min at room temperature.  The completion of the reaction 
was confirmed by TLC and the purity of the oxidised product was confirmed by NP-
HPLC with diode array detection.   
As expected, the product 15-keto-ETE ME (15-KETE ME) experienced a slight shift 
in retention due to the decrease in polarity of the keto functional group compared to a 
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hydroxy group (Fig. 7.2).  15-KETE ME was detected at 3.17 min, compared to 
4.02 min for 15-HETE ME.  The product exhibited a shift in absorbance compared to 
the starting material, from 234 nm to 275 nm.  Absorbance at ~ 280 nm is characteristic 
of the aromatic nature of conjugated ketones.  The starting material, 15S-HETE ME 
was not detected in the reaction mixture.  
 
Figure 7.2 NP-HPLC chromatograms of A: 15-HETE ME starting material; and B: the 15-keto-ETE 
ME (15-KETE ME) product of the Dess-Martin periodinane oxidation reaction.  Signals were 
collected at 234 nm (dashed line) for the detection of 15-HETE ME, and 270 nm (dotted line) for the 
detection of 15-KETE ME. 
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A small amount of isomerisation of Z,E to E,E isomers during the DMP oxidation of 
linoleic and linolenic acid hydroperoxides to the ketone derivatives has been reported 
previously [309].  In the study by Iacazio [309] an increase of up to 4% isomerisation 
was reported using DMP reagent.  However in the current study E,E isomers were not 
observed in NP-HPLC analyses.  
7.3.2 Luche reduction:  Formation of racemic hydroxy fatty acids from the 
corresponding conjugated ketones 
The Luche reduction was utilised for the selective 1,2-reduction of the previously 
synthesised keto fatty acid.  This method employs cerium(III) chloride and sodium 
borohydride in the presence of methanol, in order to limit the competing 1,4-reduction 
reaction [312-313].  Using a slightly modified procedure (from [309]) for the Luche 
reduction of an α,β-unsaturated ketone to an unsaturated alcohol, reduction of 15-keto-
ETE ME to the corresponding racemic alcohol, 15-HETE ME, was achieved.  Products 
were analysed by NP-HPLC, and the presence of both 15S- and 15R- enantiomers of 
15-HETE ME confirmed using chiral phase HPLC. 
As indicated in Fig. 7.3, analysis by NP-HPLC showed incomplete reduction 15-keto-
ETE ME to the corresponding alcohol, 15-HETE ME.  A small amount of starting 
material (15-KETE ME) was detected in the reaction mixture following solvent 
extraction.  However despite incomplete reduction of the ketone, the reaction appeared 
to proceed through the desired 1,2-reduction to generate the unsaturated alcohol.  This 
is demonstrated by the retention of the chromophore absorbing at 234 nm (measured 
by online DAD), indicative of a conjugated diene, and the co-elution with authentic 
15-HETE ME. 
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Figure 7.3 NP-HPLC chromatograms of A: 15-keto-ETE ME; and B: the reaction products of the 
Luche reduction.  Signals were collected at 234 nm (dashed line) for the detection of 15-HETE ME 
(i.e. isolated conjugated diene), and 270 nm (dotted line) for the detection of 15-KETE ME (i.e. 
conjugated oxodiene). 
To confirm the racemisation of 15-HETE ME the product was analysed by chiral phase 
HPLC and compared to the starting material (15S-HETE ME from 15-sLOX-1 
catalysis).  As indicated in Fig. 7.4 (solid line), 15S-HETE is the major isomer (96.5%) 
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catalysed by 15-sLOX-1, in agreement with previous reports of the enzyme as an S-
dioxygenase [111, 113-115, 119, 147, 149].  Small amounts (3.5%) of 15R-HETE are 
also produced.  As shown in Fig. 7.4 (dashed line) the selective 1,2-reduction of 15-
keto-ETE ME to the corresponding hydroxy fatty acid resulted in the production of a 
racemic mixture of 15S- and 15R-HETE ME in a ratio of 49:51 (15S-:15R-).   
 
Figure 7.4 Chiral phase HPLC analysis of (15-sLOX-1 catalysed) 15S-HETE ME (solid line) and 
racemic 15-HETE ME (dashed line).  Signal collected at 234 nm. 
Chiral phase HPLC analyses of products were also performed using time-of-flight 
mass spectrometry (TOF-MS) detection, where both enantiomers were detected with 
mass/charge ratios consistent with a formula of C21H34O3 with a sodium adduct 
([M+Na]+ calculated for C21H34O3Na 357.24002).  
The major advantage of the Luche reaction is that the selective 1,2-reduction 
(generating the allylic alcohol) is favoured over the 1,4-reduction (which generates a 
saturated alcohol) [312-313].  Cerium(III) chloride (CeCl3) is a selective Lewis acid 
and catalyses the methanolysis of sodium borohydride, generating various sodium 
  
 
226 
 
(mono, di and tri)-methoxyborohydrides (Scheme 7.2) [313-314].  These species are 
harder reducing agents than hydride species (e.g. sodium borohydride) according to 
HSAB principles, therefore reduction of the carbonyl carbon is selectively favoured to 
produce the alkoxide intermediate [312-314].  CeCl3 also activates methanol 
generating the acidic proton required to form the hydroxy group from the alkoxide 
[314]. 
 
Scheme 7.2 Luche reaction mechanism using sodium borohydride and cerium(III) chloride in 
methanol (reproduced from [313]). 
Experiments were also performed using sodium borohydride only as the reducing 
agent.  In these experiments the conjugated alcohol was not detected, however the 
appearance of a peak in NP-HPLC which had an absorbance at ≤ 210 nm indicated the 
reaction proceeded through the undesirable 1,4 reduction [315].   
7.3.3 Derivatisation of 13S-hydroxy-ODE ME to the corresponding 13S- and 13R-
benzoate esters 
To enable stereochemical analysis of the hydroxy-fatty acid products by circular 
dichroism (CD) spectroscopy, the compounds required derivatisation to incorporate a 
secondary chromophore (Fig. 7.5).  Coupling of the two chromophores in 13R/S-
benzoate-ODE ME results in the differential absorption of optically polarised light 
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which may be measured by CD spectroscopy.  This generates positive or negative 
Cotton effects, depending on the rotation (left or right) of the interacting chromophores 
[307].   
 
Figure 7.5 Derivatisation of 13S-HODE ME to the corresponding enantiomeric benzoate ester 
derivatives using method A – direct esterification, and method B – Mitsonobu reaction. R1 – C5H11 
(methyl); R2 – C8H15O2 (carboxylic acid). 
13R-benzoate-ODE ME 
The Mitsonobu reaction, employing benzoic acid as the derivatising agent, was used 
for the production of 13R-benzoate-ODE ME from 13S-HODE ME.  This reaction 
catalyses the simultaneous esterification and inversion of stereochemistry of secondary 
alcohols.  Using benzoic acid the reaction has been shown to result in high yields of 
the ester product [316] and proceeds with clean inversion of stereochemistry under 
mild reaction conditions [317-318].  The order of addition of reagents in the Mitsonobu 
reaction is important, with the final addition of diethyl azodicarboxylate to the reaction 
mixture proposed to catalyse the formation of the Morrsion-Brunn-Huisgen betaine 
[317].  This leads to the formation of a postulated alkoxyphosphonium salt 
intermediate and subsequent nucleophilic substitution of the alcohol by the 
carboxylate group of benzoic acid [316-318].   
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The Mitsonobu reaction was found to be successful for generating the 13R-benzoate 
enantiomer from 13S- starting material.  The use of this type of reaction, where 
complete inversion of stereochemistry is achieved, eliminates the requirement to 
obtain or synthesise chirally-pure R-enantiomers of the hydroxy fatty acids.  
Recovered product from preparative TLC was subjected to 1H-NMR spectroscopy, and 
compared to the predicted proton spectrum (Fig. 7.6A).  As shown in Fig. 7.6B, the 
introduction of the benzoate group to the structure was confirmed by 1H-NMR, with 
resonance peaks at 7.4 – 8.2 ppm indicative of aromatic protons. 
The derivatised product from the Mitsonobu-type reaction (13R-benzoate-ODE ME) 
and the starting material (13S-HODE ME) were also analysed by NP-HPLC.  AS 
shown in Fig. 7.7, 13R-benzoate-ODE ME eluted earlier than the more polar 13S-
HODE ME starting material.  The introduction of the benzoate group also resulted in 
an increase in absorbance at 280 nm for both 13S- and 13R-benzoate derivatives, in 
addition to absorption at 234 nm from the existing conjugated diene moiety.     
  
 
22
9 
  
 
Fi
gu
re
 7
.6
 A
: P
re
di
ct
ed
 1 H
-N
M
R
 sp
ec
tru
m
 o
f (
9Z
,1
1E
)-1
3-
be
nz
oa
te
-o
ct
ad
ec
ad
ie
no
ic
 a
ci
d 
m
et
hy
l e
st
er
 (
ge
ne
ra
te
d 
us
in
g 
‘n
m
rd
b.
or
g’
 N
M
R
 p
re
di
ct
io
n 
so
ft
w
ar
e)
.  
B
: 
Ex
pe
rim
en
ta
l 1
H
-N
M
R
 sp
ec
tru
m
 o
f (
9Z
,1
1E
)-1
3R
-b
en
zo
at
e-
oc
ta
de
ca
di
en
oi
c 
ac
id
 m
et
hy
l e
st
er
, c
ol
le
ct
ed
 in
 C
D
3O
D
.
  
 
 
Figure 7.7 Overlaid NP-HPLC chromatograms of 13R-benzoate-ODE ME (Rf 0.68) and 13S-HODE-
ME (Rf 0.54) containing TLC fractions. Signals measured at 234 nm. 
13S-benzoate-ODE ME 
Several protocols (varying in time, temperature, amine base and ester derivative) were 
also tested and modified for the derivatisation of 13S-HODE using benzoyl chloride 
to the corresponding 13S-benzoate ester [307, 319].   
Various tertiary amine bases were tested as chloride scavengers, including 1,8-
diazabicyclo-[5.4.0]undec-7-ene (DBU), triethylamine (TEA), and 
diisopropylethylamine (DIPEA), with DBU found to be most suitable.  In addition, 
reactions were performed using naphthoyl chloride to produce the naphthoate ester 
derivative, however these reactions were unsuccessful in generating the desired 
compounds.  DMAP was found to be a suitable catalyst for the activation of the 
carbonyl group of benzoyl chloride with a reaction time of 12 h at room temperature, 
successfully producing 13S-benzoate-ODE ME without further purification.  The 
importance of dry solvents was also highlighted in this protocol, as the presence of 
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water results in the formation of benzoic acid which cannot undergo the desired 
reaction. 
7.3.4 Circular dichroism spectroscopy 
The two purified derivatised compounds were analysed by CD spectroscopy in 
acetonitrile solvent.  Prior to analysis the concentration of the samples was adjusted to 
~ 1 AU (by UV-visible spectroscopy at 235 nm).  As shown in Fig. 7.8, 13S-benzoate-
ODE ME generated a negative Cotton effect at 223 nm and a positive Cotton effect at 
240nm, indicative of S-stereochemistry [307, 319].  Whereas the corresponding 13R-
enantiomer generated the reverse spectrum (i.e. positive at 222 nm and negative at 238 
nm).  In contrast, 13S-HODE ME starting material was CD silent (results not shown).   
 
Figure 7.8 CD spectra of 13S- and 13R-benzoate-ODE ME, measured in acetonitrile.  Absorbance 
was adjusted to ~ 1 AU prior to CD analysis. 
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7.4 Conclusion 
Due to the limited availability of chiral standards for hydroxy fatty acids the first aim 
of this chapter was to produce a racemic mixture of 15R/S-HETE ME from a chirally 
pure starting material.  15S-HETE ME was successfully oxidised to the corresponding 
ketone using the DMP reagent, the ketone was then subjected to Luche reduction to 
yield racemic 15-HETE ME.  The final product was evaluated using chiral phase 
HPLC, exhibiting a 15S-:15R- ratio of 49:51.  The protocols described provide a 
valuable method to synthesise chiral standards of 15-sLOX-1 products which may not 
be available commercially. 
The second aim of this chapter was to catalyse the conversion of 13S-HODE ME to 
optically-active 13S- and 13R-benzoate ester derivatives, for subsequent analysis by 
CD spectroscopy.  For the production of 13S-benzoate-ODE ME a direct esterification 
was performed, using benzoic acid, DBU and DMAP as the derivatising agents.  In 
this method the stereochemistry of the hydroxy group was conserved in the product, 
generating Cotton effects characteristic of S-chirality when analysed by CD 
spectroscopy.  For the production of 13R-benzoate-ODE ME from the same starting 
material (13S-HODE ME), a Mitsonobu reaction was employed using benzoic acid, 
TPP and DEAD.  Analysis of the final product exhibited R-chirality Cotton effects in 
the CD spectrum, indicating complete inversion of stereochemistry was achieved using 
the modified method.  The advantage of these reactions for the stereochemical analysis 
of 15-sLOX-1 products is that the same S-chirality starting material is used for the 
production of both R- and S-derivatives, therefore eliminating the requirement to 
obtain pure samples of the opposing enantiomer.    
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8.  APPENDIX 
 
 
Table 8.1 Review of lipoxygenase catalysis (including enzyme/substrate concentrations, critical 
experimental variables and reaction products) from plant, mammal, fungal and bacterial sources.  
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ro
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 m
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ro
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-o
ct
ad
ec
en
oi
c 
ac
id
 
~2
9%
 
U
se
 o
f S
nC
l 2 
to
 t
ra
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 m
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D
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O
D
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[1
14
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at
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ra
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R
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m
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m
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m
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m
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 m
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A
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 m
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-
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0.
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M
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ra
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D
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m
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m
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ra
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N
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D
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m
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 re
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0.
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ra
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m
M
 
0.
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D
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 o
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] 
 
 
A
RA
-P
C-
de
ox
yc
ho
la
te
 
m
ix
ed
 (P
DM
) 
m
ic
el
le
s 
0.
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N
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N
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0.
05
 M
 N
a-
bo
ra
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ra
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N
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So
yb
ea
n 
15
-
LO
X-
1 
(A
la
54
2G
ly
 
m
ut
an
t)
 
1 
μg
 
LA
 
0.
1 
m
M
 
0.
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ra
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D
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in
 th
re
e 
1 
m
g 
po
rt
io
ns
 a
t 
T0
, T
10
 a
nd
 T
20
 m
in
 
U
nk
no
w
n 
po
la
r 
co
m
po
un
d 
14
%
 
 
  
 
25
5 
 
  
LO
X 
am
ou
nt
 
Su
bs
tr
at
e 
[S
ub
st
ra
te
] 
R
ea
ct
io
n 
m
ed
iu
m
 
pH
 
Su
rf
ac
ta
nt
s 
A
dd
it
iv
e/
ot
he
r 
Te
m
p.
 
O
2 
Ti
m
e 
Pr
od
uc
ts
 
Co
m
m
en
ts
 
R
ef
. 
12
-H
PE
TE
 <
1%
 
8-
H
PE
TE
 <
1%
 
(6
,8
,1
1,
13
)-
5S
,1
5S
-d
iH
ET
E 
~2
0%
 
(5
,9
,1
1,
13
)8
S,
15
S-
di
H
ET
E 
~8
%
 
Ba
rl
ey
 s
ee
d 
LO
X 
40
0 
un
it
s 
LA
 
50
 m
M
 
0.
1 
M
 N
a-
bo
ra
te
 
8.
0 
 
 
5°
C 
2.
5 
ba
r 
O
2 
90
 m
in
 
(1
0E
,1
2Z
)-
9S
-H
O
D
E 
44
%
 
(9
Z,
11
E)
-1
3S
-H
O
D
E 
1.
5%
 
 
[3
34
] 
 
 
A
LA
 
50
 m
M
 
0.
1 
M
 N
a-
bo
ra
te
 
8.
0 
 
 
5°
C 
2.
5 
ba
r 
O
2 
90
 m
in
 
(1
0E
,1
2Z
,1
5Z
)-9
S-
H
PO
Tr
E 
39
%
 
(1
0E
,1
2Z
,1
4E
)-
9,
16
-d
iH
PO
Tr
E 
~2
.5
%
 
(1
0E
,1
2E
,1
4E
)-
9,
16
-d
iH
PO
Tr
E 
~2
.5
%
  
 
Ba
rl
ey
 s
ee
d 
LO
X 
N
S 
LA
 
0.
2 
m
M
 
0.
1 
M
 N
a-
ph
os
ph
at
e 
7.
0 
 
 
A
m
bi
en
t 
B 
1 
h 
(1
0E
,1
2Z
)-
9S
-H
PO
D
E 
>9
5%
 
 
[3
35
] 
 
A
RA
 
0.
2 
m
M
 
0.
1 
M
 N
a-
ph
os
ph
at
e 
7.
0 
 
 
A
m
bi
en
t 
B 
1 
h 
5S
-H
PE
TE
 >
85
%
 
15
%
 c
on
ve
rs
io
n 
 
Fu
sa
riu
m
 
ox
ys
po
ru
m
 
(F
ox
LO
X)
 
10
-1
00
 μ
g 
pu
ri
fie
d 
pr
ot
ei
n 
LA
 
0.
89
 m
M
 
0.
05
 M
 T
ri
s/
H
Cl
 
8.
0 
 
 
A
m
bi
en
t 
N
S 
30
-6
0 
m
in
 1
3-
H
O
D
E 
74
%
 
al
l-t
ra
ns
-1
3-
H
O
D
E 
9%
 
 9
-H
O
D
E 
9%
 
al
l-t
ra
ns
-9
-H
O
D
E 
8%
 
 
[3
36
] 
 
 
A
LA
 
0.
90
 m
M
 
0.
05
 M
 T
ri
s/
H
Cl
 
8.
0 
 
 
A
m
bi
en
t 
N
S 
30
-6
0 
m
in
 1
3-
H
O
Tr
E 
83
%
 
12
-H
O
Tr
E 
5%
 
16
-H
O
Tr
E 
5%
 
al
l-t
ra
ns
-1
3-
H
O
Tr
E 
2%
 
9-
H
O
Tr
E 
4%
 
al
l-t
ra
ns
-9
-H
O
Tr
E 
1%
 
 
 
 
 
G
LA
 
0.
90
 m
M
 
0.
05
 M
 T
ri
s/
H
Cl
 
8.
0 
 
 
A
m
bi
en
t 
N
S 
30
-6
0 
m
in
 1
3-
H
O
Tr
E 
52
%
 
al
l-t
ra
ns
-1
3-
H
O
Tr
E 
6%
 
10
-H
O
Tr
E 
5%
 
9-
H
O
Tr
E 
22
%
 
al
l-t
ra
ns
-9
-H
O
Tr
E 
4%
 
6-
H
O
TE
 1
4%
 
 
 
 
 
A
RA
 
0.
82
 m
M
 
0.
05
 M
 T
ri
s/
H
Cl
 
8.
0 
 
 
A
m
bi
en
t 
N
S 
30
-6
0 
m
in
 1
5-
H
ET
E 
92
%
 
11
-H
ET
E 
8%
  
al
l-t
ra
ns
-1
1-
H
ET
E 
(t
ra
ce
) 
8-
H
ET
E 
(t
ra
ce
) 
 
 
  
 
25
6 
 
  
LO
X 
am
ou
nt
 
Su
bs
tr
at
e 
[S
ub
st
ra
te
] 
R
ea
ct
io
n 
m
ed
iu
m
 
pH
 
Su
rf
ac
ta
nt
s 
A
dd
it
iv
e/
ot
he
r 
Te
m
p.
 
O
2 
Ti
m
e 
Pr
od
uc
ts
 
Co
m
m
en
ts
 
R
ef
. 
Fu
sa
riu
m
 
ox
ys
po
ru
m
 
(F
ox
LO
X)
 
2 
m
l c
ru
de
 
ly
sa
te
 
su
pe
rn
at
an
t 
A
LA
 
0.
36
 m
M
 
K-
ph
os
ph
at
e 
(C
on
c.
 N
S)
 
N
S 
 
 
23
°C
 
N
S 
30
 m
in
 
13
S-
H
O
TE
 
13
S-
ep
ox
y-
11
-h
yd
ro
xy
-(9
Z,
15
Z)
-
oc
ta
de
ca
di
en
oi
c 
ac
id
 
9-
m
et
ho
xy
-1
6-
hy
dr
ox
y-
(1
0,
12
,1
4)
-
oc
ta
de
ca
tr
ie
no
ic
 a
ci
d 
(2
 is
om
er
s,
 
1:
1)
 
15
,1
6-
di
hy
dr
ox
y-
(9
,1
1,
13
)-
oc
ta
de
ca
tr
ie
no
ic
 a
ci
d 
9,
16
-d
ih
yd
ro
xy
-(1
0,
12
,1
4)
-
oc
ta
de
ca
tr
ie
no
ic
 a
ci
d 
(2
 is
om
er
s,
 
1:
1)
 
 
[3
36
] 
Fu
sa
riu
m
 
ox
ys
po
ru
m
 
(F
ox
LO
X)
 
10
-1
00
 μ
g 
pu
ri
fie
d 
pr
ot
ei
n 
LA
 (F
FA
, M
E 
an
d 
PC
 d
er
iv
at
iv
es
)  
0.
71
 - 
1.
1 
 m
M
 0
.0
5 
M
 T
ri
s-
H
Cl
 
8.
0 
0.
1%
 v
/v
 s
od
iu
m
 
de
ox
yc
ho
la
te
 
10
%
 v
/v
 g
ly
ce
ro
l 
30
0 
m
M
 N
aC
l  
A
m
bi
en
t 
N
S 
60
 m
in
 
13
S-
H
PO
D
E 
(m
aj
or
 p
ro
du
ct
 fr
om
 a
ll 
de
ri
va
tiv
es
)  
 
[3
36
] 
A
ca
ry
oc
hl
or
is
 
m
ar
in
a 
LO
X 
N
S 
LA
 
N
S 
0.
05
 M
 T
ri
s-
H
Cl
 
7.
5 
 
15
0 
m
M
 N
aC
l 
2 
m
M
 S
nC
l 2 
A
m
bi
en
t 
N
S 
a 
9R
-H
O
D
E 
84
%
 
9S
-H
O
D
E 
3%
 
13
-H
O
D
E 
13
%
 
A
.m
ar
in
a 
ha
s 
G
ly
 a
t 
th
e 
cr
uc
ia
l 
G
ly
/A
la
 s
ite
 t
he
re
fo
re
 R
-s
pe
ci
fic
 
[3
37
] 
 
 
A
LA
 
N
S 
0.
05
 M
 T
ri
s-
H
Cl
 
7.
5 
 
15
0 
m
M
 N
aC
l 
2 
m
M
 S
nC
l 2 
A
m
bi
en
t 
N
S 
a 
(9
Z,
13
E,
15
Z)
-1
2R
-H
O
Tr
E 
99
%
 
13
-H
O
Tr
E 
(m
in
or
) 
9-
H
O
Tr
E 
(m
in
or
) 
 
 
 
 
St
ea
ri
do
ni
c 
ac
id
 
N
S 
0.
05
 M
 T
ri
s-
H
Cl
 
7.
5 
 
15
0 
m
M
 N
aC
l 
2 
m
M
 S
nC
l 2 
A
m
bi
en
t 
N
S 
a 
(6
Z,
9Z
,1
3E
,1
5Z
)-1
2-
H
O
TE
 
 
 
 
 
A
RA
 
N
S 
0.
05
 M
 T
ri
s-
H
Cl
 
7.
5 
 
15
0 
m
M
 N
aC
l 
2 
m
M
 S
nC
l 2 
A
m
bi
en
t 
N
S 
a 
11
R-
H
ET
E 
98
%
 
 
 
 
 
EP
A 
N
S 
0.
05
 M
 T
ri
s-
H
Cl
 
7.
5 
 
15
0 
m
M
 N
aC
l 
2 
m
M
 S
nC
l 2 
A
m
bi
en
t 
N
S 
a 
(5
Z,
8Z
,1
1Z
,1
5E
,1
7Z
)-1
4-
H
EP
A 
 
 
 
 
D
H
A 
N
S 
0.
05
 M
 T
ri
s-
H
Cl
 
7.
5 
 
15
0 
m
M
 N
aC
l 
2 
m
M
 S
nC
l 2 
A
m
bi
en
t 
N
S 
a 
(4
Z,
7Z
,1
0Z
,1
3Z
,1
7E
,1
9Z
)-1
6-
H
D
H
A 
 
 
Pl
at
el
et
 1
2-
LO
X 
1.
2 
x 
10
9  
di
sr
up
te
d 
pl
at
el
et
s 
A
RA
 
15
 μ
M
 
PB
S 
(D
ul
be
cc
o'
s)
 
7.
4 
 
 
37
°C
 
~ 
12
 μ
M
 
5 
m
in
 
12
-H
ET
E 
~ 
80
%
 
12
-o
xo
do
de
ca
tr
ie
no
ic
 a
ci
d 
~1
7%
 
12
-K
ET
E 
~ 
2%
 
 
[1
83
] 
 
 
 
 
 
 
 
 
 
~ 
20
0 
μM
 
5m
in
 
12
-H
ET
E 
~ 
86
%
 
12
-o
xo
do
de
ca
tr
ie
no
ic
 a
ci
d 
~ 
9%
 
12
-K
ET
E 
~ 
2%
 
 
 
  
 
25
7 
 
  
LO
X 
am
ou
nt
 
Su
bs
tr
at
e 
[S
ub
st
ra
te
] 
R
ea
ct
io
n 
m
ed
iu
m
 
pH
 
Su
rf
ac
ta
nt
s 
A
dd
it
iv
e/
ot
he
r 
Te
m
p.
 
O
2 
Ti
m
e 
Pr
od
uc
ts
 
Co
m
m
en
ts
 
R
ef
. 
 
 
 
 
 
 
 
 
 
~ 
72
0 
μM
 
5m
in
 
12
-H
ET
E 
~ 
89
%
 
12
-o
xo
do
de
ca
tr
ie
no
ic
 a
ci
d 
~ 
9%
 
12
-K
ET
E 
~ 
2%
 
 
 
H
um
an
  5
-L
O
X 
58
 μ
g 
(5
Z,
8,
Z,
11
Z,
14
Z)
-
16
(±
)-
H
ET
E 
0.
1 
m
M
 
0.
1 
M
 T
ris
-H
Cl
 
7.
25
  
21
.5
 μ
M
 A
TP
 
2 
μM
 C
aC
l2
  
0.
1 
μM
 E
D
TA
 
1.
8 
μM
 C
16
-P
C 
A
m
bi
en
t 
N
S 
15
 m
in
 
5,
16
R-
dI
H
ET
E 
5,
16
S-
di
H
ET
E 
H
ig
he
r 
re
ac
ti
on
 ra
te
 w
ith
 1
6R
-
H
ET
E 
th
an
 1
6S
-H
ET
E 
[1
86
] 
H
um
an
 5
-L
O
X 
N
S 
14
S-
H
D
H
A 
N
S 
N
S 
N
S 
 
 
N
S 
N
S 
N
S 
(4
Z,
8E
,1
0Z
,1
2E
,1
6Z
,1
9Z
)-7
S,
14
S-
di
hy
dr
ox
y-
D
H
A 
D
ou
bl
e 
di
ox
yg
en
at
io
n 
pr
od
uc
t o
f 
14
S-
H
D
H
A 
[7
8]
 
H
um
an
 
le
uk
oc
yt
e 
LO
X 
60
 ×
 1
06
 
ce
lls
/m
l 
15
-H
PE
TE
 
0.
00
75
 m
M
 
N
S 
N
A 
 
2 
μM
 Io
no
ph
or
e 
A
23
18
7 
37
°C
 
N
S 
5 
m
in
 
5S
,1
5S
-d
iH
ET
E 
 
 
Po
rc
in
e 
LO
X 
75
 u
ni
ts
 
D
H
A 
0.
1 
m
M
 
0.
1 
M
 T
ris
-H
Cl
 
7.
5 
0.
03
 %
 T
w
ee
n-
20
 
5 
m
M
 E
D
TA
 
4°
C 
N
A 
30
 m
in
 
14
-H
D
H
A 
17
-H
D
H
A 
 
11
-H
D
H
A 
7,
14
-d
iH
DH
A 
8,
14
-d
iH
DH
A 
<1
0%
 c
on
ve
rs
io
n 
[1
24
] 
 
 
D
PA
n-
3 
0.
1 
m
M
 
0.
1 
M
 T
ris
-H
Cl
 
7.
5 
0.
03
 %
 T
w
ee
n-
20
 
5 
m
M
 E
D
TA
 
4°
C 
N
A 
30
 m
in
 
14
-H
D
PA
n-
3 
>9
0%
 
17
-H
D
PA
n-
3 
11
-H
D
PA
n-
3 
8,
14
-d
iH
DP
A
n-
3 
 
 
 
 
D
PA
-6
 
0.
1 
m
M
 
0.
1 
M
 T
riS
-H
Cl
 
7.
5 
0.
03
 %
 T
w
ee
n-
20
 
5 
m
M
 E
D
TA
 
4°
C 
N
A 
30
 m
in
 
14
-H
D
PA
n-
6 
>9
0%
 
17
-H
D
PA
n-
6 
11
-H
D
PA
n-
6 
8-
H
D
PA
n-
6 
7,
14
-d
iH
DP
A
n-
6 
8,
14
-d
iH
DP
A
n-
6 
 
 
Po
rc
in
e 
LO
X 
5.
4 
U
/m
l 
D
H
A 
0.
15
 m
M
 
0.
05
 M
 K
-
ph
os
ph
at
e 
7.
4 
0.
02
 %
 T
w
ee
n-
20
 
 
N
S 
N
S 
N
S 
14
S-
H
D
H
A 
 
[7
8]
 
Po
rc
in
e 
le
uk
oc
yt
e 
5 -
LO
X 
0.
15
 m
g 
(1
-1
4 C
)-
A
RA
 
0.
02
5 
m
M
 
0.
05
 M
 K
-
ph
os
ph
at
e  
7.
4 
 
2 
m
M
 C
aC
l 2 
2m
M
 A
TP
 
24
°C
 
N
S 
5 
m
in
 
5-
H
PE
TE
 9
2%
 
 
[3
26
] 
Po
rc
in
e 
le
uk
oc
yt
e 
12
-
LO
X 
0.
80
 m
g 
(1
-1
4 C
)-
A
RA
 
0.
04
 m
M
 
0.
05
 M
 K
-
ph
os
ph
at
e 
7.
4 
 
2 
m
M
 C
aC
l 2 
2m
M
 A
TP
 
24
°C
 
N
S 
5 
m
in
 
12
-H
PE
TE
 
 
[3
26
] 
  
 
25
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LO
X 
am
ou
nt
 
Su
bs
tr
at
e 
[S
ub
st
ra
te
] 
R
ea
ct
io
n 
m
ed
iu
m
 
pH
 
Su
rf
ac
ta
nt
s 
A
dd
it
iv
e/
ot
he
r 
Te
m
p.
 
O
2 
Ti
m
e 
Pr
od
uc
ts
 
Co
m
m
en
ts
 
R
ef
. 
Po
rc
in
e 
le
uk
oc
yt
e 
12
-
LO
X 
0.
80
 m
g 
5-
H
PE
TE
 
N
S 
0.
05
 M
 K
-
ph
os
ph
at
e  
7.
4 
 
2 
m
M
 C
aC
l 2 
2m
M
 A
TP
 
24
°C
 
N
S 
5 
m
in
 
5S
,1
2S
-d
iH
ET
E 
 
[3
26
] 
Ra
bb
it
 
re
ti
cu
lo
cy
te
 
LO
X 
0.
5 
nm
ol
/m
l L
A
 
1-
5 
m
g 
0.
1 
M
 K
-p
ho
sp
ha
te
 
7.
4 
 
 
A
m
bi
en
t 
N
S 
10
 m
in
 
9Z
,1
1E
-1
3-
H
O
D
E 
98
%
 (9
7:
3 
S:
R)
 
10
E,
12
Z-
9-
H
O
D
E 
2%
 (r
ac
em
ic
) 
 
[1
79
] 
 
V
LD
L 
1-
5 
m
g 
0.
1 
M
 K
-p
ho
sp
ha
te
 
7.
4 
 
 
A
m
bi
en
t 
N
S 
10
 m
in
 
15
-H
ET
E 
10
%
 (8
8:
12
 S
:R
) 
9Z
,1
1E
-1
3-
H
O
D
E 
71
%
 (7
7:
23
 S
:R
) 
9E
,1
1E
-1
3-
H
O
D
E 
5%
 (r
ac
em
ic
) 
10
E,
12
Z-
9-
H
O
D
E 
8%
 
10
E,
12
E-
9-
H
O
D
E 
6%
 
~ 
0.
5 
- 3
 %
 c
on
ve
rs
io
n 
of
 
lip
op
ro
te
in
s 
 
 
 
LD
L 
1-
5 
m
g 
0.
1 
M
 K
-p
ho
sp
ha
te
 
7.
4 
 
 
A
m
bi
en
t 
N
S 
10
 m
in
 
15
-H
ET
E 
13
%
 (8
6:
14
 S
:R
) 
9Z
,1
1E
-1
3-
H
O
D
E 
65
%
 (7
9:
21
 S
:R
) 
9E
,1
1E
-1
3-
H
O
D
E 
5%
 
10
E,
12
Z-
9-
H
O
D
E 
15
%
 (r
ac
em
ic
) 
10
E,
12
E-
9-
H
O
D
E 
2%
 
 
 
 
 
H
D
L 
1-
5 
m
g 
0.
1 
M
 K
-p
ho
sp
ha
te
 
7.
4 
 
 
A
m
bi
en
t 
N
S 
10
 m
in
 
15
-H
ET
E 
18
%
 (8
3:
17
 S
:R
) 
9Z
,1
1E
-1
3-
H
O
D
E 
52
%
 (8
0:
20
 S
:R
) 
9E
,1
1E
-1
3-
H
O
D
E 
7%
 
10
E,
12
Z-
9-
H
O
D
E 
20
%
 (r
ac
em
ic
) 
10
E,
12
E-
9-
H
O
D
E 
3%
 
 
 
 
 
Ch
yl
om
ic
ro
ns
 
1-
5 
m
g 
0.
1 
M
 K
-p
ho
sp
ha
te
 
7.
4 
 
 
A
m
bi
en
t 
N
S 
10
 m
in
 
15
-H
ET
E 
24
%
  
9Z
,1
1E
-1
3-
H
O
D
E 
56
%
 
9E
,1
1E
-1
3-
H
O
D
E 
6%
 
10
E,
12
Z-
9-
H
O
D
E 
9%
 
10
E,
12
E-
9-
H
O
D
E 
5%
 
 
 
Ra
bb
it
 
re
ti
cu
lo
cy
te
 
LO
X 
18
4 
μg
 
A
RA
 
0.
1 
m
M
 
0.
1 
M
 K
-p
ho
sp
ha
te
 
7.
4 
 
4.
6 
m
M
 s
od
iu
m
 
ch
ol
at
e 
0.
5 
%
 (v
/v
) e
th
an
ol
 
V
ig
or
ou
s 
st
irr
in
g 
0°
C 
N
S 
N
S 
15
-H
PE
TE
 (m
aj
or
) 
12
-H
PE
TE
 (m
in
or
) 
 
[1
81
] 
 
 
 
 
 
 
37
°C
 
N
S 
N
S 
(6
E,
8Z
,1
1Z
,1
3E
)-
5S
,1
5S
-d
iP
ET
E 
(m
aj
or
)  
(5
Z,
9E
,1
1Z
,1
3E
)-
8S
,1
5S
-d
iP
ET
E 
(m
aj
or
) 
13
-h
yd
ro
xy
-1
4,
15
-e
po
xy
-E
Tr
E 
(m
aj
or
) 
14
,1
5-
di
H
ET
E 
(m
in
or
) 
(5
Z,
9E
,1
1E
,1
3E
)-
8S
,1
5S
-d
iH
ET
E 
 
(5
Z,
9E
,1
1E
,1
3E
)-
8R
,1
5S
-d
iH
ET
E 
A
ll-
tr
an
s 
8,
15
-d
iH
ET
Es
 p
ro
du
ce
d 
th
ro
ug
h 
th
e 
le
uk
ot
ri
en
e 
pa
th
w
ay
 
(1
4,
15
-L
TA
4)
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X 
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tr
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e 
[S
ub
st
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te
] 
R
ea
ct
io
n 
m
ed
iu
m
 
pH
 
Su
rf
ac
ta
nt
s 
A
dd
it
iv
e/
ot
he
r 
Te
m
p.
 
O
2 
Ti
m
e 
Pr
od
uc
ts
 
Co
m
m
en
ts
 
R
ef
. 
Ra
bb
it
 
re
ti
cu
lo
cy
te
 
LO
X 
27
6 
μg
 
A
RA
 
0.
1 
m
M
 
0.
2 
M
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